View Filing Data

Amortization of prior service cost, tax

^[1]

^[1]

Amortization of prior service cost, after tax

^[1]

Amortization of loss, pre-tax

^[1]

Amortization of loss, tax

^[1]

(3)

Amortization of loss, after tax

^[1]

Defined benefit plans, net, pre-tax

^[1]

Defined benefit plans, net, tax

^[1]

(14)

Defined benefit plans, net, after-tax

^[1]

Other comprehensive loss, pre-tax

(230)

Other comprehensive loss, tax

(14)

Other comprehensive loss, after-tax

(244)

Comprehensive (loss) income, pre-tax

(418)

550

576

Comprehensive (loss) income, tax

(149)

(152)

Comprehensive (loss) income, after-tax

(334)

401

424

Comprehensive income attributable to noncontrolling interests, pre-tax

Comprehensive income attributable to noncontrolling interests, tax

Comprehensive income attributable to noncontrolling interests, after-tax

Comprehensive (loss) income attributable to Chemours, pre-tax

(418)

549

575

Comprehensive (loss) income attributable to Chemours, tax

(149)

(152)

Comprehensive (loss) income attributable to Chemours, after-tax

$ (334)

$ 400

$ 423

[1]	These other comprehensive income (loss) components are included in the computation of net periodic benefit costs. Refer to Note 21 for further information.

Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash	$ 366	$ 0
Accounts and notes receivable - trade, net	859	846
Inventories	972	1,052
Prepaid expenses and other	104	43
Total current assets	2,301	1,941
Property, plant and equipment	9,015	9,282
Less: Accumulated depreciation	(5,838)	(5,974)
Net property, plant and equipment	3,177	3,308
Goodwill	166	198
Other intangible assets, net	10	11
Investments in affiliates	136	124
Other assets	508	377
Total assets	6,298	5,959
Current liabilities:
Accounts payable	973	1,046
Short-term borrowings and current maturities of long-term debt	39	0
Other accrued liabilities	454	352
Total current liabilities	1,466	1,398
Long-term debt	3,915	0
Other liabilities	553	464
Deferred income taxes	234	424
Total liabilities	6,168	2,286
Commitments and contingent liabilities
Equity
Common stock (par value $0.01 per share; 810,000,000 shares authorized; 181,069,751 shares issued and outstanding as of December 31, 2015)	2	0
Additional paid-in capital	775	0
DuPont Company Net Investment, prior to separation	0	3,650
Accumulated deficit	(115)	0
Accumulated other comprehensive (loss) income	(536)	19
Total Chemours stockholders' equity	126	3,669
Noncontrolling interests	4	4
Total equity	130	3,673
Total liabilities and equity	$ 6,298	$ 5,959

Consolidated Balance Sheets (Parenthetical)	Dec. 31, 2015 $ / shares shares
Statement of Financial Position [Abstract]
Common stock , par value (USD per share) \| $ / shares	$ 0.01
Common stock, shares authorized	810,000,000
Common stock, shares issued	181,069,751
Common stock, shares outstanding	181,069,751

Consolidated Statements of Stockholders' Equity - USD ($) $ in Millions	Total	Common Stock [Member]	DePont Company Net Investment [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Noncontrolling Interests [Member]	Accumulated Deficit [Member]
Total stockholders' equity, beginning balance at Dec. 31, 2012	$ 3,167		$ 3,146	$ 0	$ 19	$ 2	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	424		423			1
Other comprehensive loss	0
Net transfers from DuPont	(374)		(374)
Total stockholders' equity, ending balance at Dec. 31, 2013	3,217		3,195	0	19	3	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	401		400			1
Other comprehensive loss	0
Net transfers from DuPont	55		55
Total stockholders' equity, ending balance at Dec. 31, 2014	3,673		3,650	0	19	4	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	(90)		25				(115)
Other comprehensive loss	(244)				(244)
Issuance of Common Stock at separation (in shares)		180,966,833
Issuance of Common Stock at separation	0	$ 2		(2)
Common Stock issued - compensation plans (in shares)		102,918
Establishment of pension plans, net and related accumulated other comprehensive income (loss)	(43)		268		(311)
Dividends declared	(105)		(100)	(5)
Non-cash debt exchange	(507)		(507)
Cash provided at separation by DuPont	247		247
Net transfers from DuPont	(2,814)		(3,583)	769
Stock-based compensation expense	13			13			0
Shares, ending balance at Dec. 31, 2015		181,069,751
Total stockholders' equity, ending balance at Dec. 31, 2015	$ 130	$ 2	$ 0	$ 775	$ (536)	$ 4	$ (115)

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Operating activities
Net (loss) income	$ (90)	$ 401	$ 424
Adjustments to reconcile net (loss) income to cash provided by operating activities:
Depreciation and amortization	267	257	261
Amortization of deferred financing costs and issuance discount	8	0	0
Other operating charges and credits, net	7	18	13
Loss (gain) on sale of assets and businesses	9	(40)	(7)
Equity in earnings of affiliates, net of dividends received of $23, $19 and $19	0	1	(1)
Deferred tax benefit	(198)	(22)	(14)
Asset related charges	206	0	0
Accounts and notes receivable - trade, net	(64)	4	(37)
Inventories and other operating assets	19	(29)	(75)
Accounts payable and other operating liabilities	18	(85)	234
Cash provided by operating activities	182	505	798
Investing activities
Purchases of property, plant and equipment	(519)	(604)	(438)
Proceeds from sales of assets, net	12	32	14
Foreign exchange contract settlements	42	0	0
Investment in affiliates	(32)	(8)	0
Other investing activities	0	20	0
Cash used for investing activities	(497)	(560)	(424)
Financing activities
Proceeds from issuance of debt, net	3,491	0	0
Debt repayments	(10)	0	0
Dividends paid	(105)	0	0
Debt issuance costs	(79)	0	0
Cash provided at separation by DuPont	247	0	0
Net transfers (to) from DuPont	(2,857)	55	(374)
Cash provided by (used for) financing activities	687	55	(374)
Effect of exchange rate changes on cash	(6)	0	0
Increase in cash	366	0	0
Cash at beginning of year	0	0
Cash at end of year	366	0	0
Cash paid during the year for:
Interest, net of amounts capitalized	103	0	0
Income taxes, net of refunds	53	0	0
Non-cash change in property, plant and equipment included in accounts payable	$ 45	$ (11)	$ 0

Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Statement of Cash Flows [Abstract]
Dividends received	$ 23	$ 19	$ 19

Background and Description of the Business	12 Months Ended
Background and Description of the Business	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Background and Description of the Business	Background and Description of the Business The Chemours Company (Chemours or the Company) delivers customized solutions with a wide range of industrial and specialty chemical products for markets including plastics and coatings, refrigeration and air conditioning, general industrial, mining and oil refining. Principal products include titanium dioxide (TiO₂), refrigerants, industrial fluoropolymer resins, sodium cyanide, sulfuric acid and aniline. Chemours consists of three reportable segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. Chemours is globally operated with manufacturing facilities, sales centers, administrative offices and warehouses located throughout the world. Chemours' operations are primarily located in the United States (U.S.), Canada, Mexico, Brazil, the Netherlands, Belgium, China, Taiwan, Japan, Switzerland, Singapore, Hong Kong, India, the United Kingdom, and France. As of December 31, 2015, Chemours consists of 35 production facilities globally, five dedicated to Titanium Technologies, 16 dedicated to Fluoroproducts, 13 dedicated to Chemical Solutions and one that supports multiple Chemours segments. Effective prior to the opening of trading on the New York Stock Exchange (NYSE) on July 1, 2015 (the Distribution Date), E. I. du Pont de Nemours and Company (DuPont) completed the previously announced separation of the businesses comprising DuPont’s Performance Chemicals reporting segment, and certain other assets and liabilities, into Chemours, a separate and distinct public company. The separation was completed by way of a distribution of all of the then-outstanding shares of common stock of Chemours through a dividend in kind of Chemours’ common stock (par value $0.01) to holders of DuPont common stock (par value $0.30) as of the close of business on June 23, 2015 (the Record Date) (the transaction referred to herein as the Distribution). On the Distribution Date, each holder of DuPont's common stock received one share of Chemours' common stock for every five shares of DuPont's common stock held on the Record Date. The spin-off was completed pursuant to a separation agreement and other agreements with DuPont related to the spin-off, including an employee matters agreement, a tax matters agreement, a transition services agreement and an intellectual property cross-license agreement. These agreements govern the relationship between Chemours and DuPont following the spin-off and provided for the allocation of various assets, liabilities, rights and obligations. These agreements also include arrangements for transition services to be provided by DuPont to Chemours. Unless the context otherwise requires, references in these Notes to the Consolidated Financial Statements to "we," "us," "our," "Chemours" and the "Company" refer to The Chemours Company and its consolidated subsidiaries after giving effect to the Distribution. Basis of Presentation The accompanying Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the U.S. (GAAP). In the opinion of management, all adjustments considered necessary for a fair statement of the results have been included. Certain reclassifications of prior year's data have been made to conform to the current presentation, primarily relating to the adoption of Accounting Standards Update (ASU) No. 2015-17, "Income Taxes (Topic 740) - Balance Sheet Classification of Deferred Taxes" (see recent accounting pronouncements in Note 3 for further information). Unless otherwise stated, references to years relate to Chemours' fiscal years. The notes that follow are an integral part of the Consolidated Financial Statements. Chemours did not operate as a separate, stand-alone entity for the full period covered by Consolidated Financial Statements. Prior to our spin-off on July 1, 2015, Chemours operations were included in DuPont's financial results in different legal forms, including but not limited to wholly-owned subsidiaries for which Chemours was the sole business, components of legal entities in which Chemours operated in conjunction with other DuPont businesses and a majority owned joint venture. For periods prior to July 1, 2015, the accompanying Consolidated Financial Statements have been prepared from DuPont’s historical accounting records and are presented on a stand-alone basis as if the business operations had been conducted independently from DuPont. Prior to January 1, 2015, aside from a Japanese entity that is a dual-resident for U.S. federal income tax purposes, there was no direct ownership relationship among all the other various legal entities comprising Chemours. Prior to July 1, 2015, DuPont and its subsidiaries’ net investments in these operations is shown in lieu of Stockholder’s Equity in the Consolidated Financial Statements. The Consolidated Financial Statements include the historical operations, assets and liabilities of the legal entities that are considered to comprise the Chemours business, including certain environmental remediation and litigation obligations of DuPont and its subsidiaries that Chemours may be required to indemnify pursuant to the separation-related agreements executed prior to the spin-off. All of the allocations and estimates in the Consolidated Financial Statements prior to July 1, 2015 are based on assumptions that management believes are reasonable. However, the Consolidated Financial Statements included herein may not be indicative of the financial position, results of operations and cash flows of Chemours in the future or if Chemours had been a separate, stand-alone entity during the periods presented. The net transfers from DuPont on the Consolidated Statements of Stockholder's Equity include a non-cash contribution from DuPont of $109 for the year ended December 31, 2015. This non-cash contribution occurred during physical separation activities at shared production facilities in the U.S. prior to the spin-off and certain assets identified at separation. It was determined that assets previously managed by other DuPont businesses would be transferred to and managed by Chemours.

Basis of Presentation	12 Months Ended
Basis of Presentation	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Background and Description of the Business The Chemours Company (Chemours or the Company) delivers customized solutions with a wide range of industrial and specialty chemical products for markets including plastics and coatings, refrigeration and air conditioning, general industrial, mining and oil refining. Principal products include titanium dioxide (TiO₂), refrigerants, industrial fluoropolymer resins, sodium cyanide, sulfuric acid and aniline. Chemours consists of three reportable segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. Chemours is globally operated with manufacturing facilities, sales centers, administrative offices and warehouses located throughout the world. Chemours' operations are primarily located in the United States (U.S.), Canada, Mexico, Brazil, the Netherlands, Belgium, China, Taiwan, Japan, Switzerland, Singapore, Hong Kong, India, the United Kingdom, and France. As of December 31, 2015, Chemours consists of 35 production facilities globally, five dedicated to Titanium Technologies, 16 dedicated to Fluoroproducts, 13 dedicated to Chemical Solutions and one that supports multiple Chemours segments. Effective prior to the opening of trading on the New York Stock Exchange (NYSE) on July 1, 2015 (the Distribution Date), E. I. du Pont de Nemours and Company (DuPont) completed the previously announced separation of the businesses comprising DuPont’s Performance Chemicals reporting segment, and certain other assets and liabilities, into Chemours, a separate and distinct public company. The separation was completed by way of a distribution of all of the then-outstanding shares of common stock of Chemours through a dividend in kind of Chemours’ common stock (par value $0.01) to holders of DuPont common stock (par value $0.30) as of the close of business on June 23, 2015 (the Record Date) (the transaction referred to herein as the Distribution). On the Distribution Date, each holder of DuPont's common stock received one share of Chemours' common stock for every five shares of DuPont's common stock held on the Record Date. The spin-off was completed pursuant to a separation agreement and other agreements with DuPont related to the spin-off, including an employee matters agreement, a tax matters agreement, a transition services agreement and an intellectual property cross-license agreement. These agreements govern the relationship between Chemours and DuPont following the spin-off and provided for the allocation of various assets, liabilities, rights and obligations. These agreements also include arrangements for transition services to be provided by DuPont to Chemours. Unless the context otherwise requires, references in these Notes to the Consolidated Financial Statements to "we," "us," "our," "Chemours" and the "Company" refer to The Chemours Company and its consolidated subsidiaries after giving effect to the Distribution. Basis of Presentation The accompanying Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the U.S. (GAAP). In the opinion of management, all adjustments considered necessary for a fair statement of the results have been included. Certain reclassifications of prior year's data have been made to conform to the current presentation, primarily relating to the adoption of Accounting Standards Update (ASU) No. 2015-17, "Income Taxes (Topic 740) - Balance Sheet Classification of Deferred Taxes" (see recent accounting pronouncements in Note 3 for further information). Unless otherwise stated, references to years relate to Chemours' fiscal years. The notes that follow are an integral part of the Consolidated Financial Statements. Chemours did not operate as a separate, stand-alone entity for the full period covered by Consolidated Financial Statements. Prior to our spin-off on July 1, 2015, Chemours operations were included in DuPont's financial results in different legal forms, including but not limited to wholly-owned subsidiaries for which Chemours was the sole business, components of legal entities in which Chemours operated in conjunction with other DuPont businesses and a majority owned joint venture. For periods prior to July 1, 2015, the accompanying Consolidated Financial Statements have been prepared from DuPont’s historical accounting records and are presented on a stand-alone basis as if the business operations had been conducted independently from DuPont. Prior to January 1, 2015, aside from a Japanese entity that is a dual-resident for U.S. federal income tax purposes, there was no direct ownership relationship among all the other various legal entities comprising Chemours. Prior to July 1, 2015, DuPont and its subsidiaries’ net investments in these operations is shown in lieu of Stockholder’s Equity in the Consolidated Financial Statements. The Consolidated Financial Statements include the historical operations, assets and liabilities of the legal entities that are considered to comprise the Chemours business, including certain environmental remediation and litigation obligations of DuPont and its subsidiaries that Chemours may be required to indemnify pursuant to the separation-related agreements executed prior to the spin-off. All of the allocations and estimates in the Consolidated Financial Statements prior to July 1, 2015 are based on assumptions that management believes are reasonable. However, the Consolidated Financial Statements included herein may not be indicative of the financial position, results of operations and cash flows of Chemours in the future or if Chemours had been a separate, stand-alone entity during the periods presented. The net transfers from DuPont on the Consolidated Statements of Stockholder's Equity include a non-cash contribution from DuPont of $109 for the year ended December 31, 2015. This non-cash contribution occurred during physical separation activities at shared production facilities in the U.S. prior to the spin-off and certain assets identified at separation. It was determined that assets previously managed by other DuPont businesses would be transferred to and managed by Chemours.

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Dec. 31, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies These Consolidated Financial Statements have been prepared in accordance with GAAP. The significant accounting policies described below, together with the other notes that follow, are an integral part of the Consolidated Financial Statements. Preparation of Financial Statements The preparation of the Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of revenues and expenses, including allocations of costs as discussed above, during the reporting period. Management’s estimates are based on historical experience, facts and circumstances available at the time and various other assumptions that we believe are reasonable. Actual results could differ from those estimates. Principles of Consolidation and Combination The Consolidated Financial Statements include the accounts Chemours and its subsidiaries, and entities in which a controlling interest is maintained. For those consolidated subsidiaries in which the Company's ownership is less than 100%, the outside shareholders' interests are shown as noncontrolling interests. Investments in companies in which Chemours, directly or indirectly, owns 20% to 50% of the voting stock and has the ability to exercise significant influence over operating and financial policies of the investee are accounting for using the equity method of accounting. As a result, Chemours' share of the earnings or losses of such equity affiliates is included in the accompanying Consolidated Statements of Operations and our share of these companies' stockholders' equity is included in the accompanying Consolidated Balance Sheets. The financial statements for the periods prior to our spin-off on July 1, 2015 include the combined assets, liabilities, revenues, and expenses of Chemours. We eliminated all intercompany accounts and transactions in the preparation of the accompanying Consolidated and Combined Financial Statements. Revenue Recognition Revenue is recognized when the earnings process is complete. Revenue for product sales is recognized when products are shipped to the customer in accordance with the terms of the agreement, when title and risk of loss have been transferred, collectability is reasonably assured and pricing is fixed or determinable. Revenue associated with advance payments are recorded as deferred revenue and are recognized as shipments are made and title, ownership and risk of loss pass to the customer. Accruals are made for sales returns and other allowances based on historical experience. Cash sales incentives are accounted for as a reduction in sales and noncash sales incentives are recorded as a charge to cost of goods sold at the time the revenue or selling expense, depending on the nature of the incentive, is recorded. Amounts billed to customers for shipping and handling fees are included in net sales and costs incurred by Chemours for the delivery of goods are classified as cost of goods sold in the Consolidated Statements of Operations. Taxes on revenue-producing transactions are excluded from net sales. Licensing and royalty income is recognized in accordance with agreed upon terms, when performance obligations are satisfied, the amount is fixed or determinable and collectability is reasonably assured. Cash and Cash Equivalents Cash and cash equivalents generally include cash, time deposits or highly liquid investments with original maturities of three months or less. Prior to the spin-off, Chemours participated in DuPont’s centralized cash management and financing programs (see Note 4 for additional information). Receivables and Allowance for Doubtful Accounts Receivables are recognized net of an allowance for doubtful accounts. The allowance for doubtful accounts reflects the best estimate of losses inherent in Chemours’ accounts receivable portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other available evidence. Accounts receivable are written off when management determines that they are uncollectible. Inventories Chemours’ inventories are valued at the lower of cost or market. Inventories held at substantially all U.S. locations are valued using the last-in, first-out (LIFO) method. Inventories held outside the U.S. are determined by the average cost method. Elements of cost in inventories include raw materials, direct labor, and manufacturing overhead. Stores and supplies are valued at cost or market, whichever is lower; cost is generally determined by the average cost method. Approximately 61% and 52% of inventory is on a LIFO basis as of December 31, 2015 and 2014, respectively. The remainder is accounted for using the average cost method. Property, Plant and Equipment Property, plant and equipment is carried at cost and is depreciated using the straight-line method. Property, plant and equipment placed in service prior to 1995 is depreciated under the sum-of-the-years’ digits method or other substantially similar methods. Substantially all equipment and buildings are depreciated over useful lives ranging from 15 to 25 years. Capitalizable costs associated with computer software for internal use are amortized on a straight-line basis over five to seven years. When assets are surrendered, retired, sold or otherwise disposed of, their gross carrying values and related accumulated depreciation are removed from the balance sheet and included in determining gain or loss on such disposals. Repair and maintenance costs that materially add to the value of the asset or prolong its useful life are capitalized and depreciated based on the extension to the useful life. Capitalized repair and maintenance costs are recorded on the Consolidated Balance Sheets in other assets. Direct Financing Type Leases Certain of Chemours’ facilities are located on land owned by third parties. The plant and equipment built on this land is constructed by, owned, and operated by Chemours for the exclusive benefit of the third party landlord. The useful lives of the equipment are generally shorter than the lease term, or there exists a purchase option for the third party to acquire the equipment at the end of the lease term. Based on an analysis of the underlying agreements, management has determined that these agreements and property represent a direct financing type lease, whereby Chemours is the lessor of its equipment to the third party landlords. As such, the related plant and equipment are reported as leases receivable. The current portion is included in accounts and notes receivable - trade, net (see Note 10) and the non-current portion is included in other assets (see Note 14) in the Consolidated Balance Sheets. The equipment has zero net book value within property, plant and equipment. Goodwill and Other Intangible Assets The excess of the purchase price over the estimated fair value of the net assets acquired, including identified intangibles, is recorded as goodwill. Goodwill is tested for impairment annually on October 1; however, these tests are performed more frequently when events or changes in circumstances indicate that the asset may be impaired. Impairment exists when carrying value exceeds fair value. Goodwill is evaluated for impairment at the reporting unit level. Evaluating goodwill for impairment is a two-step process. In the first step, Chemours compares the carrying value of net assets to the fair value of the related operations. Chemours’ methodology for estimating the fair value of its reporting units is using the income approach based on the present value of future cash flows. The factors considered in determining the cash flows include: 1) macroeconomic conditions; 2) industry and market considerations; 3) costs of raw materials, labor or other costs having a negative effect on earnings and cash flows; 4) overall financial performance; and 5) other relevant entity-specific events. If the fair value is determined to be less than the carrying value, a second step is performed to compute the amount of the impairment. Definite-lived intangible assets, such as purchased and licensed technology, patents, trademarks, and customer lists are amortized over their estimated useful lives, generally for periods ranging from five to 20 years. The reasonableness of the useful lives of these assets is continually evaluated. Impairment of Long-Lived Assets Chemours evaluates the carrying value of long-lived assets to be held and used when events or changes in circumstances indicate the carrying value may not be recoverable. For purposes of recognition or measurement of an impairment loss, the assessment is performed on the asset or asset group at the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. To determine the level at which the assessment is performed, Chemours considers factors such as revenue dependency, shared costs and the extent of vertical integration. The carrying value of a long-lived asset is considered impaired when the total projected undiscounted cash flows from the use and eventual disposition of an asset or asset group are separately identifiable and are less than its carrying value. In that event, a loss is recognized based on the amount by which the carrying value exceeds the fair value of the long-lived asset. The fair value methodology used is an estimate of fair market value which is made based on prices of similar assets or other valuation methodologies including present value techniques. Long-lived assets to be disposed of other than by sale are classified as held for use until their disposal. Long-lived assets to be disposed of by sale are classified as held for sale and are reported at the lower of carrying amount or fair market value less cost to sell. Depreciation is discontinued for long-lived assets classified as held for sale. Research and Development Research and development costs are expensed as incurred. Research and development expenses include costs (primarily consisting of employee costs, materials, contract services, research agreements, and other external spend) relating to the discovery and development of new products, enhancement of existing products and regulatory approval of new and existing products. Environmental Liabilities and Expenditures Chemours accrues for remediation activities when it is probable that a liability has been incurred and a reasonable estimate of the liability can be made. Environmental liabilities and expenditures included in the Consolidated Financial Statements include claims for matters that are liabilities of DuPont and its subsidiaries, that Chemours may be required to indemnify pursuant to the separation-related agreements executed prior to the spin-off. Accruals for environmental matters are recorded in cost of goods sold when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. Accrued liabilities do not include claims against third parties and are not discounted. Costs related to environmental remediation are charged to expense in the period incurred. Other environmental costs are also charged to expense in the period incurred, unless they increase the value of the property or reduce or prevent contamination from future operations, in which case they are capitalized and amortized. Asset Retirement Obligations Chemours records asset retirement obligations at fair value at the time the liability is incurred. Fair value is measured using expected future cash outflows discounted at Chemours’ credit-adjusted risk-free interest rate, which are considered level 3 inputs. Accretion expense is recognized as an operating expense classified within cost of goods sold on the Consolidated Income Statements using the credit-adjusted risk-free interest rate in effect when the liability was recognized. The associated asset retirement obligations are capitalized as part of the carrying amount of the long-lived asset and depreciated over the estimated remaining useful life of the asset, generally for periods ranging from two to 25 years. Litigation Chemours accrues for litigation matters when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. Litigation liabilities and expenditures included in the Consolidated Financial Statements represent litigation matters that are liabilities of DuPont and its subsidiaries, that Chemours may be required to indemnify pursuant to the separation-related agreements executed prior to the spin-off. Legal costs such as outside counsel fees and expenses are charged to expense in the period services are received. Insurance Chemours insures certain risks where permitted by law or regulation, including workers' compensation, vehicle liability and employee related benefits. Liabilities associated with these risks are estimated in part by considering historical claims experience, demographic factors and other actuarial assumptions. For other risks, the Company uses a combination of insurance and self-insurance, reflecting comprehensive reviews of relevant risks. A receivable for an insurance recovery is generally recognized when the loss has occurred and collection is considered probable. Prior to the spin-off, Chemours was a participant in DuPont’s self-insurance program where permitted by law or regulation, including workers’ compensation, vehicle liability and employee related benefits. Liabilities associated with these risks are estimated in part by considering historical claims experience, demographic factors, and other actuarial assumptions. For other risks, a combination of insurance and self-insurance is used, reflecting comprehensive reviews of relevant risks. The annual cost was allocated to all of the participating businesses using methodologies deemed reasonable by management. All obligations pursuant to these plans have historically been obligations of DuPont. As such, these obligations were not included in the Consolidated Balance Sheets, with the exception of self-insurance liabilities related to workers compensation, vehicle liability and employee related benefits. Defined Benefit Plans We have defined benefit plans covering certain of our employees outside the U.S., which are generally required by local regulations. The benefits, which primarily relate to pension, are accrued over the employees’ service periods. We use actuarial methods and assumptions in the valuation of defined benefit obligations and the determination of net periodic pension income or expense. Differences between actual and expected results or changes in the value of defined benefit obligations and plan assets, if any, are not recognized in earnings as they occur but rather systematically over subsequent periods. Stock-based Compensation Chemours' stock-based compensation consists of stock options and restricted stock units (RSUs) to employees and non-employee directors. Stock options are measured at fair value on the grant date or date of modification, as applicable. We recognize compensation expense on a straight-line basis over the requisite service period. The number of awards ultimately expected to vest is determined by use of an estimated forfeiture rate. The estimated forfeiture rate is based on historical data for the employee group awarded options and expected employee turnover rates, which management reevaluates each period. Income Taxes The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax basis of Chemours’ assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. Chemours recognizes income tax positions that meet the more likely than not threshold and accrues interest related to unrecognized income tax positions, which is included in other income, net in our Consolidated Statements of Operations. Income tax related penalties are included in the provision for income taxes. Chemours does not provide for income taxes on undistributed earnings of all foreign subsidiaries that are intended to be indefinitely reinvested. Prior to separation on July 1, 2015, income taxes presented attributed current and deferred income taxes of DuPont to Chemours’ stand-alone financial statements in a manner that is systematic, rational, and consistent with the asset and liability method prescribed by ASC 740, Income Taxes (ASC 740). Accordingly, Chemours’ income tax provision was prepared following the separate return method. The separate return method applies ASC 740 to the stand-alone financial statements of each member of the consolidated group as if the group member were a separate taxpayer and a stand-alone enterprise. Foreign Currency Translation Chemours identifies its separate and distinct foreign entities and groups them into two categories: (1) extensions of the parent (U.S. dollar functional currency) and (2) self-contained (local functional currency). If a foreign entity does not align with either category, factors are evaluated and a judgment is made to determine the functional currency. Chemours changes the functional currency of its separate and distinct foreign entities only when significant changes in economic facts and circumstances indicate clearly that the functional currency has changed. During the periods covered by the Consolidated Financial Statements, part of the Chemours business operated within foreign entities. For foreign entities where the U.S. dollar is the functional currency, all foreign currency-denominated asset and liability amounts are remeasured into U.S. dollars at end-of-period exchange rates, except for inventories; prepaid expenses; property, plant and equipment; goodwill and other intangible assets, which are remeasured at historical rates. Foreign currency-denominated income and expenses are remeasured at average exchange rates in effect during the period, except for expenses related to balance sheet amounts remeasured at historical exchange rates. Exchange gains and losses arising from remeasurement of foreign currency-denominated monetary assets and liabilities are included in other income, net in the period in which they occur. For foreign entities where the local currency is the functional currency, assets and liabilities denominated in local currencies are translated into U.S. dollars at end-of-period exchange rates and the resulting translation adjustments are reported as a component of accumulated other comprehensive (loss) income in equity. Assets and liabilities denominated in other than the functional currency are remeasured into the functional currency prior to translation into U.S. dollars and the resulting exchange gains or losses are included in income in the period in which they occur. Income and expenses are translated into U.S. dollars at average exchange rates in effect during the period. Beginning in 2015, when the Chemours operations were legally and operationally separated within DuPont in anticipation of the spin-off, certain of Chemours foreign entities set their local currency as the functional currency. Derivatives Chemours enters into forward currency exchange contracts to minimize volatility in earnings related to the foreign exchange gains and losses resulting from remeasuring net monetary assets that Chemours holds which are denominated in non-functional currencies. Chemours does not hold or issue financial instruments for speculative or trading purposes. The derivative assets and liabilities are reported on a gross basis in the Consolidated Balance Sheets. All gains and losses resulting from the revaluation of the derivative assets and liabilities are recognized in other income, net in the Consolidated Statements of Operations during the period in which they occurred. Please refer to Note 20 for additional information. Fair Value Measurement Under the accounting for fair value measurements and disclosures, a fair value hierarchy was established that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Chemours uses the following valuation techniques to measure fair value for its assets and liabilities: (a) Level 1—Quoted market prices in active markets for identical assets and liabilities; (b) Level 2—Significant other observable inputs (e.g. quoted prices for similar items in active markets, quoted prices for identical or similar items in markets that are not active, inputs other than quoted prices that are observable, such as interest rate and yield curves, and market-corroborated inputs); and (c) Level 3—Unobservable inputs for the asset or liability, which are valued based on management's estimates of assumptions that market participants would use in pricing the asset or liability. Recent Accounting Pronouncements In November 2015, the Financial Accounting Standards Board (FASB) issued ASU No. 2015-17, "Income Taxes (Topic 740) - Balance Sheet Classification of Deferred Taxes", to simplify the presentation of deferred income taxes and require that deferred income tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments are effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods, and earlier application is permitted for all entities as of the beginning of an interim or annual reporting period. The Company retroactively adopted this change effective in 2015 and as such the 2014 Consolidated Balance Sheet reflects the reclassifications affecting total current assets, total assets, total current liabilities and total liabilities . The reclassifications did not have a significant impact on Chemours' financial position and had no impact on its results of operations or cash flows. See Note 8 for additional information. In June 2015, the FASB issued ASU No. 2015-11, "Inventory (Topic 330), Simplifying the Measurement of Inventory," which requires an entity to measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Currently, the inventory standard requires an entity to measure inventory at the lower of cost or market. Market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. The amendment does not apply to inventory that is measured using LIFO or the retail inventory method but applies to all other inventory, which includes inventory that is measured using first-in, first-out (FIFO) or average cost. The amendment is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, and should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. Chemours is currently evaluating the impact of adopting this guidance. In May 2015, the FASB issued ASU No. 2015-07, "Fair Value Measurement (Topic 820) - Disclosures for Investment in Certain Entities that Calculate Net Asset Value per Share or its Equivalent." This guidance removes the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value per share practical expedient. The guidance also removes the requirement to make certain disclosures for all investments that are eligible to be measured at fair value using the net asset value per share practical expedient. Rather, those disclosures are limited to investments for which the entity has elected to measure the fair value using that practical expedient. The amendment is effective for fiscal years beginning after December 15, 2015 and interim periods within those fiscal years. A reporting entity should apply the amendments retrospectively to all periods presented and earlier application is permitted. Chemours adopted this guidance effective January 1, 2016. The adoption is not expected to have a significant impact on our financial position and results of operations. In April 2015, the FASB issued ASU No. 2015-05, "Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement," which provides guidance about whether a cloud computing arrangement includes a software license. The customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If the cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. This guidance is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2015, and early adoption is permitted. Chemours adopted this guidance effective January 1, 2016. The adoption is not expected to have a significant impact on our financial position and results of operations. In April 2015, the FASB issued ASU No. 2015-03, “Interest — Imputation of Interest (Subtopic 835-30),” which requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The guidance is effective for public entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015 with early adoption permitted, including adoption in an interim period. Chemours adopted this guidance for the quarter ending June 30, 2015. The adoption of this standard had no impact on Chemours’ results of operations or cash flows. Due to the accounting change described above, Chemours recorded debt issuance costs incurred for the issuance of its senior secured term loans and senior unsecured notes as a reduction of the liability on the Consolidated Balance Sheets. See Note 18 for additional information. In February 2015, the FASB issued ASU No. 2015-02, “Consolidation (Topic 810): Amendments to the Consolidation Analysis.” The amendments modify the evaluation of whether limited partnerships and similar legal entities are variable interest entities (VIEs) or voting interest entities and eliminate the presumption that a general partner should consolidate a limited partnership. The amendment is effective for public entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. Chemours adopted this guidance effective January 1, 2016. The adoption is not expected to have a significant impact on our financial position and results of operations. In May 2014, the FASB and the International Accounting Standards Board (IASB) jointly issued ASU No. 2014-09, "Revenue from Contracts with Customers (Topic 606)," which clarifies the principles for recognizing revenue and develops a common revenue standard for GAAP and International Financial Reporting Standards (IFRS). The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The guidance is effective for public entities for annual and interim periods beginning after December 15, 2016 (original effective date). In July 2015, the FASB approved a deferral of the effective date of this guidance to provide entities with adequate time to effectively implement the new revenue standard and adoption as of the original effective date is permitted. The Company is currently evaluating the impact of adopting this guidance on its financial position and results of operations. In April 2014, the FASB issued ASU No. 2014-08, “Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity,” amending existing requirements for reporting discontinued operations and disposals of components of an entity. The amended guidance limits the discontinued operations reporting to disposal transactions that represent strategic shifts having a major effect on operations and financial results. The amendment also enhances disclosures and requires assets and liabilities of a discontinued operation to be classified as such for all periods presented in the financial statements. Chemours adopted this guidance effective on January 1, 2015. Due to the change in requirements for reporting discontinued operations described above, presentation and disclosures of future disposal transactions after adoption may be different than under current standards.

Relationship with DuPont and Related Entities

12 Months Ended

Dec. 31, 2015

Relationship with DuPont and Related Entities

Prior to the spin-off, Chemours was managed and operated in the normal course of business with other affiliates of DuPont. Accordingly, certain shared costs were allocated to Chemours and reflected as expenses in the stand-alone Consolidated Financial Statements. Management of DuPont and Chemours considered the allocation methodologies used to be reasonable and appropriate reflections of the historical DuPont expenses attributable to Chemours for purposes of the stand-alone financial statements. The expenses reflected in the Consolidated Financial Statements may not be indicative of expenses that will be incurred by Chemours in the future.

Subsequent to July 1, 2015, DuPont was no longer a related party of Chemours. Chemours' ongoing relationship with DuPont is governed by a separation agreement and other agreements with DuPont related to the spin-off, including an employee matters agreement, a tax matters agreement, a transition services agreement and an intellectual property cross-license agreement. These agreements provided for the allocation of various assets, liabilities, rights and obligations, and include arrangements for transition services to be provided by DuPont to Chemours.

(a) Related Party Sales

Prior to the spin-off, including certain periods covered by the Consolidated Financial Statements, Chemours sold finished goods to DuPont and its non-Chemours businesses.

Related party sales to DuPont include the following amounts:



Selling Segment	Year Ended December 31,
Selling Segment	2015			2014		2013
Titanium Technologies	$	2	¹	$	—	$	6
Fluoroproducts	34		¹	45		37
Chemical Solutions	21		¹	65		78
Total	$	57		$	110	$	121

¹ Subsequent to the spin-off on July 1, 2015, transactions with DuPont businesses were not considered related party transactions.

(b) Leveraged Services and Corporate Costs

Prior to the spin-off on July 1, 2015, DuPont incurred significant corporate costs for services provided to Chemours as well as other DuPont businesses. These costs included expenses for information systems, accounting, other financial services such as treasury and audit, purchasing, human resources, legal, facilities, engineering, corporate research and development, corporate stewardship, marketing and business analysis support.

A portion of these costs benefited multiple or all DuPont businesses, including Chemours, and were allocated to Chemours and its reportable segments using methods based on proportionate formulas involving total costs or other various allocation methods that management considered consistent and reasonable. Other Chemours corporate costs are not allocated to the reportable segments and are reported in Corporate and Other.

The allocated leveraged functional service expenses and general corporate expenses included in the Consolidated Statements of Operations were $238 (through June 30, 2015), $492 and $519 for the years ended December 31, 2015, 2014 and 2013, respectively. Allocated leveraged functional service expenses and general corporate expenses were recorded in the Consolidated Statements of Operations within the following captions:



	Year Ended December 31,
	2015			2014		2013
Selling, general and administrative expense	$	205	¹	$	411	$	436
Research and development expense	10		¹	49		50
Cost of goods sold	23		¹	32		33
Total	$	238		$	492	$	519

¹Subsequent to the spin-off on July 1, 2015, transactions with DuPont businesses were not considered related party transactions. Accordingly, no costs were allocated after the July 1, 2015 spin-off date.

For a portion of the periods presented, Chemours participated in DuPont’s centralized cash management and financing programs. Disbursements were made through centralized accounts payable systems which were operated by DuPont. Cash receipts were transferred to centralized accounts, also maintained by DuPont. As cash was disbursed and received by DuPont, it was accounted for by Chemours through DuPont Company Net Investment.

The separation agreements set forth a process to true-up cash and working capital transferred to us from DuPont at separation. In January 2016, Chemours and DuPont entered into an agreement, contingent upon the credit agreement amendment (described in Note 18), which provided for the extinguishment of payment obligations of cash and working capital true-ups previously contemplated in the separation agreements. As a result, Chemours was not required to make any payments to DuPont, nor did DuPont make any payments to Chemours. In addition, the agreement set forth an advance payment of approximately $190, which was paid to Chemours in February 2016, for certain specified goods and services that Chemours expects to provide to DuPont over the next twelve to fifteen months under existing agreements with Chemours.

(d) Tax Matters Agreement

Chemours and DuPont entered into a tax matters agreement that governs the parties’ respective rights, responsibilities and obligations with respect to tax liabilities and benefits, tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings and other matters regarding taxes. In general, under the agreement, DuPont is responsible for any U.S. federal, state and local taxes (and any related interest, penalties or audit adjustments) reportable on a consolidated, combined or unitary return that includes DuPont or any of its subsidiaries and Chemours and/or any of its subsidiaries for any periods or portions thereof ending on or prior to the date of the Separation and Chemours is responsible for any U.S. federal, state, local and foreign taxes (and any related interest, penalties or audit adjustments) that are imposed on Chemours and/or any of its subsidiaries for all tax periods, whether before or after the date of the distribution.

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

Research and Development Expense	12 Months Ended
Research and Development Expense	Dec. 31, 2015
Research and Development [Abstract]
Research and Development Expense	Research and Development Expense Research and development expense directly incurred by Chemours was $87, $94 and $114 for the years ended December 31, 2015, 2014 and 2013, respectively. Research and development expense also includes $10, $49 and $50 for the years ended December 31, 2015, 2014 and 2013, respectively, which represents an assignment of costs associated primarily with DuPont’s Corporate Central Research and Development long-term research activities. This assignment was based on the cost of research projects for which Chemours was determined to be the sponsor or co-sponsor. All research services provided by DuPont’s Central Research and Development to Chemours were specifically requested by Chemours, covered by service-level agreements and billed based on usage. DuPont research and development services were no longer used after the separation on July 1, 2015.

The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.

Restructuring and Related Activities [Abstract]

Employee Separation and Asset Related Charges, Net

12 Months Ended

Dec. 31, 2015

Employee Separation and Asset Related Charges, Net

For the years ended December 31, 2015, 2014 and 2013, Chemours recorded charges for employee separation and asset related charges as follows:



	Year Ended December 31,
	2015		2014		2013
Employee Separation Charges	$	137	$	18	$	2
Asset Related Charges - Restructuring	133		3		—
Asset Related Charges - Impairment ¹	48		—		—
Decommissioning and other charges - Restructuring	15		—		—
Total	$	333	$	21	$	2

¹ See Note 12 for further information.

Transformation Plan

During the third quarter of 2015, Chemours announced a plan to transform the Company by reducing structural costs, growing market positions, optimizing its portfolio, refocusing investments, and enhancing its organization (the "Transformation Plan"). Through a combination of higher free cash flow from operations, lower capital spending, and potential proceeds from asset sales, the Company anticipates reducing its leverage ratio (net debt to Adjusted EBITDA (see Note 23 for definition)). Key actions initiated under the Transformation Plan since the separation included Titanium Technologies plant and production line closures, Fluoroproduct line closures, Reactive Metals Solutions (RMS) plant closure and other cost reduction initiatives including global workforce reduction.

Titanium Technologies Plant Closures: In August 2015, the Company announced the closure of its Edge Moor, Delaware manufacturing site located in the U.S. The Edge Moor plant produced TiO₂ product for use in the paper industry and other applications where demand has steadily declined, resulting in underused capacity at the plant. In addition, the Company permanently shut down one underused TiO₂production line at its New Johnsonville, Tennessee plant. The Company stopped production at Edge Moor in September 2015 and immediately began decommissioning the plant. The Company expects to complete decommissioning activities in first quarter of 2016 and will begin dismantling thereafter. Dismantling and removal activities are expected to be completed in early 2017.

As a result, the Company recorded charges of approximately $140, which consisted of employee separation costs of $11, property, plant and equipment and other asset impairment charges of $115, and decommission costs and other charges of $14. The Company also expects to incur additional charges of approximately $50 for decommissioning, dismantling and removal costs through early 2017, which will be expensed as incurred.

Fluoroproducts Restructuring: Also, in August 2015, in an effort to improve the profitability of the Fluoroproducts segment, management approved the shutdown of certain production lines of the segment’s manufacturing facilities in the U.S. As a result, the Company recorded restructuring charges of approximately $21, which consist of property, plant and equipment accelerated depreciation of $18, employee separation costs of $2, and decommissioning and other costs of $1. The Company expects to incur additional charges of approximately $5 for decommissioning, dismantling and removal costs during 2016, which will be expensed as incurred.

RMS Closure: Also during the fourth quarter of 2015, the Company announced the completion of the strategic review of its RMS business and the decision to stop production at the Niagara Falls, New York site by the end of December 2016. The Niagara Falls plant has approximately 200 employees and contractors that will be impacted by this action. In the fourth quarter of 2015, the Company recorded approximately $12 of employee separation costs. Additional restructuring charges of approximately $15 for contract termination, decommissioning and site redevelopment are expected to be incurred in 2016 through 2018. Impairment of RMS related assets were recorded in the third quarter of 2015 (see Note 12 for further information).

Global Restructuring Programs

In November 2015, Chemours announced an additional global workforce reduction of approximately 430 positions. This action is part of ongoing efforts to streamline and simplify the structure of the organization worldwide and to reduce costs. As a result of these actions, the Company recorded approximately $48 of employee separation costs during the fourth quarter of 2015. The headcount reduction is expected to be completed in 2016 and related payments are expected to be substantially complete in 2017.

In June 2015, in light of continued weakness in the global titanium dioxide market cycle and continued foreign currency impacts due to the strengthening of the U.S. dollar, Chemours implemented a restructuring plan to reduce and simplify its cost structure. This plan resulted in a global workforce reduction of more than 430 positions. As a result, we recorded a pre-tax charge of $64 for employee separation costs in the year ended December 31, 2015. The actions associated with this charge and all related payments are expected to be substantially complete by the end of 2016.

In 2014, Chemours implemented a restructuring plan to increase productivity and recorded a pre-tax charge of $19 related to this initiative. The charge consisted of $16 related to employee separation costs and $3 for asset shut-down costs. The actions associated with this charge and all related payments are substantially complete as of December 31, 2015.

The charges related to our programs and impairments impacted segment earnings for the years ended December 31, 2015 and 2014 as follows:



	Titanium Technologies		Fluoroproducts		Chemical Solutions		Total
Year ended December 31, 2015
Titanium Technologies plant closures	$	140	$	—	$	—	$	140
Fluoroproducts restructuring and other asset impairment	—		24		—		24
RMS plant closure	—		—		57		57
2015 Restructuring	33		54		25		112		¹
	$	173	$	78	$	82	$	333
Year ended December 31, 2014
2014 Restructuring	$	3	$	16	$	—	$	19

¹ Includes approximately $24 related to corporate overhead functions that was allocated to our segments.

The following table shows the change in our significant liability account balances.



	Titanium Technologies Site Closures		Chemical Solutions Site Closures		2015 Restructuring			2014 Restructuring			Total
Balance as of December 31, 2013	$	—	$	—	$	—		$	—		$	—
Charges to income for the year ended December 31, 2014	—		—		—			16			16
Charges to liability accounts:
Payments	—		—		—			(2		)	(2		)
Net currency translation adjustment	—		—		—			(2		)	(2		)
Balance as of December 31, 2014	—		—		—			12			12
Charges to income for the year ended December 31, 2015	11		12		112			—			135
Charges to liability accounts:
Payments	—		—		(39		)	(11		)	(50		)
Net currency translation adjustment ¹	—		—		—			—			—
Balance as of December 31, 2015	$	11	$	12	$	73		$	1		$	97

¹ Net currency translation adjustment for the year ended December 31, 2015 was less than $1.

Other Income, Net

12 Months Ended

Dec. 31, 2015

Other Income and Expenses [Abstract]

Other Income, Net



	Year Ended December 31,
	2015			2014			2013
Leasing, contract services and miscellaneous income	$	25		$	17		$	24
Royalty income¹	19			28			24
Gain on purchase of equity method investment	—			—			7
(Loss) gain on sale of assets and businesses ²	(9		)	40			—
Exchange gains (losses), net ³	19			(66		)	(31		)
Total other income, net	$	54		$	19		$	24

¹ Royalty income is primarily for technology and trademark licensing.

²In 2015, the Company sold its subsidiary in Sweden for proceeds of $4 that resulted in a loss on sale of $9 in the Fluoroproducts segment. In 2014, the gain of $40 includes gains on sales of businesses of $30 and $4 in the Fluoroproducts and Titanium Technologies segments, respectively. The remaining $6 related to gain on other sale of assets in the Fluoroproducts segment.

³Chemours uses foreign currency forward contracts to offset its net exposure, by currency, related to its non-functional currency-denominated monetary assets and liabilities. See Note 20 for further information. The pre-tax exchange gains are recorded in other income, net and the related tax impact is recorded in provision for income taxes in the Consolidated Statements of Operations. The $19 net exchange gain for the year ended December 31, 2015 includes a gain on derivatives of $42, partially offset by a $23 pre-tax exchange loss on non-functional monetary assets and liabilities as a result of the strengthening of the U.S. dollar against the Mexican peso, Euro, Thai baht, Chinese yuan and other currencies. Exchange losses in 2014 and 2013, respectively, were primarily driven by the strengthening of the U.S. Dollar versus the Swiss franc and the Euro in 2014, and a strengthening of the U.S. dollar versus the Venezuelan bolivar and the Brazilian real in 2013.

Income Taxes

12 Months Ended

Dec. 31, 2015

Income Tax Disclosure [Abstract]

Income Taxes



	Year Ended December 31,
(Dollars in millions)	2015				2014			2013
Current tax expense:
U.S. federal	$	37		¹	$	85		$	67
U.S. state and local	1			¹	13			11
International	62				73			88
Total current tax expense	100				171			166
Deferred tax (benefit) expense:
U.S. federal	(187		)		(20		)	(4		)
U.S. state and local	(14		)		(3		)	(2		)
International	3				1			(8		)
Total deferred tax benefit	(198		)		(22		)	(14		)
Total (benefit from) provision for income taxes	$	(98	)		$	149		$	152

¹ Recorded pursuant to the tax matters agreement.

The significant components of deferred tax assets and liabilities are as follows:



(Dollars in millions)	December 31, 2015			December 31, 2014
Deferred tax assets-noncurrent:
Other assets and other accrued liabilities	$	257		$	188
Tax loss carryforwards	124			36
Total deferred tax assets-noncurrent	381			224
Valuation allowance	—			(36		)
Total deferred tax assets, net	381			188

Deferred tax liabilities-noncurrent:
Goodwill and other intangibles	—			(2		)
Accrued expenses and other liabilities	(7		)	(34		)
Property, plant and equipment	(530		)	(533		)
Inventories and other assets	(31		)	(33		)
Total deferred tax liabilities-noncurrent	(568		)	(602		)
Net deferred tax liability	$	(187	)	$	(414	)

An analysis of the Company's effective tax rate is as follows:



	Year Ended December 31,
(Dollars in millions)	2015		2014		2013
Statutory U.S. federal income tax rate	35.0	%	35.0	%	35.0	%
State income taxes, net of federal benefit	5.1	%	1.0	%	1.0	%
Benefit from (lower effective tax rate) on international operations-net	12.0	%	(9.6	)%	(10.2	)%
Valuation allowance	—	%	2.0	%	1.2	%
Exchange (gains) losses	0.5	%	2.7	%	2.3	%
Depletion	3.4	%	(3.9	)%	(4.1	)%
Goodwill	(3.2	)%	—	%	—	%
Section 199 deduction	—	%	(0.7	)%	(0.8	)%
Other, net	(0.5	)%	0.6	%	2.0	%
Total effective tax rate	52.3	%	27.1	%	26.4	%

(Loss) income before income taxes for U.S. and international operations was:



	Year Ended December 31,
(Dollars in millions)	2015			2014		2013
U.S. (including exports)	$	(492	)	$	244	$	224
International	304			306		352
Total pre-tax (loss) income	$	(188	)	$	550	$	576

Chemours recorded a tax benefit of $98 for the year ended December 31, 2015 and provisions of $149 and $152 for the years ended December 31, 2014 and 2013, respectively. The $247 decrease in the tax provision was primarily due to tax benefits recognized from the restructuring and asset impairment charges in the U.S. recorded in the second half of 2015, partially offset by earnings in foreign jurisdictions.

The decrease in state income tax provision and the corresponding increase in the state effective tax rate, net of federal benefit, for the year ended December 31, 2015 as compared to 2014 and 2013 is due to the tax benefit recognized from the restructuring and asset impairment charges in the U.S. The tax benefit from international operations is primarily driven by Chemours’ overall geographic mix of earnings. The Company did not have valuation allowance as of December 31, 2015 as compared to 2014 and 2013, as the valuation allowance relates to pre-spin assets that are the responsibilities of DuPont pursuant to the tax matters agreement. Exchange (gains) losses principally reflect the impact of non-taxable gains and losses resulting from remeasurement of foreign currency-denominated monetary assets and liabilities. Depletion represents the tax benefit from the percentage depletion deductions taken pursuant to Section 613 of the Code. Goodwill represents the tax effect of the goodwill reallocation based on Chemours’ new business reporting units and impairment charges, as described in Note 13. In addition, Chemours is entitled to a domestic manufacturing deduction relating to income from certain qualifying domestic production activities pursuant to Section 199 of the Code in tax years 2014 and 2013, as well as a one-time tax benefit recognized in 2014 relating to a tax accounting method change. Consistent with the discussion in Note 2, the pre-spin effective tax rate stated herein may not be indicative of the future effective tax rate of Chemours as a result of the separation from DuPont.

Under the tax laws of various jurisdictions in which the Company operates, deductions or credits that cannot be fully utilized for tax purposes during the current year may be carried forward or back, subject to statutory limitations, to reduce taxable income or taxes payable in the future or prior years. At December 31, 2015, the tax effect of such carryforwards is $124. Of this amount, $25 expires in 2026, $90 expires in 2036, and $9 expires from 2021 to 2036, the majority of which expires in 2036. Based on analysis of the cumulative earnings from the prior three years, the Company determined it is more likely than not that these assets will be fully utilized.

At December 31, 2015, in connection with the spin-off, the Company deemed approximately $1.5 billion of unremitted earnings of subsidiaries outside the U.S. as indefinitely reinvested. No deferred tax liability has been recognized with regard to the remittance of such earnings. It is not practical to estimate the income tax liability that might be incurred if such earnings were remitted to the U.S.

Each year, Chemours and/or its subsidiaries, files income tax returns in the U.S. federal jurisdiction and various states and non-U.S. jurisdictions. These tax returns are subject to examination and possible challenge by the taxing authorities. Positions challenged by the taxing authorities may be settled or appealed by Chemours and/or DuPont in accordance with the tax matters agreement. As a result, income tax uncertainties are recognized in Chemours’ Consolidated Financial Statements in accordance with accounting for income taxes, when applicable. It is reasonably possible that changes to Chemours' global unrecognized tax benefits could be significant; however, due to the uncertainty regarding the timing of completion of audits and possible outcomes, a current estimate of the range of such changes that may occur within the next twelve months cannot be made.

As previously discussed in Note 3, prior to our spin-off, Chemours was included in DuPont's consolidated income tax returns, and Chemours’ income taxes for those periods are computed and reported herein under the “separate return method.” Use of the separate return method may result in differences when the sum of the amounts allocated to stand-alone tax provisions are compared with amounts presented in Consolidated Financial Statements. In that event, the related deferred tax assets and liabilities could be significantly different from those presented herein for these periods. Certain tax attributes, e.g. net operating loss carryforwards, which were actually reflected in DuPont’s consolidated financial statements may or may not exist at the stand-alone Chemours level. Chemours’ Consolidated Financial Statements do not reflect any amounts due to DuPont for income tax related matters prior to separation as it is assumed that all such amounts due to DuPont were settled on December 31 of each year.

The following table shows the change in our unrecognized tax benefit.



	Year Ended December 31,
(Dollars in millions)	2015				2014			2013
Total unrecognized tax benefits as of January 1	$	39			$	26		$	24
Gross amounts of decreases in unrecognized tax benefits as a result of adjustments to tax provisions taken during the prior period	—				(1		)	(1		)
Gross amounts of increases in unrecognized tax benefits as a result of tax positions taken during the current period	—				15			5
Reduction to unrecognized tax benefits as a result of a lapse of the applicable statute of limitations	(32		)	¹	(1		)	(2		)
Total unrecognized tax benefits as of December 31	$	7			$	39		$	26

Total unrecognized tax benefits, if recognized, that would impact the effective tax rate	$	—			$	39		$	26
Total amount of interest and penalties recognized in the Consolidated Statements of Operations	1			¹	2			2
Total amount of interest and penalties recognized in the Consolidated Balance Sheets	—				8			6

¹ Recorded pursuant to the tax matters agreement.

The following is a rollforward of the deferred tax asset valuation allowance for the years ended December 31, 2015, 2014 and 2013.



	Year Ended December 31,
(Dollars in millions)	2015			2014		2013
Balance at beginning of period	$	36		$	26	$	19
Net charges to income tax expense	—			10		7
Release of valuation allowance ¹	(36		)	—		—
Balance at end of period	$	—		$	36	$	26

¹ Release of valuation allowance during 2015 was primarily related to the tax attributes retained by DuPont pursuant to the tax matters agreement.

Earnings Per Share of Common Stock

12 Months Ended

Dec. 31, 2015

Earnings Per Share [Abstract]

Earnings Per Share of Common Stock

The table below shows a reconciliation of the numerator and denominator for basic and diluted earnings per share calculations for the periods indicated.



	Year Ended December 31,
	2015			2014			2013
Numerator:
Net (loss) income attributable to Chemours	$	(90	)	$	400		$	423
Denominator:
Weighted-average number of common shares outstanding- Basic	180,993,623			180,966,833		¹	180,966,833		¹
Dilutive effect of the Company's employee compensation plans²	—			—			—
Weighted average number of common shares outstanding - Diluted ²	180,993,623			180,966,833			180,966,833

¹ For 2013 and 2014, pro forma earnings per share (EPS) was calculated based on 180,966,833 shares of Chemours common stock that were distributed to DuPont shareholders on July 1, 2015.

²Diluted (loss) earnings per share is calculated using net (loss) income available to common shareholders divided by diluted weighted-average shares of common shares outstanding during each period, which includes unvested restricted shares. Diluted earnings per share considers the impact of potentially dilutive securities except in periods in which there is a loss because the inclusion of the potential common shares would have an antidilutive effect. Chemours had no equity awards outstanding prior to the spin-off.

The following average number of stock options were antidilutive and, therefore, were not included in the diluted earnings per share calculation:



	Year Ended December 31,
	2015	2014	2013
Average number of stock options	8,358,894	—	—

Accounts and Notes Receivable - Trade, Net

12 Months Ended

Dec. 31, 2015

Receivables [Abstract]

Accounts and Notes Receivable - Trade, Net

Accounts and Notes Receivable – Trade, Net



	December 31, 2015		December 31, 2014
Accounts receivable—trade, net ¹	$	757	$	746
VAT, GST and other taxes ²	68		62
Leases receivable—current	13		12
Other receivables ³	21		26
Total	$	859	$	846

¹Accounts receivable – trade is net of allowances of $4 and $4 as of December 31, 2015 and 2014, respectively. Allowances are equal to the estimated uncollectible amounts.

²Value Added Tax (VAT) and Goods and Services Tax (GST).

³Other receivables consist of notes receivable, advances and other deposits.

Accounts and notes receivable are carried at amounts that approximate fair value. Bad debt expense was less than $1 for the year ended December 31, 2015, and $1 and $2 for the years ended December 31, 2014 and 2013, respectively.

Direct Financing Leases

At two of its facilities in the U.S. (Borderland and Morses Mill), Chemours has constructed fixed assets on land that it leases from third parties. Management has analyzed these arrangements and determined these assets represent a direct financing lease, whereby Chemours is the lessor of this equipment. Chemours has recorded leases receivable of $138 and $149 at December 31, 2015 and 2014, respectively, which represent the balance of the minimum future lease payments receivable. The current portion of leases receivable is included in accounts and notes receivable - trade, net, as shown above. The long-term portion of leases receivable is included in other assets, as shown in Note 14. Management has evaluated the realizable value of these leased assets and determined no impairment existed at December 31, 2015 or December 31, 2014. There is no estimated future residual value of these leased assets.

Inventories

12 Months Ended

Dec. 31, 2015

Inventory, Net [Abstract]

Inventories



	December 31, 2015			December 31, 2014
Finished products	$	613		$	611
Semi-finished products	172			173
Raw materials, stores and supplies	433			521
Subtotal	1,218			1,305
Adjustment of inventories to LIFO basis	(246		)	(253		)
Total	$	972		$	1,052

Inventory values, before LIFO adjustment, are generally determined by the average cost method, which approximates current cost. Inventories are valued using the LIFO method at substantially all of the U.S. locations, which comprised $744 and $684 or 61% and 52% of inventories before the LIFO adjustments at December 31, 2015 and December 31, 2014, respectively. The remainder of inventory held in international locations and certain U.S. locations is valued using the average cost method.

Property, Plant, and Equipment

12 Months Ended

Dec. 31, 2015

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment

Chemours' property, plant and equipment consisted of:



	December 31, 2015			December 31, 2014
Equipment	$	7,327		$	7,500
Buildings	737			778
Construction in progress	804			852
Land	111			116
Mineral rights	36			36
Total	9,015			9,282
Accumulated depreciation	(5,838		)	(5,974		)
Net property, plant and equipment	$	3,177		$	3,308

Depreciation expense amounted to $264, $254 and $255 for the years ended December 31, 2015, 2014 and 2013, respectively. Property, plant and equipment includes gross assets under capital leases of $7 and $6 at December 31, 2015 and 2014, respectively. Interest expense capitalized as part of property, plant and equipment was $21 for the year ended December 31, 2015. Chemours did not incur interest in the years ended December 31, 2014 or 2013.

During the third quarter of 2015, in connection with the strategic evaluation of the Chemical Solutions portfolio, excluding cyanides, the Company determined that the carrying value of the RMS manufacturing facility of the Chemical Solutions segment may not be recoverable given the strategic decision to discontinue investment in the business. An impairment evaluation was performed which indicated that the carrying amount of this asset group in the U.S. was not recoverable when compared to the expected undiscounted cash flows. Based on management’s assessment of the fair value of the asset group, the Company determined that the carrying value of that asset group exceeded the fair value and as a result, a $45 pre-tax impairment charge was recorded in the Chemical Solutions segment. The fair value of the asset group was determined using an income approach based on the present value of the estimated future cash flows. The key assumptions used included growth rates and cash flow projections, discount rate, tax rate and an estimated terminal value. The amount was recorded in employee separation and asset related charges, net in the Consolidated Statements of Operations. Refer to Note 6 for additional information.

Asset Held for Sale

In November 2015, the Company signed a definitive agreement to sell its aniline facility in Beaumont, Texas to The Dow Chemical Company (Dow) for approximately $140 in cash, subject to customary approvals and closing conditions. The Company expects the transaction to close and record a gain in the Chemical Solutions segment in the quarter ending March 31, 2016. As of December 31, 2015, the asset disposal group of approximately $46 was classified as held-for-sale within the caption prepaid expenses and other in the Consolidated Balance Sheets.

Goodwill and Other Intangible Assets, Net

12 Months Ended

Dec. 31, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Other Intangible Assets, Net

Goodwill: The following table summarizes changes in the carrying amount of goodwill by reportable segment:



	Titanium Technologies		Fluoroproducts		Chemical Solutions			Total
Balance as of December 31, 2013	$	13	$	85	$	100		$	198
Impairment charge	—		—		—			—
Other adjustments	—		—		—			—
Balance as of December 31, 2014	13		85		100			198
Impairment charge	—		—		(25		)	(25		)
Other adjustments	—		—		(7		)	(7		)
Balance as of December 31, 2015	$	13	$	85	$	68		$	166

Accumulated impairment losses as of December 31, 2015, 2014 and 2013 included in goodwill are $25, $0, and $0, respectively.

The Company has three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions (see further discussion of reportable segments in Note 23). The Company defines its reporting units as its operating segments for Titanium Technologies; however, the Fluoroproducts and Chemical Solutions segments represent three and seven reporting units, respectively.

In the third quarter of 2015, in connection with the strategic evaluation of the Chemical Solutions portfolio, the Company realigned the reporting structure of the portfolio, specifically the level at which segment management regularly reviews operating results. The Company now identifies seven reporting units for purposes of goodwill allocation and impairment assessment. These seven reporting units are Aniline, Clean & Disinfect, Cyanides, Methylamines, Reactive Metal Solutions, Sulfur, and Vazo. Chemical Solutions remains a single operating segment.

In addition, in connection with the spin-off on July 1, 2015, the Fluoroproducts segment changed its organizational structure, which changed its reporting units from Fluorochemicals and Fluoropolymers to Fluorochemicals, Industrial Resins and Diversified Technologies.

In connection with the goodwill allocation to the new reporting units in Fluoroproducts and Chemical Solutions segments during the third quarter of 2015, we evaluated the reporting units for impairment and determined that the estimated fair values of those reporting units, except for the Sulfur reporting unit, were substantially in excess of the carrying value, indicating that goodwill was not impaired. We performed the second step of the impairment test for Sulfur and determined that the implied fair value of goodwill was lower than its carrying value, resulting in a full impairment of the Sulfur reporting unit's goodwill. As a result, Chemours recorded a $25 million pre-tax impairment charge for goodwill during the year ended December 31, 2015 in the Chemicals Solutions reportable segment.

The Company also performed its annual impairment tests for Titanium Technologies and Fluorochemicals goodwill and determined that no goodwill impairment existed as of December 31, 2015, and the fair value of each reporting unit substantially exceeded its carrying value.

Chemours estimates the fair value of its reporting units using the income approach based on the present value of estimated future cash flows, discounted at a risk-adjusted market rate, including a growth rate to calculate the terminal value. The Company’s forecasted future cash flows, which incorporate anticipated future revenue growth and related expenses to support the growth, were used to calculate fair value. The factors considered in determining the cash flows include: 1) macroeconomic conditions; 2) industry and market considerations; 3) costs of raw materials, labor or other costs having a negative effect on earnings and cash flows; 4) overall financial performance; and 5) other relevant entity-specific events. The discount rate used represents the weighted average cost of capital for the reporting units considering the risks and uncertainty inherent in the cash flows of the reporting units and in the internally developed forecasts. The implied fair value of the goodwill in step two was determined by allocating the fair value of the reporting units to all of the assets and liabilities as if the reporting units had been acquired in a business combination and its fair value was the purchase price paid to be acquired. The use of these unobservable inputs resulted in the fair value estimate being classified as a Level 3 asset measured at fair value on a nonrecurring basis subsequent to its original recognition.

The determination of whether or not goodwill is impaired involves a significant level of judgment in the assumptions underlying the approaches used to determine the estimated fair value of our reporting units. Chemours believes that assumptions and rates used in the impairment assessment are reasonable. However, these assumptions are judgmental and variations in any assumptions could result in materially different calculations of fair value. The Company will continue to evaluate goodwill on an annual basis as of October 1, and whenever events or changes in circumstances, such as significant adverse changes in operating results, market conditions or changes in management’s business strategy, indicate that there may be a probable indicator of impairment. It is possible that the assumptions used by management related to the evaluation may change or that actual results may vary significantly from management’s estimates.

Other Intangible Assets, Net: The following table summarizes the gross carrying amounts and accumulated amortization of other intangible assets by major class:



	December 31, 2015							December 31, 2014
	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Customer lists	$	13	$	(10	)	$	3	$	13	$	(10	)	$	3
Patents	19		(17		)	2		19		(15		)	4
Purchased trademarks	5		(2		)	3		5		(1		)	4
Purchased and licensed technology	8		(6		)	2		5		(5		)	—
Total	$	45	$	(35	)	$	10	$	42	$	(31	)	$	11

The aggregate pre-tax amortization expense for definite-lived intangible assets was $3, $3 and $6 for the years ended December 31, 2015, 2014 and 2013, respectively. The estimated aggregate pretax amortization expense for 2016, 2017, 2018, 2019 and 2020 is $3, $2, $1, $1 and $1, respectively. Definite-lived intangible assets are amortized over their estimated useful lives, generally for periods ranging from 5 to 20 years. The reasonableness of the useful lives of these assets is continually evaluated. There are no indefinite-lived intangible assets.

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Other Assets

12 Months Ended

Dec. 31, 2015

Other Assets



	December 31, 2015		December 31, 2014
Leases receivable - non-current¹	$	125	$	137
Capitalized repair and maintenance costs	149		185
Pension assets ²	138		—
Advances and deposits	11		17
Deferred income taxes	47		10
Miscellaneous ³	38		28
Total	$	508	$	377

¹Leases receivable includes direct financing leases of property at two locations. See Note 10 for further information.

²Pension assets represent pension plans commencing in 2015. See Note 21 for further information.

³Miscellaneous includes prepaid expenses for royalty fees, vendor supply agreements and taxes other than income taxes, deferred financing fees related to the Revolving Credit Facility of $19 at December 31, 2015, as well as capitalized expenses for the preparation of future landfill cells at Titanium Technologies’ New Johnsonville plant site.

Accounts Payable

12 Months Ended

Dec. 31, 2015

Accounts Payable



	December 31, 2015		December 31, 2014
Trade payables	$	945	$	1,004
VAT and other payables	28		42
Total	$	973	$	1,046

Other Accrued Liabilities



	December 31, 2015		December 31, 2014
Compensation and other employee-related costs	$	109	$	109
Employee separation costs ¹	76		12
Accrued litigation ²	11		7
Environmental remediation ²	68		69
Income taxes	32		—
Customer rebates	53		59
Deferred revenue	20		28
Accrued interest	21		—
Miscellaneous ³	64		68
Total	$	454	$	352

¹See Note 6 for further information.

² See Note 19 for further discussion of environmental remediation and accrued litigation.

³ Miscellaneous primarily includes accrued utility expenses, property taxes, an accrued indemnification liability and other miscellaneous expenses.

Other Accrued Liabilities

12 Months Ended

Dec. 31, 2015

Other Accrued Liabilities

Accounts Payable



	December 31, 2015		December 31, 2014
Trade payables	$	945	$	1,004
VAT and other payables	28		42
Total	$	973	$	1,046

Other Accrued Liabilities



	December 31, 2015		December 31, 2014
Compensation and other employee-related costs	$	109	$	109
Employee separation costs ¹	76		12
Accrued litigation ²	11		7
Environmental remediation ²	68		69
Income taxes	32		—
Customer rebates	53		59
Deferred revenue	20		28
Accrued interest	21		—
Miscellaneous ³	64		68
Total	$	454	$	352

¹See Note 6 for further information.

² See Note 19 for further discussion of environmental remediation and accrued litigation.

³ Miscellaneous primarily includes accrued utility expenses, property taxes, an accrued indemnification liability and other miscellaneous expenses.

Other Liabilities

12 Months Ended

Dec. 31, 2015

Other Liabilities Disclosure [Abstract]

Other Liabilities



	December 31, 2015		December 31, 2014
Environmental remediation ¹	$	223	$	226
Employee-related costs ²	108		32
Employee separation costs ³	23		—
Accrued litigation ¹	58		52
Asset retirement obligations ¹	41		43
Deferred revenue	11		13
Miscellaneous ⁴	89		98
Total	$	553	$	464

¹ See Note 19 for further details on environmental remediation, asset retirement obligations and accrued litigation.

² See Note 21 for further details on long-term employee benefits.

³See Note 6 for further information.

⁴ Miscellaneous primarily includes an accrued indemnification liability.

Debt

12 Months Ended

Dec. 31, 2015

Debt Disclosure [Abstract]

Debt

In conjunction with Chemours' separation from DuPont, Chemours entered into approximately $3,995 of financing transactions on May 12, 2015. Long-term debt, net of an unamortized discount on the Term Loan Facility of $7, was comprised of the following at December 31, 2015:



	December 31, 2015
Long-term debt:
Senior secured term loan, net of issue discount	$	1,493
Senior unsecured notes:
6.625%, due May 2023	1,350
7.00%, due May 2025	750
6.125%, due May 2023 (€360)	395
Other	26
Total	4,014
Less: Unamortized debt issuance costs	60
Less: Short-term borrowings and current maturities	39
Total long-term debt	$	3,915

Senior Secured Credit Facilities

On May 12, 2015, Chemours entered into a credit agreement that provides for a seven-year senior secured term loan (the Term Loan Facility) in a principal amount of $1,500 repayable in equal quarterly installments at a rate of one percent of the original principal amount per year, with the balance payable on the final maturity date. The Term Loan Facility was issued with a $7 original issue discount and bears variable interest rate subject to a floor of 3.75%. The proceeds from the Term Loan Facility were used to fund a portion of the distribution to DuPont, along with related fees and expenses.

The credit agreement also provided for a five-year senior secured revolving credit facility (the Revolving Credit Facility), which has been reduced to $750 as part of the amendment completed on February 19, 2016. The proceeds of any loans made under the Revolving Credit Facility can be used for capital expenditures, acquisitions, working capital needs and other general corporate purposes. We had no borrowings outstanding under our Revolving Credit Facility at December 31, 2015, and we had $129 in letters of credit issued and outstanding under this facility. The Revolving Credit Facility bears variable interest of a range based on our total net leverage ratio between (a) 0.50% and 1.25% for base rate loans and (b) 1.50% and 2.25% for LIBOR loans. The applicable margin was 1.25% for base rate loans and 2.25% for LIBOR loans as of December 31, 2015. In addition, we are required to pay a commitment fee on the average daily unused amount of the Revolving Credit Facility at a rate based on our total net leverage ratio, between 0.20% and 0.35%. Commitment fees are currently assessed at a rate of 0.35%.

During the third quarter of 2015, Chemours and its Revolving Credit Facility lenders entered into an amendment to the Revolving Credit Facility that strengthened Chemours' financial position by providing enhanced liquidity to implement the Transformation Plan. The amendment modified the consolidated EBITDA definition in the covenant calculation to include pro forma benefits of announced cost reduction initiatives.

During the first quarter of 2016, Chemours and its Revolving Credit Facility lenders entered into a second amendment to the Revolving Credit Facility that (a) replaced the total net leverage ratio financial covenant with senior secured net leverage ratio; (b) reduced the minimum required levels of interest expense coverage ratio covenant; (c) increased the limits and extended the time horizon for inclusion of pro forma benefits of announced cost reduction initiatives into Consolidated EBITDA definition for the purposes of calculating financial maintenance covenants; and (d) reduced the revolver availability from $1,000 to $750. These changes provide further flexibility to Chemours to sustain the prolonged downturn in the business and enhance its liquidity to implement the Transformation Plan.

The credit agreement contains financial covenants which, solely with respect to the Revolving Credit Facility as amended, require Chemours not to exceed a maximum senior secured net leverage ratio of 3.50 to 1.00 and to maintain a minimum interest coverage ratio of 1.75 to 1.00 until December 31, 2016. In addition, the credit agreement contains customary affirmative and negative covenants that, among other things, limit or restrict Chemours and its subsidiaries' ability, subject to certain exceptions, to incur liens, merge, consolidate or sell, transfer or lease assets, make investments, pay dividends, transact with subsidiaries and incur indebtedness. The credit agreement also contains customary representations and warranties and events of default. Chemours was in compliance with its debt covenants as of December 31, 2015.

Chemours’ obligations under the senior secured credit facilities are guaranteed on a senior secured basis by all of its material domestic subsidiaries, subject to certain agreed upon exceptions. The obligations under the senior secured credit facilities are also, subject to certain agreed upon exceptions, secured by a first priority lien on substantially all of Chemours and its material wholly-owned domestic subsidiaries’ assets, including 100% of the stock of domestic subsidiaries and 65% of the stock of certain foreign subsidiaries.

Senior Unsecured Notes

On May 12, 2015, Chemours issued senior unsecured notes (the Notes) with an aggregate principal of approximately $2,503 in a private placement subject to a registration rights arrangement.

All of the notes, including the 2023 notes with an aggregate principal amount of $1,350, the 2025 notes with an aggregate principal amount of $750 and the 2023 Euro notes with an aggregate principal amount of €360 (or $395 as of December 31, 2015), require payment of principal at maturity and interest semi-annually in cash in arrears on May 15 and November 15 of each year.

The proceeds from the Notes were used to fund the cash and in-kind distributions to DuPont and to pay related fees and expenses. The in-kind distribution to DuPont of $507 aggregate principal amount of Chemours 2025 Notes were exchanged by DuPont with third parties for certain DuPont notes.

Chemours is required to register the Notes with the Securities and Exchange Commission within 465 days after the original issue date. If Chemours fails to do so, it would be required to pay additional interest at a rate of 0.25% for the first 90 days following a registration default and additional 0.25% per annum with respect to each subsequent 90-day period, up to a maximum rate of 0.50%, until the registration requirements are met. Application is also expected to be made to the Irish Stock Exchange for the approval of listing particulars in relation to the Euro notes prior to the first anniversary of the issue date of the Euro notes.

Each series of Notes is or will be fully and unconditionally guaranteed, jointly and severally, by Chemours’ existing and future domestic subsidiaries that guarantee (the Guarantors) the Senior Secured Credit Facilities or that guarantee other indebtedness of Chemours or any guarantor in an aggregate principal amount in excess of $75 million (the Guarantees). The Notes are unsecured and unsubordinated obligations of Chemours. The Guarantees are unsecured and unsubordinated obligations of the Guarantors. The Notes rank equally in right of payment to all of Chemours’ existing and future unsecured unsubordinated debt and senior in right of payment to all of Chemours’ existing and future debt that is by its terms expressly subordinated in right of payment to the Notes. The Notes are subordinated to indebtedness under the Senior Secured Credit Facilities as well as any future secured debt to the extent of the value of the assets securing such debt. Chemours’ is obligated to offer to purchase the Notes at a price of (a) 101 percent of their principal amount, together with accrued and unpaid interest, if any, to the date of purchase, upon the occurrence of certain change of control events and (b) 100 percent of their principal amount, together with accrued and unpaid interest, if any, to the date of purchase, with the proceeds from certain asset dispositions. These restrictions and prohibitions are subject to certain qualifications and exceptions set forth in the Indenture, including without limitation, reinvestment rights with respect to the proceeds of asset dispositions. Chemours is permitted to redeem some or all of the 2023 Notes and Euro Notes by paying a "make-whole" premium prior to May 15, 2018. Chemours also may redeem some or all of the 2023 Notes and Euro Notes on or after May 15, 2018 and thereafter at specified redemption prices. Chemours also may redeem some or all of the 2025 Notes on or after May 15, 2020 at specified redemption prices.

Maturities

There are no debt maturities in each of the next seven years, except, in accordance with the credit agreement, Chemours has required quarterly principal payments related to the Term Loan Facility equivalent to 1.00% per annum beginning September 2015 through March 2022, with the balance due at maturity. Term Loan principal maturities over the next five years are $15 in each year from 2016 to 2020. Debt maturities related to the Term Loan Facility and the Notes in 2021 and beyond will be $3,913.

Debt Fair Value

The fair values of the Term Loan Facility, the 2023 notes, the 2025 notes and the 2023 Euro notes at December 31, 2015 were approximately $1,348, $946, $513 and $277, respectively. The estimated fair values of the Term Loan Facility and the Notes are based on quotes received from third party brokers, and are classified as Level 2 in the fair value hierarchy.

Commitments and Contingent Liabilities

12 Months Ended

Dec. 31, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingent Liabilities

(a) Guarantees

Obligations for Equity Affiliates and Others

Chemours has directly guaranteed various obligations of customers, suppliers and other third parties. At December 31, 2015 and December 31, 2014, Chemours had directly guaranteed $8 and $41 of such obligations, respectively. These represent the maximum potential amount of future (undiscounted) payments that Chemours could be required to make under the guarantees in the event of default by the guaranteed parties. No amounts were accrued at December 31, 2015 and 2014.

Chemours assesses the payment and performance risk by assigning default rates based on the duration of the guarantees. These default rates are assigned based on the external credit rating of the counterparty or through internal credit analysis and historical default history for counterparties that do not have published credit ratings. For counterparties without an external rating or available credit history, a cumulative average default rate is used.

Operating Leases

Chemours uses various leased facilities and equipment in its operations. The terms for these leased assets vary depending on the lease agreement. Future minimum lease payments (including residual value guarantee amounts) under non-cancelable operating leases are $84, $73, $62, $53 and $36 for the years ended December 31, 2016, 2017, 2018, 2019 and 2020, respectively, and $38 for the years thereafter. Net rental expense under operating leases was $83, $75 and $62 during the years ended December 31, 2015, 2014 and 2013, respectively.

(b) Asset Retirement Obligations

Chemours has recorded asset retirement obligations primarily associated with closure, reclamation and removal costs for mining operations related to the production of TiO₂ in the Titanium Technologies segment. Chemours' asset retirement obligation liabilities were $42 and $43 at December 31, 2015 and 2014, respectively. A summary of the changes in asset retirement obligations is as follows:



(Dollars in millions)	Year Ended December 31,
	2015			2014
Beginning balance	$	43		$	42
Accretion expense	1			2
Additional liabilities incurred	—			1
Changes in estimated cash flows	—			—
Settlements/payments	(2		)	(2		)
Ending balance	$	42		$	43
Current portion	$	1		$	—
Non-current portion	$	41		$	43

In addition to the matters discussed below, Chemours, by virtue of its status as a subsidiary of DuPont prior to the Distribution, is subject to or required under the separation-related agreements executed prior to the Distribution to indemnify DuPont against various pending legal proceedings arising out of the normal course of the Chemours business including product liability, intellectual property, commercial, environmental and antitrust lawsuits. It is not possible to predict the outcome of these various proceedings. Except for the PFOA litigation for which a separate assessment is provided in this Note, while management believes it is reasonably possible that Chemours could incur losses in excess of the amounts accrued, if any, for the aforementioned proceedings, it does not believe any such loss would have a material impact on Chemours' consolidated financial position, results of operations or liquidity. With respect to the litigation matters discussed below, management's estimate of the probability of loss in excess of the amounts accrued, if any, is addressed individually for each matter. In the event that DuPont seeks indemnification for adverse trial rulings or outcomes for any such matter, these indemnification claims could materially adversely affect Chemours' financial condition. Disputes between Chemours and DuPont may also arise with respect to indemnification matters, including disputes based on matters of law or contract interpretation. If and to the extent these disputes arise, they could materially adversely affect Chemours.

Asbestos

At December 31, 2015, there were approximately 2,212 lawsuits pending against DuPont alleging personal injury from exposure to asbestos. These cases are pending in state and federal court in numerous jurisdictions in the U.S. and are individually set for trial. Most of the actions were brought by contractors who worked at sites between 1950 and the 1990s. A small number of cases involve similar allegations by DuPont employees. A limited number of the cases were brought by household members of contractors or DuPont employees. Finally, certain lawsuits allege personal injury as a result of exposure to DuPont products. Chemours had an accrual of $42 and $38 related to this matter at December 31, 2015 and 2014, respectively. Additionally, Chemours had an accrual for $3 for asbestos cases outside the U.S. at December 31, 2015. Chemours reviews this estimate and related assumptions quarterly and annually updates the results of an approximate 20-year projection. Management believes that the likelihood is remote that Chemours would incur losses in excess of the amounts accrued in connection with this matter.

Benzene

In the separation, DuPont assigned its Benzene docket to Chemours. There are 29 pending cases against DuPont alleging benzene-related illnesses. These cases consist of premises matters involving contractors and deceased former employees who claim exposure to benzene while working at DuPont sites primarily in the 1960s through the 1980s, and product liability claims based on alleged exposure to benzene found in trace amounts in aromatic hydrocarbon solvents used to manufacture DuPont products, such as paints, thinners and reducers.

A benzene case (Hood v. DuPont) was tried to a verdict in Texas state court on October 20, 2015. Plaintiffs alleged that Mr. Hood's Acute Myelogenous Leukemia (AML) was the result of 24 years of occupational exposure to trace benzene found in DuPont automotive paint products and that DuPont negligently failed to warn him that its paints, reducers and thinners contained benzene that could cause cancer or leukemia. The jury found in the Plaintiffs favor awarding $6.9 in compensatory damages and $1.5 in punitive damages. Through DuPont, Chemours will appeal the verdict based upon substantial errors made at the trial court. Management believes that a loss is reasonably possible related to these matters; however, given the evaluation of each Benzene matter is highly fact driven and impacted by disease, exposure and other factors, a range of such losses cannot be reasonably estimated at this time.

PFOA

Prior to the fourth quarter of 2014, Chemours used PFOA (collectively, perfluorooctanoic acids and its salts, including the ammonium salt) as a processing aid to manufacture some fluoropolymer resins at various sites around the world including its Washington Works plant in West Virginia. Chemours had accruals of $20 and $14 related to the PFOA matters discussed below at December 31, 2015 and 2014, respectively.

The accruals include charges related to DuPont’s obligations under agreements with the U.S. Environmental Protection Agency (EPA) and voluntary commitments to the New Jersey Department of Environmental Protection. These obligations and voluntary commitments include surveying, sampling and testing drinking water in and around certain company sites and offering treatment or an alternative supply of drinking water if tests indicate the presence of PFOA in drinking water at or greater than the national Provisional Health Advisory.

Drinking Water Actions

In August 2001, a class action, captioned Leach v. DuPont, was filed in West Virginia state court alleging that residents living near the Washington Works facility had suffered, or may suffer, deleterious health effects from exposure to PFOA in drinking water.

DuPont and attorneys for the class reached a settlement in 2004 that binds about 80,000 residents. In 2005, DuPont paid the plaintiffs’ attorneys’ fees and expenses of $23 and made a payment of $70, which class counsel designated to fund a community health project. Chemours, through DuPont, funded a series of health studies which were completed in October 2012 by an independent science panel of experts (the C8 Science Panel). The studies were conducted in communities exposed to PFOA to evaluate available scientific evidence on whether any probable link exists, as defined in the settlement agreement, between exposure to PFOA and human disease. The C8 Science Panel found probable links, as defined in the settlement agreement, between exposure to PFOA and pregnancy-induced hypertension, including preeclampsia, kidney cancer, testicular cancer, thyroid disease, ulcerative colitis and diagnosed high cholesterol.

In May 2013, a panel of three independent medical doctors released its initial recommendations for screening and diagnostic testing of eligible class members. In September 2014, the medical panel recommended follow-up screening and diagnostic testing three years after initial testing, based on individual results. The medical panel has not communicated its anticipated schedule for completion of its protocol. Through DuPont, Chemours is obligated to fund up to $235 for a medical monitoring program for eligible class members and, in addition, administrative cost associated with the program, including class counsel fees. In January 2012, Chemours, through DuPont, put $1 in an escrow account to fund medical monitoring as required by the settlement agreement. The court-appointed Director of Medical Monitoring has established the program to implement the medical panel’s recommendations and the registration process, as well as eligibility screening, is ongoing. Diagnostic screening and testing has begun and associated payments to service providers are being disbursed from the escrow account. As of December 31, 2015, less than $1 has been disbursed from the escrow account related to medical monitoring.

In addition, under the settlement agreement, DuPont must continue to provide water treatment designed to reduce the level of PFOA in water to six area water districts, including the Little Hocking Water Association (LHWA) and private well users.

Class members may pursue personal injury claims against DuPont only for those human diseases for which the C8 Science Panel determined a probable link exists. At December 31, 2015, there were approximately 3,500 lawsuits filed in various federal and state courts in Ohio and West Virginia. These lawsuits are consolidated in multi-district litigation in Ohio federal court (MDL). Based on the information currently available to the Company, the majority of the lawsuits allege personal injury claims associated with high cholesterol and thyroid disease from exposure to PFOA in drinking water. There are 37 lawsuits alleging wrongful death. In the third quarter of 2014, six plaintiffs from the MDL were selected for individual trial. The first case (Bartlett v. DuPont) was tried to a verdict on October 7, 2015. The Plaintiff alleged that PFOA in drinking water caused her kidney cancer with causes of action for negligence and negligent infliction of emotional distress. The jury found in favor of the Plaintiff awarding $1.1 in damages for negligence and $0.5 for emotional distress. The jury found that DuPont’s conduct did not warrant punitive damages. DuPont Management believes that rulings made before and during the trial resulted in several significant and meritorious grounds for appeal, and an appeal to the Sixth Circuit will be filed. The second case (Wolf v. DuPont) set for trial in March 2016, has been settled for an amount well below the incremental cost of preparing for trial. There are three more trials scheduled in 2016, with the next trial starting in May 2016.

In January 2016, the court announced that starting in April 2017, 40 individual plaintiff trials will be scheduled per year. This multi-year plan pertains only to the cases claiming cancer, which represents approximately 7% of the total number of cases in the MDL. The remaining cases, comprising approximately 93% of the docket, will remain inactive.

Chemours, through DuPont, denies the allegations in these lawsuits and is defending itself vigorously. Except for the Wolf v. DuPont case, no claims have been settled or resolved during the periods presented.

Additional Actions

In addition to general claims of PFOA contamination of drinking water, LHWA brought an action claiming “imminent and substantial endangerment to health and or the environment” under the Resource Conservation and Recovery Act (RCRA). The parties reached a confidential settlement in late November 2015. Final papers were completed in February 2016.

PFOA Summary

While it is probable that the Company will incur costs related to the medical monitoring program discussed above, such costs cannot be reasonably estimated due to uncertainties surrounding the level of participation by eligible class members and the scope of testing. Chemours believes that it is reasonably possible that it could incur losses related to the MDL in Ohio federal court discussed above but such losses cannot be estimated at this time due to the uniqueness of the individual MDL plaintiff's claims and Chemours' defenses to those claims, both as to potential liability and damages on an individual claim basis, and numerous unsettled legal issues, among other factors. The trials and appeals of these matters will occur over the course of many years. Significant unfavorable outcomes in a number of cases in the MDL could have a material adverse effect on Chemours' consolidated financial position, results of operations or liquidity.

(d) Environmental

Chemours, by virtue of its status as a subsidiary of DuPont prior to the Distribution, is subject to contingencies pursuant to environmental laws and regulations that in the future may require further action to correct the effects on the environment of prior disposal practices or releases of chemical substances by Chemours or other parties. Chemours accrues for environmental remediation activities consistent with the policy set forth in Note 3. Much of this liability results from the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA, often referred to as Superfund), RCRA and similar state and global laws. These laws require Chemours to undertake certain investigative, remediation and restoration activities at sites where Chemours conducts or once conducted operations or at sites where Chemours-generated waste was disposed. The accrual also includes estimated costs related to a number of sites identified for which it is probable that environmental remediation will be required, but which are not currently the subject of enforcement activities.

Remediation activities vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, diverse regulatory agencies and enforcement policies, as well as the presence or absence of other potentially responsible parties. At December 31, 2015, the Consolidated Balance Sheets included a liability of $290, relating to these matters which, in management’s opinion, is appropriate based on existing facts and circumstances. The average time frame, over which the accrued or presently unrecognized amounts may be paid, based on past history, is estimated to be 15 to 20 years. Therefore, considerable uncertainty exists with respect to environmental remediation costs and, under adverse changes in circumstances, the potential liability may range up to approximately $611 above the amount accrued at December 31, 2015. Except for Pompton Lakes, which is discussed further below, based on existing facts and circumstances, management does not believe that any loss, in excess of amounts accrued, related to remediation activities at any individual site will have a material impact on the financial position, liquidity or results of operations of Chemours.

Pompton Lakes

The environmental remediation accrual at December 31, 2015 includes $87 related to activities at Chemours’ site in Pompton Lakes, New Jersey. Management believes that it is reasonably possible that potential liability for remediation activities at this site could range up to $119 including previously accrued amounts. This could have a material impact on the liquidity of Chemours in the period recognized. During the twentieth century, blasting caps, fuses and related materials were manufactured at Pompton Lakes. Operating activities at the site were ceased in the mid 1990s. Primary contaminants in the soil and sediments are lead and mercury. Ground water contaminants include volatile organic compounds.

Under the authority of the EPA and the New Jersey Department of Environmental Protection, remedial actions at the site are focused on investigating and cleaning up the area. Ground water monitoring at the site is ongoing and Chemours has installed and continues to install vapor mitigation systems at residences within the ground water plume. In addition, Chemours is further assessing ground water conditions. In June 2015, the EPA issued a modification to the site's RCRA permit that requires Chemours to dredge mercury contamination from a 36 acre area of the lake and remove sediment from two other areas of the lake near the shoreline. Chemours expects to spend about $50 over the next two to three years in connection with remediation activities commencing in mid-2016 at Pompton Lakes, including activities related to the EPA’s proposed plan. These amounts are included in the remediation accrual at December 31, 2015.

Financial Instruments

12 Months Ended

Dec. 31, 2015

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Financial Instruments

Derivative Instruments

Objectives and Strategies for Holding Derivative Instruments

In the ordinary course of business, Chemours enters into contractual arrangements (derivatives) to reduce its exposure to foreign currency risks. The Company has established a derivative program to be utilized for financial risk management. This program reflects varying levels of exposure coverage and time horizons based on an assessment of risk. The derivative program has procedures consistent with Chemours’ financial risk management policies and guidelines.

Foreign Currency Forward Contracts

Chemours uses foreign currency forward contracts to reduce its net exposure, by currency, related to non-functional currency-denominated monetary assets and liabilities of its operations so that exchange gains and losses resulting from exchange rate changes are minimized. These derivative instruments are not part of a cash flow hedge program or a fair value hedge program, and have not been designated as a hedge. Although all of the forward contracts are subject to an enforceable master netting agreement, Chemours has elected to present the derivative assets and liabilities on a gross basis in the Consolidated Balance Sheets. No collateral has been required for these contracts. All gains and losses resulting from the revaluation of the derivative assets and liabilities are recognized in other income, net in the Consolidated Statements of Operations during the period in which they occurred.

At December 31, 2015, there were 41 forward exchange currency contracts outstanding with an aggregate gross notional value of $288. Chemours recognized a net gain of $42 for the year ended December 31, 2015, which is recorded in other income, net in the Consolidated Statements of Operations. There were no forward contracts outstanding in 2014 or 2013.

Net Investment Hedge - Foreign Currency Borrowings

Beginning on July 1, 2015, Chemours designated its €360 million Euro notes (see Note 18) as a hedge of its net investments in certain of its international subsidiaries that use the Euro as functional currency in order to reduce the volatility in stockholders’ equity caused by the changes in foreign currency exchange rates of the Euro with respect to the U.S. Dollar. Chemours used the spot method to measure the effectiveness of the net investment hedge. Under this method, for each reporting period, the change in the carrying value of the Euro notes due to remeasurement of the effective portion is reported in accumulated other comprehensive loss in the Consolidated Balance Sheet and the remaining change in the carrying value of the ineffective portion, if any, is recognized in other income, net in the Consolidated Statements of Operations. Chemours evaluates the effectiveness of its net investment hedge quarterly at the beginning of each quarter. For the year ended December 31, 2015, Chemours did not record any ineffectiveness and recognized gain of $8 on its net investment hedges within accumulated other comprehensive income. There were no net investment hedges in 2014 or 2013.

Fair Value of Derivative Instruments

The table below presents the fair value of Chemours’ derivative assets and liabilities within the fair value hierarchy, as described in Note 3 to the Consolidated Financial Statements.



		Fair Value Using Level 2 Inputs
	Balance Sheet Location	December 31, 2015		December 31, 2014
Asset derivatives:
Foreign currency forward contracts	Accounts and notes receivable - trade, net	$	2	$	—
Total asset derivatives		$	2	$	—

Liability derivatives:
Foreign currency forward contracts	Other accrued liabilities	$	2	$	—
Total liability derivatives		$	2	$	—

We classify our foreign currency forward contracts in Level 2 as the valuation inputs are based on quoted prices and market observable data of similar instruments. For derivative assets and liabilities, standard industry models are used to calculate the fair value of the various financial instruments based on significant observable market inputs, such as foreign exchange rates and implied volatilities obtained from various market sources. Market inputs are obtained from well-established and recognized vendors of market data and subjected to tolerance and quality checks.

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5618551-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5580258-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624181-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41638-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

General Discussion of Pension and Other Postretirement Benefits [Abstract]

Long-Term Employee Benefits

12 Months Ended

Dec. 31, 2015

Long-Term Employee Benefits

Plans Covering Employees in the U.S.

Chemours sponsors a variety of employee benefit plans which cover substantially all U.S. employees. Prior to July 1, 2015, U.S. employees generally participated in DuPont’s primary pension plan, the Retirement Savings Plan and certain other long-term employee benefit plans. In conjunction with the separation on July 1, 2015, Chemours employees stopped participating in DuPont plans and became participants in newly established Chemours plans. DuPont retained all liabilities related to its U.S. plans post-separation.

On July 1, 2015, Chemours established a defined contribution plan, similar in design to the DuPont Retirement Savings plan, which covered all eligible U.S. employees. The purpose of the Plan is to encourage employees to save for their future retirement needs. The plan is a tax qualified contributory profit sharing plan, with cash or deferred arrangement, and any eligible employee of Chemours employees may participate. Chemours matches 100% of the first 6% of the employee’s contribution election. Chemours may also provide an additional discretionary retirement savings contribution to eligible employees' eligible compensation. The amount of this contribution, if any, is at the sole discretion of the Company. The plan's matching contributions vest immediately upon contribution. The discretionary contribution vests for employees with at least three years of service.

In lieu of a defined benefit plan like DuPont’s primary pension plan, Chemours provides an enhanced 401(k) contribution for employees who previously participated in DuPont’s pension plan. The enhanced benefits consist of an additional contribution of 1% to 7% of the employee’s eligible compensation depending on the employee's length of service with DuPont at the time of separation. The plan will continue for a period up to 2019, subject to early termination.

Plans Covering Employees Outside the U.S.

Pension coverage for employees of Chemours non-U.S. subsidiaries is provided, to the extent deemed appropriate, through separate plans established after separation and comparable to the DuPont plans in those countries. Obligations under such plans are funded by depositing funds with trustees, covered by insurance contracts or are unfunded.

Participation in the Plans

Prior to July 1, 2015, Chemours participated in DuPont’s U.S. and non-U.S. plans, except for the plans in the Netherlands and Taiwan, as though they were participants in a multi-employer plan with the other businesses of DuPont. The following table presents the multi-employer pension expense allocated by DuPont to Chemours for the plans in which Chemours participated prior to separation. The allocation of cost was based on active employee headcount and is included in the Consolidated Statement of Operations. These amounts do not represent cash payments to DuPont or DuPont’s plans.



	EIN / Pension	Year Ended December 31,
Plan Name	Number	2015		2014			2013
DuPont Pension and Retirement Plan (U.S.)	51-0014090/001	$	48	$	51		$	126
All other U.S. and non-U.S. Plans		5		(1		)	38

Single and Multiple Employer Plans

Beginning in the first quarter of 2015, Chemours has accounted for the plans covering its employees in the Netherlands and Taiwan as a multiple employer plan and a single employer plan, respectively. In the third quarter of 2015, in connection with the separation, additional plans in Germany, Belgium, Japan, Korea, Mexico and Switzerland were established. As of December 31, 2015, these plans were all accounted for as single employer plans.

The net periodic benefit costs for the pension and amounts recognized in other comprehensive income for the year ended December 31, 2015 were as follows:



	Year Ended December 31, 2015
Net periodic pension cost (income):
Service cost	$	16
Interest cost	19
Expected return on plan assets	(83		)
Amortization of loss	16
Amortization of prior service cost	4
Net periodic pension income	$	(28	)
Changes in plan assets and benefit obligations recognized in other comprehensive income:
Net loss	$	11
Amortization of loss	(16		)
Prior service credit	(24		)
Amortization of prior service cost	(4		)
Effect of foreign exchange rates	(33		)
Total benefit recognized in other comprehensive income	$	(66	)
Total recognized in net periodic pension income and other comprehensive income	$	(94	)

The pre-tax amounts recognized in accumulated other comprehensive loss are summarized below:



	December 31, 2015
Net loss	$	363
Prior service credit	(16		)
Total amount recognized in accumulated other comprehensive loss	$	347

The estimated pre-tax net loss and prior service cost for the defined benefit pension plans that will be amortized from accumulated other comprehensive (loss) income into net periodic benefit cost during 2016 are $20 and $2, respectively.

Summarized information on the Company's pension benefit plans is as follows:



	Year Ended December 31, 2015
Change in benefit obligation
Benefit obligation at beginning of year	$	—
Assumption and establishment of pension plans	1,332
Service cost	16
Interest cost	19
Plan participants' contributions	2
Actuarial loss (gain)	(76		)
Benefits paid	(39		)
Plan Amendments	(24		)
Settlements & Transfers	(6		)
Currency translation	(118		)
Benefit obligation at end of year	1,106
Change in plan assets
Fair value of plan assets at beginning of year	—
Assumption and establishment of pension plans	1,297
Actual loss on plan assets	(7		)
Employer contributions	16
Plan participants' contributions	2
Benefits paid	(39		)
Settlements & Transfers	(6		)
Currency translation	(123		)
Fair value of plan assets at end of year	1,140
Funded status at end of year	$	34

The net amounts recognized in the Consolidated Balance Sheet as of December 31, 2015 consist of:



Noncurrent assets	$	138
Current liabilities	(2		)
Noncurrent liabilities	(102		)
Net amount recognized	$	34

The accumulated benefit obligation for all pension plans was $1,030 as of December 31, 2015.

The following information relates to pension plans with projected and accumulated benefit obligations in excess of the fair value of plan assets at December 31, 2015:



Information for pension plans with projected benefit obligation in excess of plan assets	December 31, 2015
Projected benefit obligation	$	194
Accumulated benefit obligation	158
Fair value of plan assets	93

Information for pension plans with accumulated benefit obligations in excess of plan assets	December 31, 2015
Projected benefit obligation	$	190
Accumulated benefit obligation	157
Fair value of plan assets	90

Assumptions

The Company generally utilizes discount rates that are developed by matching the expected cash flows of each benefit plan to various yield curves constructed from a portfolio of high quality, fixed income instruments provided by the plan’s actuary as of the measurement date. The expected rate of return on assets reflects economic assumptions applicable to each country.

The following assumptions have been used to determine the benefit obligations and net benefit cost:



Weighted average assumptions used to determine benefit obligations and benefit cost	Pension Benefit Obligation at December 31, 2015		Pension Income for the year ended December 31, 2015
Discount rate	2.4	%	1.7	%
Rate of compensation increase ¹	2.6	%	3.9	%
Expected return on plan assets	N/A		7.2	%

¹ The rate of compensation increase represents the single annual effective salary increase that an average plan participant would receive during the participant's entire career at Chemours.

Plan Assets

Each pension plan's assets are invested through a master trust fund. The strategic asset allocation for the trust fund is selected by management, reflecting the results of comprehensive asset and liability modeling. Chemours establishes strategic asset allocation percentage targets and appropriate benchmarks for significant asset classes with the aim of achieving a prudent balance between return and risk. Strategic asset allocations in countries are selected in accordance with the laws and practices of those countries.

The weighted average target allocation for Chemours' pension plan assets is summarized as follows:



	December 31, 2015
Cash and cash equivalents	2.7	%
U.S. and non-U.S. equity securities	42.3	%
Fixed income securities	55.0	%
Total	100.0	%

Fixed income securities include corporate issued, government issued and asset backed securities. Corporate debt investments encompass a range of credit risk and industry diversification.

Fair value calculations may not be indicative of net realizable value or reflective of future fair values. Furthermore, although Chemours believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.

The table below presents the fair values of Chemours' pension assets by level within the fair value hierarchy, as described in Note 3, as of December 31, 2015.



	Total			Level 1		Level 2
Asset Category:
Debt - government issued	$	465		$	7	$	458
Debt - corporate issued	148			60		88
Debt - asset backed	33			—		33
U.S. and non U.S. equities	460			37		423
Derivatives - asset position	4			—		4
Derivatives - liability position	(16		)	—		(16		)
Cash and cash equivalents	40			40		—
Other	6			4		2
	1,140			$	148	$	992
Pension trust payables ¹	(3		)
Total	$	1,137

¹Payables are primarily for investment securities purchased.

For pension plan assets classified as Level 1, total fair value is either the price of the most recent trade at the time of the market close or the official close price, as defined by the exchange on which the asset is most actively traded on the last trading day of the period, multiplied by the number of units held without consideration of transaction costs.

For pension benefit plan assets classified as Level 2, where the security is frequently traded in less active markets, fair value is based on the closing price at the end of the period; where the security is less frequently traded, fair value is based on the price a dealer would pay for the security or similar securities, adjusted for any terms specific to that asset or liability. Market inputs are obtained from well-established and recognized vendors of market data and subjected to tolerance and quality checks. For derivative assets and liabilities, standard industry models are used to calculate the fair value of the various financial instruments based on significant observable market inputs, such as foreign exchange rates, commodity prices, swap rates, interest rates and implied volatilities obtained from various market sources.

Cash Flow

Defined Benefit Plan

DuPont contributed, on behalf of Chemours, $35 and $34 to its pension plans other than the principal U.S. pension plan in 2014 and 2013, respectively. DuPont contributed, on behalf of Chemours, $66 and $58 to its other long-term employee benefit plans in 2014 and 2013, respectively. DuPont contributed, on behalf of Chemours, $38 in the first half of 2015 to its pension and other long-term benefit plans and Chemours contributed $8 during 2015 to its pension plans. Chemours expects to contribute $18 to its pension plans in 2016.

Estimated future benefit payments

The following benefit payments are expected to be paid over the next five years and the five years thereafter as of December 31, 2015:



2016	$	42
2017	45
2018	44
2019	47
2020	47
2021 - 2025	250

Defined Contribution Plan

DuPont’s contributions to the plan on behalf of Chemours were allocated in the amounts of $52 and $50 for the years ended December 31, 2014 and 2013, respectively. In addition, DuPont contributed on behalf of Chemours about $26 to its defined contribution plans for the first half of 2015. From July 1 to December 31, 2015, Chemours contributed $28 to its defined contribution plan.

Stock-based Compensation

12 Months Ended

Dec. 31, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-based Compensation

Total stock-based compensation cost included in the Consolidated Statements of Operations was $17, $7 and $6 for the years ended December 31, 2015, 2014 and 2013, respectively. The income tax benefits related to stock-based compensation arrangements were $7, $3 and $2 for the years ended December 31, 2015, 2014 and 2013, respectively.

Stock-based compensation expense in prior years and until separation on July 1, 2015 was allocated to Chemours based on the portion of DuPont’s incentive stock program in which Chemours employees participated. Adopted at separation, the Chemours Company Equity and Incentive Plan grants certain employees, independent contractors, or non-employee directors of the Company different forms of awards, including stock options and RSUs. The equity and incentive plan has maximum shares reserve for the grant of 13,500,000 plus the number of shares of converted awards (described below). Chemours Compensation Committee determines the long-term incentive mix, including stock options and RSU, and may authorize new grants annually.

In accordance with the employee matters agreement between DuPont and Chemours, certain executives and employees were entitled to receive equity compensation awards of Chemours in replacement of previously outstanding awards granted under various DuPont stock incentive plans prior to the separation. In connection with the spin-off, these awards were converted into new Chemours equity awards using a formula designed to preserve the intrinsic value of the awards immediately prior to the July 1, 2015 spin-off. At the date of conversion, total intrinsic value of the converted options was $18. As a result of the conversion of these awards, we recorded an approximate $3 incremental charge in the third quarter of 2015. The terms and conditions of the DuPont awards were replicated and as necessary, adjusted to ensure that the vesting schedule and economic value of the awards was unchanged by the conversion.

Stock Options

Chemours granted non-qualified options to employees in July 2015 representing replacement of previously granted performance stock unit awards at DuPont. The July 2015 grant will cliff vest March 1, 2018 and expire 10 years from date of grant. Other than those options, Chemours' expense related to stock options was entirely related to options granted to replace outstanding option awards from DuPont that were converted to Chemours options on July 1, 2015.

The fair value related to stock options granted was determined using Black-Scholes option pricing model and the assumptions shown in the table below:



	Year Ended December 31, 2015
	Year Ended December 31, 2015
Risk-free interest rate	1.5		%
Expected term (years)	5.4
Volatility	42.0		%
Dividend yield	6.9		%
Fair value per stock option	$	3.17

The Company determined the dividend yield by dividing the expected annual dividend on the Company's stock by the option exercise price. A historical daily measurement of volatility is determined based on Chemours peer companies' average volatility adjusted for the Company's debt leverage. The risk-free interest rate is determined by reference to the yield on an outstanding U.S. Treasury note with a term equal to the expected life of the option granted. Expected life is determined by reference to Chemours peer companies expected life and the historical experience of Chemours under the DuPont stock incentive plan prior to separation.

The following table summarizes Chemours stock option activity for the year ended December 31, 2015.



	Number of Shares (in thousands)		Weighted Average Exercise Price(per share)		Weighted Average Remaining Contractual Term (years)	Aggregate Intrinsic Value (in thousands)
Outstanding, December 31, 2014	—		N/A
Converted on July 1, 2015	7,794		$	14.56
Granted	662		16.04
Exercised	(22	)	5.82
Forfeited	(150	)	17.20
Expired	—		N/A
Outstanding, December 31, 2015	8,284		$	14.66	4.82	$	—
Exercisable, December 31, 2015	5,595		$	13.79	4.21	$	—

The aggregate intrinsic values in the table above represent the total pre-tax intrinsic value (the difference between the Company's closing stock price on the last trading day of December 31, 2015 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their in-the-money options at quarter end. The amount changes based on the fair market value of the Company's stock. Total intrinsic value of options exercised for year ended December 31, 2015 was insignificant.

As of December 31, 2015, there was $5 of unrecognized stock-based compensation expense related to stock options that is expected to be recognized over a weighted-average period of 1.95 years.

RSUs

At the time of separation, in accordance with the employee matters agreement, the Company issued RSUs that serially vest over a three-year period and, upon vesting, convert one-for-one to Chemours common stock to replace similar DuPont awards. Under the existing awards, a retirement eligible employee retains any granted awards upon retirement provided the employee has rendered at least six months of service following the grant date. Additional RSUs were also granted to key senior management employees with a performance condition. These RSUs vest on the third anniversary of the date of grant subject to the satisfaction of the performance condition. The fair value of all stock-settled RSUs is based upon the market price of the underlying common stock as of the grant date.

Non-vested awards of RSUs, both with and without performance feature, as of December 31, 2015 are shown below. The weighted-average grant-date fair value of RSUs granted and converted during 2015 was $14.94.



	Number of Shares (in thousands)		Weighted Average Grant Date Fair Value (per share)
Nonvested, December 31, 2014	—		$	—
Converted on July 1, 2015	1,431		16.00
Granted	1,065		13.50
Vested	(133	)	16.00
Forfeited	(14	)	16.00
Nonvested, December 31, 2015	2,349		14.87

As of December 31, 2015, there was $23 of unrecognized stock-based compensation expense related to RSUs that is expected to be recognized over a weighted-average period of 2.12 years.

Geographic and Segment Information

12 Months Ended

Dec. 31, 2015

Segments, Geographical Areas [Abstract]

Geographic and Segment Information

Geographic Information



	For and As of the Year Ended December 31,
	2015				2014				2013
	Net Sales ¹		Net Property, Plant and Equipment		Net Sales ¹		Net Property, Plant and Equipment		Net Sales ¹		Net Property, Plant and Equipment
North America ²	$	2,570	$	2,184	$	2,759	$	2,273	$	3,138	$	2,183
Asia Pacific	1,393		136		1,548		140		1,519		138
EMEA ³	977		308		1,190		372		1,237		321
Latin America ⁴	777		549		935		523		965		330
Total	$	5,717	$	3,177	$	6,432	$	3,308	$	6,859	$	2,972

¹Net sales are attributed to countries based on customer location.

² Includes net sales in Canada of $140, $147 and $145 in 2015, 2014 and 2013, respectively. Includes net property, plant and equipment in Canada of $13, $14 and $13 in 2015, 2014 and 2013, respectively.

³EMEA includesEurope, Middle East and Africa.

⁴ Latin America includes Mexico.

Segment Information

Chemours’ operations are classified into three segments namely: Titanium Technologies, Fluoroproducts and Chemical Solutions. Corporate costs and certain legal and environmental expenses that are not aligned with the segments and foreign exchange gains and losses are reflected in Corporate and Other.

The Titanium Technologies segment is the leading global producer of TiO2, a premium white pigment used to deliver opacity. The Fluoroproducts segment is a leading global provider of fluoroproducts, such as refrigerants and industrial fluoropolymer resins. The Chemical Solutions segment is a leading North American provider of industrial and specialty chemicals, which includes cyanides, sulfur products and performance chemicals and intermediates, used in gold production, oil refining, agriculture, industrial polymers and other industries. Chemours operates globally in substantially all of its product lines.

In general, the accounting policies of the segments are the same as those described in Note 3. Products are transferred between segments on a basis intended to reflect, as nearly as practicable, the market value of the products. Segment net assets includes net working capital, net property, plant and equipment, and other noncurrent operating assets and liabilities of the segment. Depreciation and amortization includes depreciation on research and development facilities and amortization of other intangible assets, excluding write-down of assets.

Adjusted EBITDA is the primary measure of segment profitability used by the Chief Operating Decision Maker (CODM) and is defined as income (loss) before income taxes excluding the following:


•	interest expense, depreciation and amortization,


•	non-operating pension and other postretirement employee benefit costs,


•	exchange gains (losses),


•	employee separation, asset-related charges and other charges, net,


•	asset impairments,


•	gains (losses) on sale of business or assets, and


•	other items not considered indicative of our ongoing operational performance and expected to occur infrequently.

The tables presented below reflect the reclassification of certain corporate costs, certain legal and environmental expenses that are not aligned with our reportable segments, and foreign exchange gains and losses from our reportable segments into Corporate and Other. All periods presented reflect the current definition of Adjusted EBITDA.



Year Ended December 31,	Titanium Technologies		Fluoroproducts		Chemical Solutions		Corporate and Other			Total
2015
Net sales	$	2,392	$	2,230	$	1,095	$	—		$	5,717
Adjusted EBITDA	326		300		29		(82		)	573
Depreciation and amortization	125		88		52		2			267
Equity in earnings of affiliates	—		21		—		1			22
Net assets	1,659		1,567		839		(3,935		)	130
Investments in affiliates	—		127		—		9			136
Purchases of plant, property and equipment	255		142		117		5			519

2014
Net sales	$	2,937	$	2,327	$	1,168	$	—		$	6,432
Adjusted EBITDA	723		282		17		(146		)	876
Depreciation and amortization	125		83		48		1			257
Equity in earnings of affiliates	—		20		—		—			20
Net assets	1,748		1,480		782		(337		)	3,673
Investments in affiliates	—		124		—		—			124
Purchases of plant, property and equipment	365		133		106		—			604

2013
Net sales	$	3,019	$	2,379	$	1,461	$	—		$	6,859
Adjusted EBITDA	726		395		101		(238		)	984
Depreciation and amortization	117		90		53		1			261
Equity in earnings of affiliates	—		22		—		—			22
Net assets	1,390		1,387		734		(294		)	3,217
Investments in affiliates	—		123		—		—			123
Purchases of plant, property and equipment	290		96		52		—			438

Total Adjusted EBITDA reconciles to total consolidated net (loss) income in the Consolidated Statements of Operations as follows:



	Year Ended December 31,
	2015			2014			2013
Total Adjusted EBITDA	$	573		$	876		$	984
Interest	(132		)	—			—
Depreciation and amortization	(267		)	(257		)	(261		)
Non-operating pension and other postretirement employee benefit costs	3			(22		)	(114		)
Exchange gains (losses)	19			(66		)	(31		)
Asset impairments	(73		)	—			—
Restructuring charges	(285		)	(21		)	(2		)
Transaction, legal and other charges	(17		)	—			—
(Loss) gain on sale of assets and businesses	(9		)	40			—
(Loss) income before income taxes	(188		)	550			576
(Benefit from) provision for income taxes	(98		)	149			152
Net (loss) income	$	(90	)	$	401		$	424

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599

Accumulated Other Comprehensive Income (Loss)

Accumulated Other Comprehensive Income (Loss)

12 Months Ended

Dec. 31, 2015

Equity [Abstract]

The components of accumulated other comprehensive income (loss), net of income taxes, consisted of:



	Currency Translation Adjustment			Net Investment Hedge		Employee Benefits			Total
Balance at December 31, 2012	$	19		$	—	$	—		$	19
Other comprehensive income (loss)	—			—		—			—
Balance at December 31, 2013	19			—		—			19
Other comprehensive income (loss)	—			—		—			—
Balance at December 31, 2014	19			—		—			19
Assumption and establishment of pension plans, net	—			—		(311		)	(311		)
Other comprehensive income (loss)	(304		)	8		52			(244		)
Balance at December 31, 2015	$	(285	)	$	8	$	(259	)	$	(536	)

The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e640-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e716-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e709-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2015

Quarterly Financial Data (Unaudited)

The following is a summary of the quarterly results of operations for the years ended December 31, 2015 and 2014.



	For the three months ended
2015	March 31		June 30			September 30			December 31			Full Year
Net Sales	$	1,363	$	1,508		$	1,486		$	1,360		$	5,717
Cost of goods sold	1,111		1,282			1,222			1,147			4,762
Income (loss) before income taxes	58		(18		)	(107		)	(121		)	(188		)
Net income (loss)	43		(18		)	(29		)	(86		)	(90		)
Net income (loss) attributable to Chemours	43		(18		)	(29		)	(86		)	(90		)
Basic earnings (loss) per share ¹	0.24		(0.10		)	(0.16		)	(0.48		)	(0.50		)
Diluted earnings (loss) per share ¹	0.24		(0.10		)	(0.16		)	(0.48		)	(0.50		)



	For the three months ended
2014	March 31		June 30		September 30		December 31		Full Year
Net Sales	$	1,569	$	1,682	$	1,632	$	1,549	$	6,432
Cost of goods sold	1,240		1,311		1,273		1,248		5,072
Income before income taxes	132		155		143		120		550
Net income	98		116		108		79		401
Net income attributable to Chemours	98		116		107		79		400
Basic earnings per share ¹	0.54		0.64		0.59		0.44		2.21
Diluted earnings per share ¹	0.54		0.64		0.59		0.44		2.21

¹On July 1, 2015, E. I. du Pont de Nemours and Company distributed 180,966,833 shares of Chemours' common stock to holders of its common stock. Basic and diluted earnings (loss) per common share for all periods prior to July 1, 2015 were calculated using the shares distributed on July 1, 2015. Refer to Note 9 for information regarding the calculation of basic and diluted earnings per share.

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Dec. 31, 2015
Accounting Policies [Abstract]
Preparation of Financial Statements	Preparation of Financial Statements The preparation of the Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Financial Statements and the reported amounts of revenues and expenses, including allocations of costs as discussed above, during the reporting period. Management’s estimates are based on historical experience, facts and circumstances available at the time and various other assumptions that we believe are reasonable. Actual results could differ from those estimates.
Principles of Consolidation and Combination	Principles of Consolidation and Combination The Consolidated Financial Statements include the accounts Chemours and its subsidiaries, and entities in which a controlling interest is maintained. For those consolidated subsidiaries in which the Company's ownership is less than 100%, the outside shareholders' interests are shown as noncontrolling interests. Investments in companies in which Chemours, directly or indirectly, owns 20% to 50% of the voting stock and has the ability to exercise significant influence over operating and financial policies of the investee are accounting for using the equity method of accounting. As a result, Chemours' share of the earnings or losses of such equity affiliates is included in the accompanying Consolidated Statements of Operations and our share of these companies' stockholders' equity is included in the accompanying Consolidated Balance Sheets. The financial statements for the periods prior to our spin-off on July 1, 2015 include the combined assets, liabilities, revenues, and expenses of Chemours. We eliminated all intercompany accounts and transactions in the preparation of the accompanying Consolidated and Combined Financial Statements.
Revenue Recognition	Revenue Recognition Revenue is recognized when the earnings process is complete. Revenue for product sales is recognized when products are shipped to the customer in accordance with the terms of the agreement, when title and risk of loss have been transferred, collectability is reasonably assured and pricing is fixed or determinable. Revenue associated with advance payments are recorded as deferred revenue and are recognized as shipments are made and title, ownership and risk of loss pass to the customer. Accruals are made for sales returns and other allowances based on historical experience. Cash sales incentives are accounted for as a reduction in sales and noncash sales incentives are recorded as a charge to cost of goods sold at the time the revenue or selling expense, depending on the nature of the incentive, is recorded. Amounts billed to customers for shipping and handling fees are included in net sales and costs incurred by Chemours for the delivery of goods are classified as cost of goods sold in the Consolidated Statements of Operations. Taxes on revenue-producing transactions are excluded from net sales. Licensing and royalty income is recognized in accordance with agreed upon terms, when performance obligations are satisfied, the amount is fixed or determinable and collectability is reasonably assured.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents generally include cash, time deposits or highly liquid investments with original maturities of three months or less.
Receivables and Allowance for Doubtful Accounts	Receivables and Allowance for Doubtful Accounts Receivables are recognized net of an allowance for doubtful accounts. The allowance for doubtful accounts reflects the best estimate of losses inherent in Chemours’ accounts receivable portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other available evidence. Accounts receivable are written off when management determines that they are uncollectible.
Inventories	Inventories Chemours’ inventories are valued at the lower of cost or market. Inventories held at substantially all U.S. locations are valued using the last-in, first-out (LIFO) method. Inventories held outside the U.S. are determined by the average cost method. Elements of cost in inventories include raw materials, direct labor, and manufacturing overhead. Stores and supplies are valued at cost or market, whichever is lower; cost is generally determined by the average cost method. Approximately 61% and 52% of inventory is on a LIFO basis as of December 31, 2015 and 2014, respectively. The remainder is accounted for using the average cost method.
Property, Plant and Equipment	Property, Plant and Equipment Property, plant and equipment is carried at cost and is depreciated using the straight-line method. Property, plant and equipment placed in service prior to 1995 is depreciated under the sum-of-the-years’ digits method or other substantially similar methods. Substantially all equipment and buildings are depreciated over useful lives ranging from 15 to 25 years. Capitalizable costs associated with computer software for internal use are amortized on a straight-line basis over five to seven years. When assets are surrendered, retired, sold or otherwise disposed of, their gross carrying values and related accumulated depreciation are removed from the balance sheet and included in determining gain or loss on such disposals. Repair and maintenance costs that materially add to the value of the asset or prolong its useful life are capitalized and depreciated based on the extension to the useful life. Capitalized repair and maintenance costs are recorded on the Consolidated Balance Sheets in other assets.
Direct Financing Type Leases	Direct Financing Type Leases Certain of Chemours’ facilities are located on land owned by third parties. The plant and equipment built on this land is constructed by, owned, and operated by Chemours for the exclusive benefit of the third party landlord. The useful lives of the equipment are generally shorter than the lease term, or there exists a purchase option for the third party to acquire the equipment at the end of the lease term. Based on an analysis of the underlying agreements, management has determined that these agreements and property represent a direct financing type lease, whereby Chemours is the lessor of its equipment to the third party landlords. As such, the related plant and equipment are reported as leases receivable.
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets The excess of the purchase price over the estimated fair value of the net assets acquired, including identified intangibles, is recorded as goodwill. Goodwill is tested for impairment annually on October 1; however, these tests are performed more frequently when events or changes in circumstances indicate that the asset may be impaired. Impairment exists when carrying value exceeds fair value. Goodwill is evaluated for impairment at the reporting unit level. Evaluating goodwill for impairment is a two-step process. In the first step, Chemours compares the carrying value of net assets to the fair value of the related operations. Chemours’ methodology for estimating the fair value of its reporting units is using the income approach based on the present value of future cash flows. The factors considered in determining the cash flows include: 1) macroeconomic conditions; 2) industry and market considerations; 3) costs of raw materials, labor or other costs having a negative effect on earnings and cash flows; 4) overall financial performance; and 5) other relevant entity-specific events. If the fair value is determined to be less than the carrying value, a second step is performed to compute the amount of the impairment. Definite-lived intangible assets, such as purchased and licensed technology, patents, trademarks, and customer lists are amortized over their estimated useful lives, generally for periods ranging from five to 20 years. The reasonableness of the useful lives of these assets is continually evaluated.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Chemours evaluates the carrying value of long-lived assets to be held and used when events or changes in circumstances indicate the carrying value may not be recoverable. For purposes of recognition or measurement of an impairment loss, the assessment is performed on the asset or asset group at the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. To determine the level at which the assessment is performed, Chemours considers factors such as revenue dependency, shared costs and the extent of vertical integration. The carrying value of a long-lived asset is considered impaired when the total projected undiscounted cash flows from the use and eventual disposition of an asset or asset group are separately identifiable and are less than its carrying value. In that event, a loss is recognized based on the amount by which the carrying value exceeds the fair value of the long-lived asset. The fair value methodology used is an estimate of fair market value which is made based on prices of similar assets or other valuation methodologies including present value techniques. Long-lived assets to be disposed of other than by sale are classified as held for use until their disposal. Long-lived assets to be disposed of by sale are classified as held for sale and are reported at the lower of carrying amount or fair market value less cost to sell. Depreciation is discontinued for long-lived assets classified as held for sale.
Research and Development	Research and Development Research and development costs are expensed as incurred. Research and development expenses include costs (primarily consisting of employee costs, materials, contract services, research agreements, and other external spend) relating to the discovery and development of new products, enhancement of existing products and regulatory approval of new and existing products.
Environmental Liabilities and Expenditures	Environmental Liabilities and Expenditures Chemours accrues for remediation activities when it is probable that a liability has been incurred and a reasonable estimate of the liability can be made. Environmental liabilities and expenditures included in the Consolidated Financial Statements include claims for matters that are liabilities of DuPont and its subsidiaries, that Chemours may be required to indemnify pursuant to the separation-related agreements executed prior to the spin-off. Accruals for environmental matters are recorded in cost of goods sold when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. Accrued liabilities do not include claims against third parties and are not discounted. Costs related to environmental remediation are charged to expense in the period incurred. Other environmental costs are also charged to expense in the period incurred, unless they increase the value of the property or reduce or prevent contamination from future operations, in which case they are capitalized and amortized.
Asset Retirement Obligations	Asset Retirement Obligations Chemours records asset retirement obligations at fair value at the time the liability is incurred. Fair value is measured using expected future cash outflows discounted at Chemours’ credit-adjusted risk-free interest rate, which are considered level 3 inputs. Accretion expense is recognized as an operating expense classified within cost of goods sold on the Consolidated Income Statements using the credit-adjusted risk-free interest rate in effect when the liability was recognized. The associated asset retirement obligations are capitalized as part of the carrying amount of the long-lived asset and depreciated over the estimated remaining useful life of the asset, generally for periods ranging from two to 25 years.
Litigation	Litigation Chemours accrues for litigation matters when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated. Litigation liabilities and expenditures included in the Consolidated Financial Statements represent litigation matters that are liabilities of DuPont and its subsidiaries, that Chemours may be required to indemnify pursuant to the separation-related agreements executed prior to the spin-off. Legal costs such as outside counsel fees and expenses are charged to expense in the period services are received.
Insurance	Insurance Chemours insures certain risks where permitted by law or regulation, including workers' compensation, vehicle liability and employee related benefits. Liabilities associated with these risks are estimated in part by considering historical claims experience, demographic factors and other actuarial assumptions. For other risks, the Company uses a combination of insurance and self-insurance, reflecting comprehensive reviews of relevant risks. A receivable for an insurance recovery is generally recognized when the loss has occurred and collection is considered probable. Prior to the spin-off, Chemours was a participant in DuPont’s self-insurance program where permitted by law or regulation, including workers’ compensation, vehicle liability and employee related benefits. Liabilities associated with these risks are estimated in part by considering historical claims experience, demographic factors, and other actuarial assumptions. For other risks, a combination of insurance and self-insurance is used, reflecting comprehensive reviews of relevant risks. The annual cost was allocated to all of the participating businesses using methodologies deemed reasonable by management. All obligations pursuant to these plans have historically been obligations of DuPont. As such, these obligations were not included in the Consolidated Balance Sheets, with the exception of self-insurance liabilities related to workers compensation, vehicle liability and employee related benefits.
Defined Benefit Plans	Defined Benefit Plans We have defined benefit plans covering certain of our employees outside the U.S., which are generally required by local regulations. The benefits, which primarily relate to pension, are accrued over the employees’ service periods. We use actuarial methods and assumptions in the valuation of defined benefit obligations and the determination of net periodic pension income or expense. Differences between actual and expected results or changes in the value of defined benefit obligations and plan assets, if any, are not recognized in earnings as they occur but rather systematically over subsequent periods.
Stock-based Compensation	Stock-based Compensation Chemours' stock-based compensation consists of stock options and restricted stock units (RSUs) to employees and non-employee directors. Stock options are measured at fair value on the grant date or date of modification, as applicable. We recognize compensation expense on a straight-line basis over the requisite service period. The number of awards ultimately expected to vest is determined by use of an estimated forfeiture rate. The estimated forfeiture rate is based on historical data for the employee group awarded options and expected employee turnover rates, which management reevaluates each period.
Income Taxes	Income Taxes The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. The provision for income taxes represents income taxes paid or payable for the current year plus the change in deferred taxes during the year. Deferred taxes result from differences between the financial and tax basis of Chemours’ assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. Chemours recognizes income tax positions that meet the more likely than not threshold and accrues interest related to unrecognized income tax positions, which is included in other income, net in our Consolidated Statements of Operations. Income tax related penalties are included in the provision for income taxes. Chemours does not provide for income taxes on undistributed earnings of all foreign subsidiaries that are intended to be indefinitely reinvested. Prior to separation on July 1, 2015, income taxes presented attributed current and deferred income taxes of DuPont to Chemours’ stand-alone financial statements in a manner that is systematic, rational, and consistent with the asset and liability method prescribed by ASC 740, Income Taxes (ASC 740). Accordingly, Chemours’ income tax provision was prepared following the separate return method. The separate return method applies ASC 740 to the stand-alone financial statements of each member of the consolidated group as if the group member were a separate taxpayer and a stand-alone enterprise.
Foreign Currency Translation	Foreign Currency Translation Chemours identifies its separate and distinct foreign entities and groups them into two categories: (1) extensions of the parent (U.S. dollar functional currency) and (2) self-contained (local functional currency). If a foreign entity does not align with either category, factors are evaluated and a judgment is made to determine the functional currency. Chemours changes the functional currency of its separate and distinct foreign entities only when significant changes in economic facts and circumstances indicate clearly that the functional currency has changed. During the periods covered by the Consolidated Financial Statements, part of the Chemours business operated within foreign entities. For foreign entities where the U.S. dollar is the functional currency, all foreign currency-denominated asset and liability amounts are remeasured into U.S. dollars at end-of-period exchange rates, except for inventories; prepaid expenses; property, plant and equipment; goodwill and other intangible assets, which are remeasured at historical rates. Foreign currency-denominated income and expenses are remeasured at average exchange rates in effect during the period, except for expenses related to balance sheet amounts remeasured at historical exchange rates. Exchange gains and losses arising from remeasurement of foreign currency-denominated monetary assets and liabilities are included in other income, net in the period in which they occur. For foreign entities where the local currency is the functional currency, assets and liabilities denominated in local currencies are translated into U.S. dollars at end-of-period exchange rates and the resulting translation adjustments are reported as a component of accumulated other comprehensive (loss) income in equity. Assets and liabilities denominated in other than the functional currency are remeasured into the functional currency prior to translation into U.S. dollars and the resulting exchange gains or losses are included in income in the period in which they occur. Income and expenses are translated into U.S. dollars at average exchange rates in effect during the period. Beginning in 2015, when the Chemours operations were legally and operationally separated within DuPont in anticipation of the spin-off, certain of Chemours foreign entities set their local currency as the functional currency.
Derivatives	Derivatives Chemours enters into forward currency exchange contracts to minimize volatility in earnings related to the foreign exchange gains and losses resulting from remeasuring net monetary assets that Chemours holds which are denominated in non-functional currencies. Chemours does not hold or issue financial instruments for speculative or trading purposes. The derivative assets and liabilities are reported on a gross basis in the Consolidated Balance Sheets. All gains and losses resulting from the revaluation of the derivative assets and liabilities are recognized in other income, net in the Consolidated Statements of Operations during the period in which they occurred.
Fair Value Measurement	Fair Value Measurement Under the accounting for fair value measurements and disclosures, a fair value hierarchy was established that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). A financial instrument's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Chemours uses the following valuation techniques to measure fair value for its assets and liabilities: (a) Level 1—Quoted market prices in active markets for identical assets and liabilities; (b) Level 2—Significant other observable inputs (e.g. quoted prices for similar items in active markets, quoted prices for identical or similar items in markets that are not active, inputs other than quoted prices that are observable, such as interest rate and yield curves, and market-corroborated inputs); and (c) Level 3—Unobservable inputs for the asset or liability, which are valued based on management's estimates of assumptions that market participants would use in pricing the asset or liability.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In November 2015, the Financial Accounting Standards Board (FASB) issued ASU No. 2015-17, "Income Taxes (Topic 740) - Balance Sheet Classification of Deferred Taxes", to simplify the presentation of deferred income taxes and require that deferred income tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The amendments are effective for financial statements issued for annual periods beginning after December 15, 2016, and interim periods within those annual periods, and earlier application is permitted for all entities as of the beginning of an interim or annual reporting period. The Company retroactively adopted this change effective in 2015 and as such the 2014 Consolidated Balance Sheet reflects the reclassifications affecting total current assets, total assets, total current liabilities and total liabilities . The reclassifications did not have a significant impact on Chemours' financial position and had no impact on its results of operations or cash flows. See Note 8 for additional information. In June 2015, the FASB issued ASU No. 2015-11, "Inventory (Topic 330), Simplifying the Measurement of Inventory," which requires an entity to measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Currently, the inventory standard requires an entity to measure inventory at the lower of cost or market. Market could be replacement cost, net realizable value, or net realizable value less an approximately normal profit margin. The amendment does not apply to inventory that is measured using LIFO or the retail inventory method but applies to all other inventory, which includes inventory that is measured using first-in, first-out (FIFO) or average cost. The amendment is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years, and should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. Chemours is currently evaluating the impact of adopting this guidance. In May 2015, the FASB issued ASU No. 2015-07, "Fair Value Measurement (Topic 820) - Disclosures for Investment in Certain Entities that Calculate Net Asset Value per Share or its Equivalent." This guidance removes the requirement to categorize within the fair value hierarchy all investments for which fair value is measured using the net asset value per share practical expedient. The guidance also removes the requirement to make certain disclosures for all investments that are eligible to be measured at fair value using the net asset value per share practical expedient. Rather, those disclosures are limited to investments for which the entity has elected to measure the fair value using that practical expedient. The amendment is effective for fiscal years beginning after December 15, 2015 and interim periods within those fiscal years. A reporting entity should apply the amendments retrospectively to all periods presented and earlier application is permitted. Chemours adopted this guidance effective January 1, 2016. The adoption is not expected to have a significant impact on our financial position and results of operations. In April 2015, the FASB issued ASU No. 2015-05, "Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement," which provides guidance about whether a cloud computing arrangement includes a software license. The customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If the cloud computing arrangement does not include a software license, the customer should account for the arrangement as a service contract. This guidance is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2015, and early adoption is permitted. Chemours adopted this guidance effective January 1, 2016. The adoption is not expected to have a significant impact on our financial position and results of operations. In April 2015, the FASB issued ASU No. 2015-03, “Interest — Imputation of Interest (Subtopic 835-30),” which requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The guidance is effective for public entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015 with early adoption permitted, including adoption in an interim period. Chemours adopted this guidance for the quarter ending June 30, 2015. The adoption of this standard had no impact on Chemours’ results of operations or cash flows. Due to the accounting change described above, Chemours recorded debt issuance costs incurred for the issuance of its senior secured term loans and senior unsecured notes as a reduction of the liability on the Consolidated Balance Sheets. See Note 18 for additional information. In February 2015, the FASB issued ASU No. 2015-02, “Consolidation (Topic 810): Amendments to the Consolidation Analysis.” The amendments modify the evaluation of whether limited partnerships and similar legal entities are variable interest entities (VIEs) or voting interest entities and eliminate the presumption that a general partner should consolidate a limited partnership. The amendment is effective for public entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. Chemours adopted this guidance effective January 1, 2016. The adoption is not expected to have a significant impact on our financial position and results of operations. In May 2014, the FASB and the International Accounting Standards Board (IASB) jointly issued ASU No. 2014-09, "Revenue from Contracts with Customers (Topic 606)," which clarifies the principles for recognizing revenue and develops a common revenue standard for GAAP and International Financial Reporting Standards (IFRS). The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The guidance is effective for public entities for annual and interim periods beginning after December 15, 2016 (original effective date). In July 2015, the FASB approved a deferral of the effective date of this guidance to provide entities with adequate time to effectively implement the new revenue standard and adoption as of the original effective date is permitted. The Company is currently evaluating the impact of adopting this guidance on its financial position and results of operations. In April 2014, the FASB issued ASU No. 2014-08, “Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity,” amending existing requirements for reporting discontinued operations and disposals of components of an entity. The amended guidance limits the discontinued operations reporting to disposal transactions that represent strategic shifts having a major effect on operations and financial results. The amendment also enhances disclosures and requires assets and liabilities of a discontinued operation to be classified as such for all periods presented in the financial statements. Chemours adopted this guidance effective on January 1, 2015. Due to the change in requirements for reporting discontinued operations described above, presentation and disclosures of future disposal transactions after adoption may be different than under current standards.

Relationship with DuPont and Related Entities (Tables)

12 Months Ended

Dec. 31, 2015

Schedule of Related Party Transactions

Related party sales to DuPont include the following amounts:



Selling Segment	Year Ended December 31,
Selling Segment	2015			2014		2013
Titanium Technologies	$	2	¹	$	—	$	6
Fluoroproducts	34		¹	45		37
Chemical Solutions	21		¹	65		78
Total	$	57		$	110	$	121

¹ Subsequent to the spin-off on July 1, 2015, transactions with DuPont businesses were not considered related party transactions.

Allocated leveraged functional service expenses and general corporate expenses were recorded in the Consolidated Statements of Operations within the following captions:



	Year Ended December 31,
	2015			2014		2013
Selling, general and administrative expense	$	205	¹	$	411	$	436
Research and development expense	10		¹	49		50
Cost of goods sold	23		¹	32		33
Total	$	238		$	492	$	519

Employee Separation and Asset Related Charges, Net (Tables)

12 Months Ended

Dec. 31, 2015

Restructuring and Related Activities [Abstract]

Schedule of Restructuring Program

For the years ended December 31, 2015, 2014 and 2013, Chemours recorded charges for employee separation and asset related charges as follows:



	Year Ended December 31,
	2015		2014		2013
Employee Separation Charges	$	137	$	18	$	2
Asset Related Charges - Restructuring	133		3		—
Asset Related Charges - Impairment ¹	48		—		—
Decommissioning and other charges - Restructuring	15		—		—
Total	$	333	$	21	$	2

¹ See Note 12 for further information.

Schedule of Restructuring Charges

The charges related to our programs and impairments impacted segment earnings for the years ended December 31, 2015 and 2014 as follows:



	Titanium Technologies		Fluoroproducts		Chemical Solutions		Total
Year ended December 31, 2015
Titanium Technologies plant closures	$	140	$	—	$	—	$	140
Fluoroproducts restructuring and other asset impairment	—		24		—		24
RMS plant closure	—		—		57		57
2015 Restructuring	33		54		25		112		¹
	$	173	$	78	$	82	$	333
Year ended December 31, 2014
2014 Restructuring	$	3	$	16	$	—	$	19

¹ Includes approximately $24 related to corporate overhead functions that was allocated to our segments.

The following table shows the change in our significant liability account balances.



	Titanium Technologies Site Closures		Chemical Solutions Site Closures		2015 Restructuring			2014 Restructuring			Total
Balance as of December 31, 2013	$	—	$	—	$	—		$	—		$	—
Charges to income for the year ended December 31, 2014	—		—		—			16			16
Charges to liability accounts:
Payments	—		—		—			(2		)	(2		)
Net currency translation adjustment	—		—		—			(2		)	(2		)
Balance as of December 31, 2014	—		—		—			12			12
Charges to income for the year ended December 31, 2015	11		12		112			—			135
Charges to liability accounts:
Payments	—		—		(39		)	(11		)	(50		)
Net currency translation adjustment ¹	—		—		—			—			—
Balance as of December 31, 2015	$	11	$	12	$	73		$	1		$	97

¹ Net currency translation adjustment for the year ended December 31, 2015 was less than $1.

Other Income, Net (Tables)

12 Months Ended

Dec. 31, 2015

Other Income and Expenses [Abstract]

Schedule of Other Income



	Year Ended December 31,
	2015			2014			2013
Leasing, contract services and miscellaneous income	$	25		$	17		$	24
Royalty income¹	19			28			24
Gain on purchase of equity method investment	—			—			7
(Loss) gain on sale of assets and businesses ²	(9		)	40			—
Exchange gains (losses), net ³	19			(66		)	(31		)
Total other income, net	$	54		$	19		$	24

¹ Royalty income is primarily for technology and trademark licensing.

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2015

Income Tax Disclosure [Abstract]

Schedule of Components of Income Tax Provision



	Year Ended December 31,
(Dollars in millions)	2015				2014			2013
Current tax expense:
U.S. federal	$	37		¹	$	85		$	67
U.S. state and local	1			¹	13			11
International	62				73			88
Total current tax expense	100				171			166
Deferred tax (benefit) expense:
U.S. federal	(187		)		(20		)	(4		)
U.S. state and local	(14		)		(3		)	(2		)
International	3				1			(8		)
Total deferred tax benefit	(198		)		(22		)	(14		)
Total (benefit from) provision for income taxes	$	(98	)		$	149		$	152

¹ Recorded pursuant to the tax matters agreement.

Schedule of Deferred Tax Assets and Liabilities Components

The significant components of deferred tax assets and liabilities are as follows:



(Dollars in millions)	December 31, 2015			December 31, 2014
Deferred tax assets-noncurrent:
Other assets and other accrued liabilities	$	257		$	188
Tax loss carryforwards	124			36
Total deferred tax assets-noncurrent	381			224
Valuation allowance	—			(36		)
Total deferred tax assets, net	381			188

Deferred tax liabilities-noncurrent:
Goodwill and other intangibles	—			(2		)
Accrued expenses and other liabilities	(7		)	(34		)
Property, plant and equipment	(530		)	(533		)
Inventories and other assets	(31		)	(33		)
Total deferred tax liabilities-noncurrent	(568		)	(602		)
Net deferred tax liability	$	(187	)	$	(414	)

Schedule of Effective Income Tax Rate

An analysis of the Company's effective tax rate is as follows:



	Year Ended December 31,
(Dollars in millions)	2015		2014		2013
Statutory U.S. federal income tax rate	35.0	%	35.0	%	35.0	%
State income taxes, net of federal benefit	5.1	%	1.0	%	1.0	%
Benefit from (lower effective tax rate) on international operations-net	12.0	%	(9.6	)%	(10.2	)%
Valuation allowance	—	%	2.0	%	1.2	%
Exchange (gains) losses	0.5	%	2.7	%	2.3	%
Depletion	3.4	%	(3.9	)%	(4.1	)%
Goodwill	(3.2	)%	—	%	—	%
Section 199 deduction	—	%	(0.7	)%	(0.8	)%
Other, net	(0.5	)%	0.6	%	2.0	%
Total effective tax rate	52.3	%	27.1	%	26.4	%

Schedule of Income before Income Taxes

(Loss) income before income taxes for U.S. and international operations was:



	Year Ended December 31,
(Dollars in millions)	2015			2014		2013
U.S. (including exports)	$	(492	)	$	244	$	224
International	304			306		352
Total pre-tax (loss) income	$	(188	)	$	550	$	576

Schedule of Unrecognized Tax Benefits

The following table shows the change in our unrecognized tax benefit.



	Year Ended December 31,
(Dollars in millions)	2015				2014			2013
Total unrecognized tax benefits as of January 1	$	39			$	26		$	24
Gross amounts of decreases in unrecognized tax benefits as a result of adjustments to tax provisions taken during the prior period	—				(1		)	(1		)
Gross amounts of increases in unrecognized tax benefits as a result of tax positions taken during the current period	—				15			5
Reduction to unrecognized tax benefits as a result of a lapse of the applicable statute of limitations	(32		)	¹	(1		)	(2		)
Total unrecognized tax benefits as of December 31	$	7			$	39		$	26

Total unrecognized tax benefits, if recognized, that would impact the effective tax rate	$	—			$	39		$	26
Total amount of interest and penalties recognized in the Consolidated Statements of Operations	1			¹	2			2
Total amount of interest and penalties recognized in the Consolidated Balance Sheets	—				8			6

Summary of Deferred Tax Asset Valuation Allowance

The following is a rollforward of the deferred tax asset valuation allowance for the years ended December 31, 2015, 2014 and 2013.



	Year Ended December 31,
(Dollars in millions)	2015			2014		2013
Balance at beginning of period	$	36		$	26	$	19
Net charges to income tax expense	—			10		7
Release of valuation allowance ¹	(36		)	—		—
Balance at end of period	$	—		$	36	$	26

¹ Release of valuation allowance during 2015 was primarily related to the tax attributes retained by DuPont pursuant to the tax matters agreement.

Earnings Per Share of Common Stock (Tables)

12 Months Ended

Dec. 31, 2015

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

The table below shows a reconciliation of the numerator and denominator for basic and diluted earnings per share calculations for the periods indicated.



	Year Ended December 31,
	2015			2014			2013
Numerator:
Net (loss) income attributable to Chemours	$	(90	)	$	400		$	423
Denominator:
Weighted-average number of common shares outstanding- Basic	180,993,623			180,966,833		¹	180,966,833		¹
Dilutive effect of the Company's employee compensation plans²	—			—			—
Weighted average number of common shares outstanding - Diluted ²	180,993,623			180,966,833			180,966,833

¹ For 2013 and 2014, pro forma earnings per share (EPS) was calculated based on 180,966,833 shares of Chemours common stock that were distributed to DuPont shareholders on July 1, 2015.

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following average number of stock options were antidilutive and, therefore, were not included in the diluted earnings per share calculation:



	Year Ended December 31,
	2015	2014	2013
Average number of stock options	8,358,894	—	—

Accounts and Notes Receivable - Trade, Net (Tables)

12 Months Ended

Dec. 31, 2015

Receivables [Abstract]

Schedule of Accounts, Notes, Loans and Financing Receivable



	December 31, 2015		December 31, 2014
Accounts receivable—trade, net ¹	$	757	$	746
VAT, GST and other taxes ²	68		62
Leases receivable—current	13		12
Other receivables ³	21		26
Total	$	859	$	846

¹Accounts receivable – trade is net of allowances of $4 and $4 as of December 31, 2015 and 2014, respectively. Allowances are equal to the estimated uncollectible amounts.

²Value Added Tax (VAT) and Goods and Services Tax (GST).

³Other receivables consist of notes receivable, advances and other deposits.

Inventories (Tables)

12 Months Ended

Dec. 31, 2015

Inventory, Net [Abstract]

Schedule of Inventories



	December 31, 2015			December 31, 2014
Finished products	$	613		$	611
Semi-finished products	172			173
Raw materials, stores and supplies	433			521
Subtotal	1,218			1,305
Adjustment of inventories to LIFO basis	(246		)	(253		)
Total	$	972		$	1,052

Property, Plant and Equipment (Tables)

12 Months Ended

Dec. 31, 2015

Property, Plant and Equipment [Abstract]

Summary of property, plant and equipment

Chemours' property, plant and equipment consisted of:



	December 31, 2015			December 31, 2014
Equipment	$	7,327		$	7,500
Buildings	737			778
Construction in progress	804			852
Land	111			116
Mineral rights	36			36
Total	9,015			9,282
Accumulated depreciation	(5,838		)	(5,974		)
Net property, plant and equipment	$	3,177		$	3,308

Goodwill and Other Intangible Assets, Net (Tables)

12 Months Ended

Dec. 31, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill

The following table summarizes changes in the carrying amount of goodwill by reportable segment:



	Titanium Technologies		Fluoroproducts		Chemical Solutions			Total
Balance as of December 31, 2013	$	13	$	85	$	100		$	198
Impairment charge	—		—		—			—
Other adjustments	—		—		—			—
Balance as of December 31, 2014	13		85		100			198
Impairment charge	—		—		(25		)	(25		)
Other adjustments	—		—		(7		)	(7		)
Balance as of December 31, 2015	$	13	$	85	$	68		$	166

Schedule of Other Intangible Assets

The following table summarizes the gross carrying amounts and accumulated amortization of other intangible assets by major class:



	December 31, 2015							December 31, 2014
	Gross		Accumulated Amortization			Net		Gross		Accumulated Amortization			Net
Customer lists	$	13	$	(10	)	$	3	$	13	$	(10	)	$	3
Patents	19		(17		)	2		19		(15		)	4
Purchased trademarks	5		(2		)	3		5		(1		)	4
Purchased and licensed technology	8		(6		)	2		5		(5		)	—
Total	$	45	$	(35	)	$	10	$	42	$	(31	)	$	11

Other Assets (Tables)

12 Months Ended

Dec. 31, 2015

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Schedule of Other Assets



	December 31, 2015		December 31, 2014
Leases receivable - non-current¹	$	125	$	137
Capitalized repair and maintenance costs	149		185
Pension assets ²	138		—
Advances and deposits	11		17
Deferred income taxes	47		10
Miscellaneous ³	38		28
Total	$	508	$	377

¹Leases receivable includes direct financing leases of property at two locations. See Note 10 for further information.

²Pension assets represent pension plans commencing in 2015. See Note 21 for further information.

Accounts Payable (Tables)

12 Months Ended

Dec. 31, 2015

Schedule of Accounts Payable



	December 31, 2015		December 31, 2014
Trade payables	$	945	$	1,004
VAT and other payables	28		42
Total	$	973	$	1,046

Other Accrued Liabilities (Tables)

12 Months Ended

Dec. 31, 2015

Schedule of Other Accrued Liabilities



	December 31, 2015		December 31, 2014
Compensation and other employee-related costs	$	109	$	109
Employee separation costs ¹	76		12
Accrued litigation ²	11		7
Environmental remediation ²	68		69
Income taxes	32		—
Customer rebates	53		59
Deferred revenue	20		28
Accrued interest	21		—
Miscellaneous ³	64		68
Total	$	454	$	352

¹See Note 6 for further information.

² See Note 19 for further discussion of environmental remediation and accrued litigation.

³ Miscellaneous primarily includes accrued utility expenses, property taxes, an accrued indemnification liability and other miscellaneous expenses.

Other Liabilities (Tables)

12 Months Ended

Dec. 31, 2015

Other Liabilities Disclosure [Abstract]

Schedule of Other Liabilities



	December 31, 2015		December 31, 2014
Environmental remediation ¹	$	223	$	226
Employee-related costs ²	108		32
Employee separation costs ³	23		—
Accrued litigation ¹	58		52
Asset retirement obligations ¹	41		43
Deferred revenue	11		13
Miscellaneous ⁴	89		98
Total	$	553	$	464

¹ See Note 19 for further details on environmental remediation, asset retirement obligations and accrued litigation.

² See Note 21 for further details on long-term employee benefits.

³See Note 6 for further information.

⁴ Miscellaneous primarily includes an accrued indemnification liability.

Debt (Tables)

12 Months Ended

Dec. 31, 2015

Debt Disclosure [Abstract]

Schedule of Long-term Debt Instruments

Long-term debt, net of an unamortized discount on the Term Loan Facility of $7, was comprised of the following at December 31, 2015:



	December 31, 2015
Long-term debt:
Senior secured term loan, net of issue discount	$	1,493
Senior unsecured notes:
6.625%, due May 2023	1,350
7.00%, due May 2025	750
6.125%, due May 2023 (€360)	395
Other	26
Total	4,014
Less: Unamortized debt issuance costs	60
Less: Short-term borrowings and current maturities	39
Total long-term debt	$	3,915

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingent Liabilities (Tables)

12 Months Ended

Dec. 31, 2015

Summary of the changes in asset retirement obligations

A summary of the changes in asset retirement obligations is as follows:



(Dollars in millions)	Year Ended December 31,
	2015			2014
Beginning balance	$	43		$	42
Accretion expense	1			2
Additional liabilities incurred	—			1
Changes in estimated cash flows	—			—
Settlements/payments	(2		)	(2		)
Ending balance	$	42		$	43
Current portion	$	1		$	—
Non-current portion	$	41		$	43

Financial Instruments (Tables)

12 Months Ended

Dec. 31, 2015

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Assets at Fair Value

The table below presents the fair value of Chemours’ derivative assets and liabilities within the fair value hierarchy, as described in Note 3 to the Consolidated Financial Statements.



		Fair Value Using Level 2 Inputs
	Balance Sheet Location	December 31, 2015		December 31, 2014
Asset derivatives:
Foreign currency forward contracts	Accounts and notes receivable - trade, net	$	2	$	—
Total asset derivatives		$	2	$	—

Liability derivatives:
Foreign currency forward contracts	Other accrued liabilities	$	2	$	—
Total liability derivatives		$	2	$	—

Schedule of Derivative Liabilities at Fair Value

The table below presents the fair value of Chemours’ derivative assets and liabilities within the fair value hierarchy, as described in Note 3 to the Consolidated Financial Statements.



		Fair Value Using Level 2 Inputs
	Balance Sheet Location	December 31, 2015		December 31, 2014
Asset derivatives:
Foreign currency forward contracts	Accounts and notes receivable - trade, net	$	2	$	—
Total asset derivatives		$	2	$	—

Liability derivatives:
Foreign currency forward contracts	Other accrued liabilities	$	2	$	—
Total liability derivatives		$	2	$	—

Long-Term Employee Benefits (Tables)

12 Months Ended

Dec. 31, 2015

General Discussion of Pension and Other Postretirement Benefits [Abstract]

Schedule of Multiemployer Plans

The following table presents the multi-employer pension expense allocated by DuPont to Chemours for the plans in which Chemours participated prior to separation. The allocation of cost was based on active employee headcount and is included in the Consolidated Statement of Operations. These amounts do not represent cash payments to DuPont or DuPont’s plans.



	EIN / Pension	Year Ended December 31,
Plan Name	Number	2015		2014			2013
DuPont Pension and Retirement Plan (U.S.)	51-0014090/001	$	48	$	51		$	126
All other U.S. and non-U.S. Plans		5		(1		)	38

Schedules of Net Periodic Benefit Cost

The net periodic benefit costs for the pension and amounts recognized in other comprehensive income for the year ended December 31, 2015 were as follows:



	Year Ended December 31, 2015
Net periodic pension cost (income):
Service cost	$	16
Interest cost	19
Expected return on plan assets	(83		)
Amortization of loss	16
Amortization of prior service cost	4
Net periodic pension income	$	(28	)
Changes in plan assets and benefit obligations recognized in other comprehensive income:
Net loss	$	11
Amortization of loss	(16		)
Prior service credit	(24		)
Amortization of prior service cost	(4		)
Effect of foreign exchange rates	(33		)
Total benefit recognized in other comprehensive income	$	(66	)
Total recognized in net periodic pension income and other comprehensive income	$	(94	)

Schedule of Amounts Recognized in Other Comprehensive Income (Loss)

The pre-tax amounts recognized in accumulated other comprehensive loss are summarized below:



	December 31, 2015
Net loss	$	363
Prior service credit	(16		)
Total amount recognized in accumulated other comprehensive loss	$	347



	Year Ended December 31, 2015
Net periodic pension cost (income):
Service cost	$	16
Interest cost	19
Expected return on plan assets	(83		)
Amortization of loss	16
Amortization of prior service cost	4
Net periodic pension income	$	(28	)
Changes in plan assets and benefit obligations recognized in other comprehensive income:
Net loss	$	11
Amortization of loss	(16		)
Prior service credit	(24		)
Amortization of prior service cost	(4		)
Effect of foreign exchange rates	(33		)
Total benefit recognized in other comprehensive income	$	(66	)
Total recognized in net periodic pension income and other comprehensive income	$	(94	)

Summary of Benefit Obligations and Fair Value of Plan Assets and Funded Status of Plan

Summarized information on the Company's pension benefit plans is as follows:



	Year Ended December 31, 2015
Change in benefit obligation
Benefit obligation at beginning of year	$	—
Assumption and establishment of pension plans	1,332
Service cost	16
Interest cost	19
Plan participants' contributions	2
Actuarial loss (gain)	(76		)
Benefits paid	(39		)
Plan Amendments	(24		)
Settlements & Transfers	(6		)
Currency translation	(118		)
Benefit obligation at end of year	1,106
Change in plan assets
Fair value of plan assets at beginning of year	—
Assumption and establishment of pension plans	1,297
Actual loss on plan assets	(7		)
Employer contributions	16
Plan participants' contributions	2
Benefits paid	(39		)
Settlements & Transfers	(6		)
Currency translation	(123		)
Fair value of plan assets at end of year	1,140
Funded status at end of year	$	34

Schedule of Amounts Recognized in the Consolidated Balance Sheet

The net amounts recognized in the Consolidated Balance Sheet as of December 31, 2015 consist of:



Noncurrent assets	$	138
Current liabilities	(2		)
Noncurrent liabilities	(102		)
Net amount recognized	$	34

Schedule of Projected Benefit Obligations in Excess of Fair Value of Plan Assets

The following information relates to pension plans with projected and accumulated benefit obligations in excess of the fair value of plan assets at December 31, 2015:



Information for pension plans with projected benefit obligation in excess of plan assets	December 31, 2015
Projected benefit obligation	$	194
Accumulated benefit obligation	158
Fair value of plan assets	93

Information for pension plans with accumulated benefit obligations in excess of plan assets	December 31, 2015
Projected benefit obligation	$	190
Accumulated benefit obligation	157
Fair value of plan assets	90

Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets

The following information relates to pension plans with projected and accumulated benefit obligations in excess of the fair value of plan assets at December 31, 2015:



Information for pension plans with projected benefit obligation in excess of plan assets	December 31, 2015
Projected benefit obligation	$	194
Accumulated benefit obligation	158
Fair value of plan assets	93

Information for pension plans with accumulated benefit obligations in excess of plan assets	December 31, 2015
Projected benefit obligation	$	190
Accumulated benefit obligation	157
Fair value of plan assets	90

Schedule of Assumptions Used

The following assumptions have been used to determine the benefit obligations and net benefit cost:



Weighted average assumptions used to determine benefit obligations and benefit cost	Pension Benefit Obligation at December 31, 2015		Pension Income for the year ended December 31, 2015
Discount rate	2.4	%	1.7	%
Rate of compensation increase ¹	2.6	%	3.9	%
Expected return on plan assets	N/A		7.2	%

¹ The rate of compensation increase represents the single annual effective salary increase that an average plan participant would receive during the participant's entire career at Chemours.

Schedule of Allocation of Plan Assets

The weighted average target allocation for Chemours' pension plan assets is summarized as follows:



	December 31, 2015
Cash and cash equivalents	2.7	%
U.S. and non-U.S. equity securities	42.3	%
Fixed income securities	55.0	%
Total	100.0	%

The table below presents the fair values of Chemours' pension assets by level within the fair value hierarchy, as described in Note 3, as of December 31, 2015.



	Total			Level 1		Level 2
Asset Category:
Debt - government issued	$	465		$	7	$	458
Debt - corporate issued	148			60		88
Debt - asset backed	33			—		33
U.S. and non U.S. equities	460			37		423
Derivatives - asset position	4			—		4
Derivatives - liability position	(16		)	—		(16		)
Cash and cash equivalents	40			40		—
Other	6			4		2
	1,140			$	148	$	992
Pension trust payables ¹	(3		)
Total	$	1,137

¹Payables are primarily for investment securities purchased.

Schedule of Expected Benefit Payments

The following benefit payments are expected to be paid over the next five years and the five years thereafter as of December 31, 2015:



2016	$	42
2017	45
2018	44
2019	47
2020	47
2021 - 2025	250

Stock-based Compensation (Tables)

12 Months Ended

Dec. 31, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Stock Options Valuation Assumptions

The fair value related to stock options granted was determined using Black-Scholes option pricing model and the assumptions shown in the table below:



	Year Ended December 31, 2015
	Year Ended December 31, 2015
Risk-free interest rate	1.5		%
Expected term (years)	5.4
Volatility	42.0		%
Dividend yield	6.9		%
Fair value per stock option	$	3.17

Schedule of Stock Options Activity

The following table summarizes Chemours stock option activity for the year ended December 31, 2015.



	Number of Shares (in thousands)		Weighted Average Exercise Price(per share)		Weighted Average Remaining Contractual Term (years)	Aggregate Intrinsic Value (in thousands)
Outstanding, December 31, 2014	—		N/A
Converted on July 1, 2015	7,794		$	14.56
Granted	662		16.04
Exercised	(22	)	5.82
Forfeited	(150	)	17.20
Expired	—		N/A
Outstanding, December 31, 2015	8,284		$	14.66	4.82	$	—
Exercisable, December 31, 2015	5,595		$	13.79	4.21	$	—

Schedule of Restricted Stock Units Activity



	Number of Shares (in thousands)		Weighted Average Grant Date Fair Value (per share)
Nonvested, December 31, 2014	—		$	—
Converted on July 1, 2015	1,431		16.00
Granted	1,065		13.50
Vested	(133	)	16.00
Forfeited	(14	)	16.00
Nonvested, December 31, 2015	2,349		14.87

Geographic and Segment Information (Tables)

12 Months Ended

Dec. 31, 2015

Segments, Geographical Areas [Abstract]

Schedule of Net Sales and Net Property, Plant and Equipment by Geographical Area



	For and As of the Year Ended December 31,
	2015				2014				2013
	Net Sales ¹		Net Property, Plant and Equipment		Net Sales ¹		Net Property, Plant and Equipment		Net Sales ¹		Net Property, Plant and Equipment
North America ²	$	2,570	$	2,184	$	2,759	$	2,273	$	3,138	$	2,183
Asia Pacific	1,393		136		1,548		140		1,519		138
EMEA ³	977		308		1,190		372		1,237		321
Latin America ⁴	777		549		935		523		965		330
Total	$	5,717	$	3,177	$	6,432	$	3,308	$	6,859	$	2,972

¹Net sales are attributed to countries based on customer location.

³EMEA includesEurope, Middle East and Africa.

⁴ Latin America includes Mexico.

Schedule of Segment Information



Year Ended December 31,	Titanium Technologies		Fluoroproducts		Chemical Solutions		Corporate and Other			Total
2015
Net sales	$	2,392	$	2,230	$	1,095	$	—		$	5,717
Adjusted EBITDA	326		300		29		(82		)	573
Depreciation and amortization	125		88		52		2			267
Equity in earnings of affiliates	—		21		—		1			22
Net assets	1,659		1,567		839		(3,935		)	130
Investments in affiliates	—		127		—		9			136
Purchases of plant, property and equipment	255		142		117		5			519

2014
Net sales	$	2,937	$	2,327	$	1,168	$	—		$	6,432
Adjusted EBITDA	723		282		17		(146		)	876
Depreciation and amortization	125		83		48		1			257
Equity in earnings of affiliates	—		20		—		—			20
Net assets	1,748		1,480		782		(337		)	3,673
Investments in affiliates	—		124		—		—			124
Purchases of plant, property and equipment	365		133		106		—			604

2013
Net sales	$	3,019	$	2,379	$	1,461	$	—		$	6,859
Adjusted EBITDA	726		395		101		(238		)	984
Depreciation and amortization	117		90		53		1			261
Equity in earnings of affiliates	—		22		—		—			22
Net assets	1,390		1,387		734		(294		)	3,217
Investments in affiliates	—		123		—		—			123
Purchases of plant, property and equipment	290		96		52		—			438

Reconciliation of EBITDA from Segments to Consolidated

Total Adjusted EBITDA reconciles to total consolidated net (loss) income in the Consolidated Statements of Operations as follows:



	Year Ended December 31,
	2015			2014			2013
Total Adjusted EBITDA	$	573		$	876		$	984
Interest	(132		)	—			—
Depreciation and amortization	(267		)	(257		)	(261		)
Non-operating pension and other postretirement employee benefit costs	3			(22		)	(114		)
Exchange gains (losses)	19			(66		)	(31		)
Asset impairments	(73		)	—			—
Restructuring charges	(285		)	(21		)	(2		)
Transaction, legal and other charges	(17		)	—			—
(Loss) gain on sale of assets and businesses	(9		)	40			—
(Loss) income before income taxes	(188		)	550			576
(Benefit from) provision for income taxes	(98		)	149			152
Net (loss) income	$	(90	)	$	401		$	424

Accumulated Other Comprehensive Income (Loss) (Tables)

12 Months Ended

Dec. 31, 2015

Equity [Abstract]

Schedule of Components of Accumulated Other Comprehensive Income (Loss)

The components of accumulated other comprehensive income (loss), net of income taxes, consisted of:



	Currency Translation Adjustment			Net Investment Hedge		Employee Benefits			Total
Balance at December 31, 2012	$	19		$	—	$	—		$	19
Other comprehensive income (loss)	—			—		—			—
Balance at December 31, 2013	19			—		—			19
Other comprehensive income (loss)	—			—		—			—
Balance at December 31, 2014	19			—		—			19
Assumption and establishment of pension plans, net	—			—		(311		)	(311		)
Other comprehensive income (loss)	(304		)	8		52			(244		)
Balance at December 31, 2015	$	(285	)	$	8	$	(259	)	$	(536	)

Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2015

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Data

The following is a summary of the quarterly results of operations for the years ended December 31, 2015 and 2014.



	For the three months ended
2015	March 31		June 30			September 30			December 31			Full Year
Net Sales	$	1,363	$	1,508		$	1,486		$	1,360		$	5,717
Cost of goods sold	1,111		1,282			1,222			1,147			4,762
Income (loss) before income taxes	58		(18		)	(107		)	(121		)	(188		)
Net income (loss)	43		(18		)	(29		)	(86		)	(90		)
Net income (loss) attributable to Chemours	43		(18		)	(29		)	(86		)	(90		)
Basic earnings (loss) per share ¹	0.24		(0.10		)	(0.16		)	(0.48		)	(0.50		)
Diluted earnings (loss) per share ¹	0.24		(0.10		)	(0.16		)	(0.48		)	(0.50		)



	For the three months ended
2014	March 31		June 30		September 30		December 31		Full Year
Net Sales	$	1,569	$	1,682	$	1,632	$	1,549	$	6,432
Cost of goods sold	1,240		1,311		1,273		1,248		5,072
Income before income taxes	132		155		143		120		550
Net income	98		116		108		79		401
Net income attributable to Chemours	98		116		107		79		400
Basic earnings per share ¹	0.54		0.64		0.59		0.44		2.21
Diluted earnings per share ¹	0.54		0.64		0.59		0.44		2.21

Background and Description of the Business (Details)		12 Months Ended
Background and Description of the Business (Details)	Jul. 01, 2015	Dec. 31, 2015 facility segment $ / shares	Jun. 23, 2015 $ / shares
Segment Reporting Information [Line Items]
Number of reportable segments \| segment		3
Number of facilities		35
Common stock , par value (USD per share) \| $ / shares		$ 0.01	$ 0.01
Spin off transaction distribution ratio	0.2
DuPont [Member]
Segment Reporting Information [Line Items]
Common stock , par value (USD per share) \| $ / shares			$ 0.30
Operating Segments [Member]
Segment Reporting Information [Line Items]
Number of facilities		1
Titanium Technologies [Member]
Segment Reporting Information [Line Items]
Number of facilities		5
Fluoroproducts [Member]
Segment Reporting Information [Line Items]
Number of facilities		16
Chemical Solutions [Member]
Segment Reporting Information [Line Items]
Number of facilities		13

Basis of Presentation (Details) $ in Millions	12 Months Ended
Basis of Presentation (Details) $ in Millions	Dec. 31, 2015 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Noncash contribution	$ 109

Summary of Significant Accounting Policies (Details)	Dec. 31, 2015	Dec. 31, 2014
Accounting Policies [Abstract]
Percentage of LIFO inventory	61.00%	52.00%

Summary of Significant Accounting Policies - Property, Plant and Equipment (Details)	12 Months Ended
	Dec. 31, 2015
Equipment and Buildings [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	15 years
Equipment and Buildings [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	25 years
Software Development [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	5 years
Software Development [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful Life	7 years

Summary of Significant Accounting Policies - Goodwill and Other Intangible Assets and Asset Retirement Obligations (Details)	12 Months Ended
	Dec. 31, 2015
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful life	5 years
Useful life of asset retirement obligation	2 years
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, useful life	20 years
Useful life of asset retirement obligation	25 years

Relationship with DuPont and Related Entities (Related Party Purchases and Sales) (Details) - Subsidiary of Common Parent [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Related Party Transaction [Line Items]
Related party sales	$ 57	$ 110	$ 121
Operating Segments [Member] \| Titanium Technologies [Member]
Related Party Transaction [Line Items]
Related party sales	2	0	6
Operating Segments [Member] \| Fluoroproducts [Member]
Related Party Transaction [Line Items]
Related party sales	34	45	37
Operating Segments [Member] \| Chemical Solutions [Member]
Related Party Transaction [Line Items]
Related party sales	$ 21	$ 65	$ 78

Relationship with DuPont and Related Entities (Leveraged Services and Corporate Costs) (Details) - Affiliated Entity [Member] - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Related Party Transaction [Line Items]
Expenses from transactions with related party	$ 238	$ 238	$ 492	$ 519
Selling, General and Administrative Expenses [Member]
Related Party Transaction [Line Items]
Expenses from transactions with related party		205	411	436
Research and Development Expense [Member]
Related Party Transaction [Line Items]
Expenses from transactions with related party		10	49	50
Cost of Goods [Member]
Related Party Transaction [Line Items]
Expenses from transactions with related party		$ 23	$ 32	$ 33

Relationship with DuPont and Related Entities (Details) - Subsequent Event [Member] - Arrangement to Purchase Services and Materials [Member] - Affiliated Entity [Member] $ in Millions	1 Months Ended
	Feb. 25, 2016 USD ($)
Related Party Transaction [Line Items]
Amount of agreement with related party	$ 190
Minimum [Member]
Related Party Transaction [Line Items]
Remaining agreement term	12 months
Maximum [Member]
Related Party Transaction [Line Items]
Remaining agreement term	15 months

Research and Development Expense (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Research and Development [Line Items]
Research and development expense	$ 97	$ 143	$ 164
Projects Incurred by Chemours [Member]
Research and Development [Line Items]
Research and development expense	87	94	114
Corporate Central Research and Development [Member]
Research and Development [Line Items]
Research and development expense	$ 10	$ 49	$ 50

Employee Separation and Asset Related Charges, Net (Charges) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Restructuring and Related Activities [Abstract]
Employee Separation Charges	$ 137	$ 18	$ 2
Asset Related Charges - Restructuring	133	3	0
Asset Related Charges - Impairment	48	0	0
Decommissioning and other charges - Restructuring	15	0	0
Employee separation and asset related charges, net	$ 333	$ 21	$ 2

Employee Separation and Asset Related Charges, Net (Restructuring Program schedule) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning	$ 12,000,000	$ 0
Restructuring charges	135,000,000	16,000,000
Payments	(50,000,000)	(2,000,000)
Net currency translation adjustment	0	(2,000,000)
Restructuring reserve, ending	97,000,000	12,000,000
Titanium Technologies Site Closure [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning	0	0
Restructuring charges	11,000,000	0
Payments	0	0
Net currency translation adjustment	0	0
Restructuring reserve, ending	11,000,000	0
Chemical Solutions Site Closures [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning	0	0
Restructuring charges	12,000,000	0
Payments	0	0
Net currency translation adjustment	0	0
Restructuring reserve, ending	12,000,000	0
2015 Restructuring Program [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning	0	0
Restructuring charges	112,000,000	0
Payments	(39,000,000)	0
Net currency translation adjustment	0	0
Restructuring reserve, ending	73,000,000	0
2014 Restructuring Program [Member]
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning	12,000,000	0
Restructuring charges	0	16,000,000
Payments	(11,000,000)	(2,000,000)
Net currency translation adjustment	0	(2,000,000)
Restructuring reserve, ending	1,000,000	$ 12,000,000
Maximum [Member]
Restructuring Reserve [Roll Forward]
Net currency translation adjustment	$ 1,000,000

Other Income, Net (Schedule of Other Income) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Component of Other Income [Line Items]
Leasing, contract services and miscellaneous income	$ 25	$ 17	$ 24
Royalty income	19	28	24
Gain on purchase of equity method investment	0	0	7
(Loss) gain on sale of assets and businesses	(9)	40	0
Exchange gains (losses), net	19	(66)	(31)
Total other income, net	54	19	$ 24
Gain (loss) on sale of assets		40
Gain on sale of remaining assets		6
Gain on derivative	42
Exchange gains (losses),net	(23)
Operating Segments [Member] \| Fluoroproducts [Member]
Component of Other Income [Line Items]
Gain (loss) on sale of assets		30
Operating Segments [Member] \| Titanium Technologies [Member]
Component of Other Income [Line Items]
Gain (loss) on sale of assets		$ 4
Sweden [Member]
Component of Other Income [Line Items]
Proceeds from sale of subsidiary	4
Sweden [Member] \| Operating Segments [Member] \| Fluoroproducts [Member]
Component of Other Income [Line Items]
Gain (loss) on sale of assets	$ (9)

Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
Income Taxes (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Provision (benefit) for income taxes	$ (98)	$ 149	$ 152
Decrease in tax provision	247
Unremitted earnings of foreign subsidiaries	1,500
Tax Credit Carryforward [Line Items]
Tax effect of tax carryforwards	124
Expires in 2026 [Member]
Tax Credit Carryforward [Line Items]
Tax effect of tax carryforwards	25
Expires in 2036 [Member]
Tax Credit Carryforward [Line Items]
Tax effect of tax carryforwards	90
Expiration Between Years 2021 to 2036 [Member]
Tax Credit Carryforward [Line Items]
Tax effect of tax carryforwards	$ 9

Income Taxes - Provision for Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Current tax expense:
U.S. federal	$ 37	$ 85	$ 67
U.S. state and local	1	13	11
International	62	73	88
Total current tax expense	100	171	166
Deferred tax (benefit) expense:
U.S. federal	(187)	(20)	(4)
U.S. state and local	(14)	(3)	(2)
International	3	1	(8)
Total deferred tax benefit	(198)	(22)	(14)
Total (benefit from) provision for income taxes	$ (98)	$ 149	$ 152

Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets-noncurrent:
Other assets and other accrued liabilities	$ 257	$ 188
Tax loss carryforwards	124	36
Total deferred tax assets-noncurrent	381	224
Valuation allowance	0	(36)
Total deferred tax assets, net	381	188
Deferred tax liabilities-noncurrent:
Goodwill and other intangibles	0	(2)
Accrued expenses and other liabilities	(7)	(34)
Property, plant and equipment	(530)	(533)
Inventories and other assets	(31)	(33)
Total deferred tax liabilities-noncurrent	(568)	(602)
Net deferred tax liability	$ (187)	$ (414)

Income Taxes - Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Statutory U.S. federal income tax rate	35.00%	35.00%	35.00%
State income taxes, net of federal benefit	5.10%	1.00%	1.00%
Benefit from (lower effective tax rate) on international operations-net	12.00%	(9.60%)	(10.20%)
Valuation allowance	0.00%	2.00%	1.20%
Exchange (gains) losses	0.50%	2.70%	2.30%
Depletion	3.40%	(3.90%)	(4.10%)
Goodwill	(3.20%)	(0.00%)	(0.00%)
Section 199 deduction	(0.00%)	(0.70%)	(0.80%)
Other, net	(0.50%)	0.60%	2.00%
Total effective tax rate	52.30%	27.10%	26.40%

Income Taxes - Summary of Income Before Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
U.S. (including exports)									$ (492)	$ 244	$ 224
International									304	306	352
(Loss) income before income taxes	$ (121)	$ (107)	$ (18)	$ 58	$ 120	$ 143	$ 155	$ 132	$ (188)	$ 550	$ 576

Income Taxes - Unrecognized Tax Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Total unrecognized tax benefits as of January 1	$ 39	$ 26	$ 24
Gross amounts of decreases in unrecognized tax benefits as a result of adjustments to tax provisions taken during the prior period	0	(1)	(1)
Gross amounts of increases in unrecognized tax benefits as a result of tax positions taken during the current period	0	15	5
Reduction to unrecognized tax benefits as a result of a lapse of the applicable statute of limitations	(32)	(1)	(2)
Total unrecognized tax benefits as of December 31	7	39	26
Total unrecognized tax benefits, if recognized, that would impact the effective tax rate	0	39	26
Total amount of interest and penalties recognized in the Consolidated Statements of Operations	1	2	2
Total amount of interest and penalties recognized in the Consolidated Balance Sheets	$ 0	$ 8	$ 6

Income Taxes - Summary of Valuation Allowance (Details) - Valuation Allowance of Deferred Tax Assets [Member] - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at beginning of period	$ 36	$ 26	$ 19
Net charges to income tax expense	0	10	7
Release of valuation allowance	(36)	0	0
Balance at end of period	$ 0	$ 36	$ 26

Earnings Per Share of Common Stock (Earnings per Share Calculation) (Details) - USD ($)		3 Months Ended								12 Months Ended
	Jul. 01, 2015	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Numerator:
Net (loss) income attributable to Chemours		$ (86,000,000)	$ (29,000,000)	$ (18,000,000)	$ 43,000,000	$ 79,000,000	$ 107,000,000	$ 116,000,000	$ 98,000,000	$ (90,000,000)	$ 400,000,000	$ 423,000,000
Denominator:
Weighted-average number of common shares outstanding- Basic										180,993,623	180,966,833	180,966,833
Dilutive effect of the Company's employee compensation plans, shares										$ 0	$ 0	$ 0
Weighted average number of common shares outstanding - Diluted										180,993,623	180,966,833	180,966,833
Distribution of Common Stock at separation (in shares)	180,966,833

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

Changes in plan assets and benefit obligations recognized in other comprehensive income:

Earnings Per Share of Common Stock (Antidilutive Shares Excluded from Computation of Earnings per Share) (Details) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Earnings Per Share [Abstract]
Average number of stock options	8,358,894	0	0

Accounts and Notes Receivable - Trade, Net (Schedule of Accounts and Notes Receivable) (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Receivables [Abstract]
Accounts receivable—trade, net	$ 757	$ 746
VAT, GST and other taxes	68	62
Leases receivable—current	13	12
Other receivables	21	26
Total	$ 859	$ 846

Accounts and Notes Receivable - Trade, Net (Narrative) (Details)	12 Months Ended
	Dec. 31, 2015 USD ($) facility	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)
Receivables [Abstract]
Allowance for doubtful accounts receivable	$ 4,000,000	$ 4,000,000
Bad debt expense (less than $1 for year ended December 31, 2015)	$ 1,000,000	1,000,000	$ 2,000,000
Number of facilities with fixed assets constructed on land \| facility	2
Leases receivable	$ 138,000,000	$ 149,000,000
Estimated future residual value of leased assets	$ 0

Inventories (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Inventory, Net [Abstract]
Finished products	$ 613	$ 611
Semi-finished products	172	173
Raw materials, stores and supplies	433	521
Subtotal	1,218	1,305
Adjustment of inventories to LIFO basis	(246)	(253)
Total	972	1,052
LIFO inventory amount	$ 744	$ 684
Percentage of LIFO inventory	61.00%	52.00%

Property, Plant and Equipment (Details) - USD ($)	3 Months Ended	12 Months Ended
Property, Plant and Equipment (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Nov. 30, 2015
Property, Plant and Equipment, Net, by Type [Abstract]
Property, plant and equipment, gross		$ 9,015,000,000	$ 9,282,000,000
Less: Accumulated depreciation		(5,838,000,000)	(5,974,000,000)
Net property, plant and equipment		3,177,000,000	3,308,000,000	$ 2,972,000,000
Depreciation expense		264,000,000	254,000,000	255,000,000
Capital leased assets		7,000,000	6,000,000
Interest capitalized		21,000,000	0	0
Asset impairment charges		48,000,000	0	$ 0
Consideration for disposal group					$ 140,000,000
Equipment [Member]
Property, Plant and Equipment, Net, by Type [Abstract]
Property, plant and equipment, gross		7,327,000,000	7,500,000,000
Building [Member]
Property, Plant and Equipment, Net, by Type [Abstract]
Property, plant and equipment, gross		737,000,000	778,000,000
Construction in progress [Member]
Property, Plant and Equipment, Net, by Type [Abstract]
Property, plant and equipment, gross		804,000,000	852,000,000
Land [Member]
Property, Plant and Equipment, Net, by Type [Abstract]
Property, plant and equipment, gross		111,000,000	116,000,000
Mineral rights [Member]
Property, Plant and Equipment, Net, by Type [Abstract]
Property, plant and equipment, gross		36,000,000	$ 36,000,000
Operating Segments [Member] \| Chemical Solutions [Member]
Property, Plant and Equipment, Net, by Type [Abstract]
Asset impairment charges	$ 45,000,000
Disposal Group, Held-for-sale, Not Discontinued Operations [Member]
Property, Plant and Equipment, Net, by Type [Abstract]
Asset disposal group		$ 46,000,000

Goodwill and Other Intangible Assets, Net (Schedule of Goodwill) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Goodwill [Roll Forward]
Goodwill, beginning balance	$ 198	$ 198
Impairment charge	(25)	0	$ 0
Other adjustments	(7)	0
Goodwill, ending balance	166	198	198
Chemical Solutions [Member]
Goodwill [Roll Forward]
Impairment charge	(25)
Operating Segments [Member] \| Titanium Technologies [Member]
Goodwill [Roll Forward]
Goodwill, beginning balance	13	13
Impairment charge	0	0
Other adjustments	0	0
Goodwill, ending balance	13	13	13
Operating Segments [Member] \| Fluroproducts [Member]
Goodwill [Roll Forward]
Goodwill, beginning balance	85	85
Impairment charge	0	0
Other adjustments	0	0
Goodwill, ending balance	85	85	85
Operating Segments [Member] \| Chemical Solutions [Member]
Goodwill [Roll Forward]
Goodwill, beginning balance	100	100
Impairment charge	(25)	0
Other adjustments	(7)	0
Goodwill, ending balance	$ 68	$ 100	$ 100

Goodwill and Other Intangible Assets, Net (Narrative) (Details) $ in Millions	3 Months Ended	12 Months Ended
	Dec. 31, 2015 USD ($) segment	Dec. 31, 2015 USD ($) segment	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)
Indefinite-lived Intangible Assets [Line Items]
Number of reportable segments \| segment		3
Impairment charge		$ 25	$ 0	$ 0
Finite-Lived Intangible Assets [Line Items]
Amortization expense, 2016	$ 3	3
Amortization expense, 2017	2	2
Amortization expense, 2018	1	1
Amortization expense, 2019	1	1
Amortization expense, 2020	$ 1	1
Chemical Solutions [Member]
Indefinite-lived Intangible Assets [Line Items]
Impairment charge		$ 25
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life		5 years
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful life		20 years
Continuing Operations [Member]
Finite-Lived Intangible Assets [Line Items]
Aggregate pre-tax amortization expense		$ 3	3	$ 6
Operating Segments [Member] \| Chemical Solutions [Member]
Indefinite-lived Intangible Assets [Line Items]
Number of reportable segments for purposes of goodwill \| segment	7
Impairment charge		$ 25	$ 0

Goodwill and Other Intangible Assets, Net (Schedule of Other Intangible Assets) (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	$ 45	$ 42
Intangible Assets, Accumulated Amortization	(35)	(31)
Intangible Assets, Net	10	11
Customer Lists [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	13	13
Intangible Assets, Accumulated Amortization	(10)	(10)
Intangible Assets, Net	3	3
Patents [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	19	19
Intangible Assets, Accumulated Amortization	(17)	(15)
Intangible Assets, Net	2	4
Purchased trademarks [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	5	5
Intangible Assets, Accumulated Amortization	(2)	(1)
Intangible Assets, Net	3	4
Purchased and licensed technology [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Intangible Assets, Gross	8	5
Intangible Assets, Accumulated Amortization	(6)	(5)
Intangible Assets, Net	$ 2	$ 0

Other Assets (Details) $ in Millions	12 Months Ended
Other Assets (Details) $ in Millions	Dec. 31, 2015 USD ($) location	Dec. 31, 2014 USD ($)
Debt Instrument [Line Items]
Leases receivable - non-current	$ 125	$ 137
Capitalized repair and maintenance costs	149	185
Noncurrent assets	138	0
Advances and deposits	11	17
Deferred income taxes	47	10
Miscellaneous	38	28
Total	$ 508	$ 377
Direct financing leases, number of locations \| location	2
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Deferred financing fee	$ 19

Accounts Payable (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Payables and Accruals [Abstract]
Trade payables	$ 945	$ 1,004
VAT and other payables	28	42
Total	$ 973	$ 1,046

Other Accrued Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Accrued Liabilities, Current [Abstract]
Compensation and other employee-related costs	$ 109	$ 109
Employee separation costs	76	12
Accrued litigation	11	7
Environmental remediation	68	69
Income taxes	32	0
Customer rebates	53	59
Deferred revenue	20	28
Accrued interest	21	0
Miscellaneous	64	68
Total	$ 454	$ 352

Other Liabilities (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Other Liabilities [Abstract]
Environmental remediation	$ 223	$ 226
Employee-related costs	108	32
Employee separation costs	23	0
Accrued litigation	58	52
Asset retirement obligations	41	43
Deferred revenue	11	13
Miscellaneous	89	98
Total	$ 553	$ 464

Debt (Components of Long-Term Debt) (Details) € in Millions, $ in Millions	Dec. 31, 2015 USD ($)	Dec. 31, 2015 EUR (€)	May 12, 2015 USD ($)	May 12, 2015 EUR (€)	Dec. 31, 2014 USD ($)
Debt Instrument [Line Items]
Long-term debt, gross			$ 3,995
Long-term debt	$ 4,014
Less: Unamortized debt issuance costs	60
Less: Short-term borrowings and current maturities	39				$ 0
Total long-term debt	3,915				$ 0
Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt, gross			2,503
Senior Notes [Member] \| 6.625% Senior Notes Due May 2023 [Member]
Debt Instrument [Line Items]
Long-term debt, gross			1,350
Long-term debt	$ 1,350
Debt instrument interest rate	6.625%	6.625%
Senior Notes [Member] \| 7.00% Senior Notes Due May 2025 [Member]
Debt Instrument [Line Items]
Long-term debt, gross			750
Long-term debt	$ 750
Debt instrument interest rate	7.00%	7.00%
Senior Notes [Member] \| Senior Notes 6.125% Due May 2023 [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 395	€ 360		€ 360
Long-term debt	$ 395
Debt instrument interest rate	6.125%	6.125%
Other Payables [Member]
Debt Instrument [Line Items]
Long-term debt	$ 26
The Term Loan Facility [Member]
Debt Instrument [Line Items]
Unamortized discount	7		$ 7
Long-term debt	$ 1,493
Debt instrument interest rate	1.00%	1.00%

Debt (Senior Secured Credit Facilities) (Details)		12 Months Ended
Debt (Senior Secured Credit Facilities) (Details)	May 12, 2015 USD ($)	Dec. 31, 2015 USD ($)	Feb. 19, 2016 USD ($)
Line of Credit Facility [Line Items]
Long-term debt		$ 4,014,000,000
Domestic Subsidiary [Member]
Line of Credit Facility [Line Items]
Collateral as percentage of common stock	100.00%
Foreign Subsidiary [Member]
Line of Credit Facility [Line Items]
Collateral as percentage of common stock	65.00%
The Term Loan Facility [Member]
Line of Credit Facility [Line Items]
Debt instrument term	7 years
Line of credit facility, maximum borrowing capacity	$ 1,500,000,000
Periodic payment, percentage of face amount	1.00%
Unamortized discount	$ 7,000,000	7,000,000
Stated percentage rate, minimum	3.75%
Long-term debt		1,493,000,000
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Debt instrument term	5 years
Line of credit facility, maximum borrowing capacity	$ 1,000,000,000
Long-term debt		0
Letters of credit outstanding		$ 129,000,000
Commitment fee percentage	0.35%
Maximum net leverage ratio		3.50
Minimum interest coverage ratio		1.75
Revolving Credit Facility [Member] \| Minimum [Member]
Line of Credit Facility [Line Items]
Unused capacity commitment fee percentage	0.20%
Revolving Credit Facility [Member] \| Maximum [Member]
Line of Credit Facility [Line Items]
Unused capacity commitment fee percentage	0.35%
Revolving Credit Facility [Member] \| Base Rate [Member]
Line of Credit Facility [Line Items]
Variable rate		1.25%
Revolving Credit Facility [Member] \| Base Rate [Member] \| Minimum [Member]
Line of Credit Facility [Line Items]
Variable rate	0.50%
Revolving Credit Facility [Member] \| Base Rate [Member] \| Maximum [Member]
Line of Credit Facility [Line Items]
Variable rate	1.25%
Revolving Credit Facility [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Variable rate		2.25%
Revolving Credit Facility [Member] \| London Interbank Offered Rate (LIBOR) [Member] \| Minimum [Member]
Line of Credit Facility [Line Items]
Variable rate	1.50%
Revolving Credit Facility [Member] \| London Interbank Offered Rate (LIBOR) [Member] \| Maximum [Member]
Line of Credit Facility [Line Items]
Variable rate	2.25%
Subsequent Event [Member] \| Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Line of credit facility, maximum borrowing capacity			$ 750,000,000

Debt (Senior Unsecured Notes) (Details) € in Millions	May 12, 2015 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2015 EUR (€)	May 12, 2015 EUR (€)
Debt Instrument [Line Items]
Long-term debt, gross	$ 3,995,000,000
Senior Notes [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 2,503,000,000
Debt Instrument, interest rate, additional	0.25%			0.25%
Threshold consecutive days following registration default	90 days
Threshold consecutive days following registration default, additional	90 days
Interest rate additional maximum	0.50%			0.50%
Obligation threshold for debt to become guaranteed	$ 75,000,000
Repurchase price obligation, percentage of principal amount redeemed in event of change of control	101.00%			101.00%
Repurchase price obligation, percentage of principal amount redeemed in event of change of asset dispositions	100.00%			100.00%
Senior Notes [Member] \| 6.625% Senior Notes Due May 2023 [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 1,350,000,000
Senior Notes [Member] \| 7.00% Senior Notes Due May 2025 [Member]
Debt Instrument [Line Items]
Long-term debt, gross	750,000,000
Debt Instrument, face amount	$ 507,000,000
Senior Notes [Member] \| Senior Notes 6.125% Due May 2023 [Member]
Debt Instrument [Line Items]
Long-term debt, gross		$ 395,000,000	€ 360	€ 360

Debt (Maturities and Fair Value) (Details) $ in Millions	12 Months Ended
Debt (Maturities and Fair Value) (Details) $ in Millions	Dec. 31, 2015 USD ($)
Debt Instrument [Line Items]
Years with no long term debt maturities, except term loan facilities	7 years
Senior Notes [Member] \| 6.625% Senior Notes Due May 2023 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.625%
Senior Notes [Member] \| 7.00% Senior Notes Due May 2025 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	7.00%
Senior Notes [Member] \| Senior Notes 6.125% Due May 2023 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	6.125%
Level 2 [Member] \| Senior Notes [Member] \| 6.625% Senior Notes Due May 2023 [Member]
Debt Instrument [Line Items]
Notes, fair value	$ 946
Level 2 [Member] \| Senior Notes [Member] \| 7.00% Senior Notes Due May 2025 [Member]
Debt Instrument [Line Items]
Notes, fair value	513
Level 2 [Member] \| Senior Notes [Member] \| Senior Notes 6.125% Due May 2023 [Member]
Debt Instrument [Line Items]
Notes, fair value	$ 277
The Term Loan Facility [Member]
Debt Instrument [Line Items]
Debt instrument interest rate	1.00%
2016	$ 15
2017	15
2018	15
2019	15
2020	15
2021 and beyond	3,913
The Term Loan Facility [Member] \| Level 2 [Member]
Debt Instrument [Line Items]
Line of credit facility, fair value	$ 1,348

Commitments and Contingent Liabilities (Guarantees) (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Guarantee obligations	$ 8	$ 41

Commitments and Contingent Liabilities (Operating Leases) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
Future minimum lease payments, 2016	$ 84
Future minimum lease payments, 2017	73
Future minimum lease payments, 2018	62
Future minimum lease payments, 2019	53
Future minimum lease payments, 2020	36
Future minimum lease payments, thereafter	38
Net expense under operating leases	$ 83	$ 75	$ 62

Commitments and Contingent Liabilities (Asset Retirement Obligations) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Asset retirement obligation liabilities	$ 43	$ 42	$ 42	$ 43
Asset Retirement Obligation, Roll Forward Analysis [Roll Forward]
Beginning balance	43	42
Accretion expense	1	2
Additional liabilities incurred	0	1
Changes in estimated cash flows	0	0
Settlements/payments	(2)	(2)
Ending balance	$ 42	$ 43
Current portion			1	0
Non-current portion			$ 41	$ 43

Commitments and Contingent Liabilities (Litigation) (Narrative) (Details) resident in Thousands		1 Months Ended		12 Months Ended
	Oct. 20, 2015 USD ($)	Jan. 31, 2016 trial	May 31, 2013 water_district doctor	Dec. 31, 2015 USD ($) lawsuit	Dec. 31, 2005 USD ($)	Dec. 31, 2004 resident	Dec. 31, 2014 USD ($)	Sep. 30, 2014 plantiff	Jan. 31, 2012 USD ($)
Loss Contingencies [Line Items]
Loss contingency, potential additional loss				$ 611,000,000
Asbestos Issue [Member]
Loss Contingencies [Line Items]
Lawsuits alleging personal injury - Filed \| lawsuit				2,212
Accrual balance				$ 42,000,000			$ 38,000,000
Annual review projection period				20 years
Asbestos Issue [Member] \| Non-US [Member]
Loss Contingencies [Line Items]
Accrual balance				$ 3,000,000
Benzene Related Illness [Member]
Loss Contingencies [Line Items]
Lawsuits alleging illness \| lawsuit				29
Years of exposure to benzene	24 years
Compensatory damages awarded	$ 6,900,000
Punitive damages awarded	$ 1,500,000
PFOA Matters [Member]
Loss Contingencies [Line Items]
Accrual balance				$ 20,000,000			$ 14,000,000
PFOA Matters: Drinking Water Actions [Member]
Loss Contingencies [Line Items]
Binding settlement agreement, class size \| resident						80
Number of doctors to release initial screening recommendations \| doctor			3
PFOA Matters: Drinking Water Actions [Member] \| Payment for Plaintiffs Attorney Fees [Member]
Loss Contingencies [Line Items]
Settlement payments					$ 23,000,000
PFOA Matters: Drinking Water Actions [Member] \| Payment to fund community health project [Member]
Loss Contingencies [Line Items]
Settlement payments					$ 70,000,000
PFOA Matters: Drinking Water Actions [Member] \| Funding for medical monitoring program [Member]
Loss Contingencies [Line Items]
Loss contingency, potential additional loss				235,000,000
Escrow deposit									$ 1,000,000
Escrow deposit disbursements (less than)				$ 1,000,000
PFOA Matters: Additional Actions [Member]
Loss Contingencies [Line Items]
Lawsuits alleging personal injury - Filed \| lawsuit				3,500
Lawsuits alleging wrongful death \| lawsuit				37
PFOA MDL Plaintiffs selected for individual trial \| plantiff								6
Damages awarded due to negligence				$ 1,100,000
Damages awarded due to emotional distress				$ 500,000
Subsequent Event [Member] \| PFOA Matters: Drinking Water Actions [Member]
Loss Contingencies [Line Items]
Expected number of scheduled plaintiff trials annually \| trial		40
Percentage of total cases in MDL claiming cancer		7.00%
Percentage of cases to remain inactive		93.00%
Parent Company [Member] \| PFOA Matters: Drinking Water Actions [Member]
Loss Contingencies [Line Items]
Number of water districts Company must provide treatment \| water_district			6

Commitments and Contingent Liabilities (Environmental) (Narrative) (Details)	1 Months Ended	12 Months Ended
	Jun. 30, 2015 USD ($) a	Dec. 31, 2015 USD ($)
Environmental Remediation [Line Items]
Accrual for environmental remediation activities		$ 290,000,000
Loss contingency, potential additional loss		611,000,000
Pompton Lakes [Member] \| Lead and Mercury Emissions [Member]
Environmental Remediation [Line Items]
Accrual for environmental remediation activities		87,000,000
Loss contingency, potential additional loss		$ 119,000,000
Area of lake \| a	36
Environmental remediation expense	$ 50,000,000
Minimum [Member]
Environmental Remediation [Line Items]
Average time frame of disbursements of environmental site remediation		15 years
Minimum [Member] \| Pompton Lakes [Member] \| Lead and Mercury Emissions [Member]
Environmental Remediation [Line Items]
Average time frame of disbursements of environmental site remediation	2 years
Maximum [Member]
Environmental Remediation [Line Items]
Average time frame of disbursements of environmental site remediation		20 years
Maximum [Member] \| Pompton Lakes [Member] \| Lead and Mercury Emissions [Member]
Environmental Remediation [Line Items]
Average time frame of disbursements of environmental site remediation	3 years

Financial Instruments (Details) € in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2015 USD ($) contract	Dec. 31, 2015 EUR (€) contract	May 12, 2015 USD ($)	May 12, 2015 EUR (€)	Dec. 31, 2014 contract	Dec. 31, 2013 contract
Derivative [Line Items]
Long-term debt, gross			$ 3,995
Senior Notes [Member]
Derivative [Line Items]
Long-term debt, gross			$ 2,503
Senior Notes 6.125% Due May 2023 [Member] \| Senior Notes [Member]
Derivative [Line Items]
Long-term debt, gross	$ 395	€ 360		€ 360
Designated as Hedging Instrument [Member]
Derivative [Line Items]
Recognized gain on derivative net investment hedge	$ 8
Foreign Exchange Contract [Member]
Derivative [Line Items]
Number of forward exchange currency contracts \| contract	41	41			0	0
Derivative notional value	$ 288
Foreign Exchange Contract [Member] \| Not Designated as Hedging Instrument [Member] \| Other Income [Member]
Derivative [Line Items]
Derivative gain	$ 42

Financial Instruments (Schedule of the Fair Value of Derivative Instruments) (Details) - Fair Value, Measurements, Recurring [Member] - Level 2 [Member] - Not Designated as Hedging Instrument [Member] - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Derivatives, Fair Value [Line Items]
Asset derivatives	$ 2	$ 0
Liability derivatives	2	0
Foreign Exchange Contract [Member] \| Accounts and notes receivable - trade, net [Member]
Derivatives, Fair Value [Line Items]
Asset derivatives	2	0
Foreign Exchange Contract [Member] \| Other accrued liabilities [Member]
Derivatives, Fair Value [Line Items]
Liability derivatives	$ 2	$ 0

Long-Term Employee Benefits (Narrative) (Details) - USD ($) $ in Millions	6 Months Ended		12 Months Ended
	Dec. 31, 2015	Jun. 30, 2015	Dec. 31, 2014	Dec. 31, 2013
Defined Contribution Plan Disclosure [Line Items]
Employer contributions during period	$ 28
Parent Company [Member]
Defined Contribution Plan Disclosure [Line Items]
Employer matching contribution percent of match	100.00%
Employer matching contribution percent of employees' gross pay	6.00%
Employer contribution vesting period	3 years
Employer contributions during period		$ 26	$ 52	$ 50
Minimum [Member]
Defined Contribution Plan Disclosure [Line Items]
Employer matching contribution percent of employees' gross pay	1.00%
Maximum [Member]
Defined Contribution Plan Disclosure [Line Items]
Employer matching contribution percent of employees' gross pay	7.00%

Long-Term Employee Benefits (Multiemployer Plan) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
DuPont Pension and Retirement Plan (U.S.) [Member]
Multiemployer Plans [Line Items]
Pension and other postretirement benefit expense	$ 48	$ 51	$ 126
Other U.S. and non-U.S. Plans [Member]
Multiemployer Plans [Line Items]
Pension and other postretirement benefit expense	$ 5	$ (1)	$ 38

Long-Term Employee Benefits (Schedule of Net Periodic Benefit Cost and Amounts Recognized in Other Comprehensive Income) (Details) - USD ($)
$ in Millions

12 Months Ended

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Net loss

$ 11

$ 0

Amortization of loss

^[1]

(16)

Prior service credit

(24)

Effect of foreign exchange rates

^[1]

(4)

(33)

Total benefit recognized in other comprehensive income

^[1]

(66)

$ 0

Foreign Pension Plan [Member]

Net periodic pension cost (income):

Service cost

Interest cost

Expected return on plan assets

(83)

Amortization of loss

Net periodic benefit cost

(28)

Changes in plan assets and benefit obligations recognized in other comprehensive income:

Net loss

Amortization of loss

(16)

Prior service credit

(24)

Effect of foreign exchange rates

(4)

(33)

Total benefit recognized in other comprehensive income

(66)

Total recognized in net periodic pension income and other comprehensive income

$ (94)

[1]	These other comprehensive income (loss) components are included in the computation of net periodic benefit costs. Refer to Note 21 for further information.

Long-Term Employee Benefits (Amounts Recognized in Accumulated Other Comprehensive Loss) (Details) - Foreign Pension Plan [Member] $ in Millions	12 Months Ended
	Dec. 31, 2015 USD ($)
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Net loss	$ 363
Prior service credit	(16)
Total amount recognized in accumulated other comprehensive loss	347
Estimated net loss to be amortized into net periodic benefit cost in the next fiscal year	20
Prior service cost to be amortized into net periodic benefit cost in the next fiscal year	$ 2

Long-Term Employee Benefits (Change in Benefit Obligation and Plan Assets) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Assumption and establishment of pension plans	$ 1,297
Foreign Pension Plan [Member]
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Benefit obligation at beginning of year	0
Assumption and establishment of pension plans	1,332
Service cost	16
Interest cost	19
Plan participants' contributions	2
Actuarial loss (gain)	(76)
Benefits paid	(39)
Plan Amendments	(24)
Settlements & Transfers	(6)
Currency translation	(118)
Benefit obligation at end of year	1,106
Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets at beginning of year	0
Actual loss on plan assets	(7)
Employer contributions	16
Plan participants' contributions	2
Benefits paid	(39)
Settlements & Transfers	(6)
Currency translation	(123)
Fair value of plan assets at end of year	1,140
Funded status at end of year	$ 34

Long-Term Employee Benefits (Amounts Recognized in Balance Sheet) (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014
Defined Benefit Plan Disclosure [Line Items]
Noncurrent assets	$ 138	$ 0
The accumulated benefit obligation for all pension plans	1,030
Foreign Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Noncurrent assets	138
Current liabilities	(2)
Noncurrent liabilities	(102)
Net amount recognized	$ 34

Long-Term Employee Benefits (Summary of Projected Benefit Obligations and Accumulated Benefit Obligations in Excess of Plan Assets) (Details) - Foreign Pension Plan [Member] $ in Millions	Dec. 31, 2015 USD ($)
Information for pension plans with projected benefit obligation in excess of plan assets
Projected benefit obligation	$ 194
Accumulated benefit obligation	158
Fair value of plan assets	93
Information for pension plans with accumulated benefit obligations in excess of plan assets
Projected benefit obligation	190
Accumulated benefit obligation	157
Fair value of plan assets	$ 90

Long-Term Employee Benefits (Assumptions) (Details) - Foreign Pension Plan [Member]	12 Months Ended
	Dec. 31, 2015
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]
Discount rate	2.40%
Rate of compensation increase	2.60%
Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]
Discount rate	1.70%
Rate of compensation increase	3.90%
Expected return on plan assets	7.20%

Long-Term Employee Benefits (Plan Assets) (Details) - Foreign Pension Plan [Member] - USD ($) $ in Millions	Jan. 01, 2015	Dec. 31, 2015	Dec. 31, 2014
Defined Benefit Plan Disclosure [Line Items]
Target plan asset allocations	100.00%
Fair value of plan assets		$ 1,140	$ 0
Fair value of plan liabilities		(3)
Fair value of plan assets, net of plan liabilities		1,137
Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		148
Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		992
Cash and Cash Equivalents [Member]
Defined Benefit Plan Disclosure [Line Items]
Target plan asset allocations	2.70%
Fair value of plan assets		40
Cash and Cash Equivalents [Member] \| Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		40
Cash and Cash Equivalents [Member] \| Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0
Fixed Income Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Target plan asset allocations	55.00%
Equity securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Target plan asset allocations	42.30%
Fair value of plan assets		460
Equity securities [Member] \| Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		37
Equity securities [Member] \| Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		423
Derivatives - Asset Position[Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		4
Derivatives - Asset Position[Member] \| Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0
Derivatives - Asset Position[Member] \| Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		4
Derivative Liability Position [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		(16)
Derivative Liability Position [Member] \| Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0
Derivative Liability Position [Member] \| Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		(16)
Other [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		6
Other [Member] \| Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		4
Other [Member] \| Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		2
Government Issued [Member] \| Fixed Income Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		465
Government Issued [Member] \| Fixed Income Securities [Member] \| Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		7
Government Issued [Member] \| Fixed Income Securities [Member] \| Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		458
Corporate Issued [Member] \| Fixed Income Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		148
Corporate Issued [Member] \| Fixed Income Securities [Member] \| Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		60
Corporate Issued [Member] \| Fixed Income Securities [Member] \| Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		88
Asset backed [Member] \| Fixed Income Securities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		33
Asset backed [Member] \| Fixed Income Securities [Member] \| Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		0
Asset backed [Member] \| Fixed Income Securities [Member] \| Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets		$ 33

Long-Term Employee Benefits (Cash Flow) (Details) - USD ($) $ in Millions	6 Months Ended		12 Months Ended
	Dec. 31, 2015	Jun. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Foreign Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Employer contributions			$ 16
Estimated future employer contributions in current fiscal year			18
Defined Benefit Plan, Expected Future Benefit Payments, Fiscal Year Maturity [Abstract]
2016	$ 42		42
2017	45		45
2018	44		44
2019	47		47
2020	47		47
2021 - 2025	250		$ 250
Foreign Pension Plan [Member] \| Parent Company [Member]
Defined Benefit Plan Disclosure [Line Items]
Employer contributions	$ 8	$ 38		$ 35	$ 34
Other Long-Term Employee Benefit Plans [Member] \| Parent Company [Member]
Defined Benefit Plan Disclosure [Line Items]
Employer contributions				$ 66	$ 58

Stock-based Compensation (Details) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended	6 Months Ended	12 Months Ended
	Jul. 31, 2015	Sep. 30, 2015 USD ($)	Dec. 31, 2015 USD ($) $ / shares	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Jul. 01, 2015 USD ($) shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation cost				$ 17	$ 7	$ 6
Income tax benefit				7	$ 3	$ 2
Stock Compensation Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Intrinsic value							$ 18
Conversion of stock incremental cost		$ 3
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period	10 years
Unrecognized compensation cost related to stock options			$ 5	$ 5
Unrecognized compensation cost period for recognition				1 year 11 months 12 days
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost period for recognition				2 years 1 month 13 days
Stock-based compensation award vesting period				3 years
Common stock conversion ratio				1
Restricted stock units granted and converted, weighted average grant date fair value (in dollars per share) \| $ / shares			$ 14.94
Unrecognized compensation cost related to restricted stock units			$ 23	$ 23
Chemours Company Equity and Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for grants plus the number of converted awards \| shares							13,500,000

Stock-based Compensation (Stock Option Assumptions) (Details) - Employee Stock Option [Member]	12 Months Ended
	Dec. 31, 2015 $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.50%
Expected term (years)	5 years 4 months 24 days
Volatility	42.00%
Dividend yield	6.90%
Fair value per stock option (in dollars per share)	$ 3.17

Stock-based Compensation (Stock Option Activity) (Details) - Employee Stock Option [Member] $ / shares in Units, shares in Thousands, $ in Thousands	6 Months Ended	12 Months Ended
	Dec. 31, 2015 USD ($) $ / shares shares	Dec. 31, 2015 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options outstanding, number of shares, beginning balance	7,794
Options granted, number of shares	662
Options exercised, number of shares	(22)
Options forfeited, number of shares	(150)
Options expired, number of shares	0
Options outstanding, number of shares, ending balance	8,284	8,284
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Options outstanding, weighted average exercise price, beginning balance (in dollars per share) \| $ / shares	$ 14.56
Options granted, weighted average exercise price (in dollars per share) \| $ / shares	16.04
Options exercised, weighted average exercise price (in dollars per share) \| $ / shares	5.82
Options forfeited, weighted average exercise price (in dollars per share) \| $ / shares	17.20
Options outstanding, weighted average exercise price, ending balance (in dollars per share) \| $ / shares	$ 14.66	$ 14.66
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options exercisable, number of shares	5,595	5,595
Options exercisable, weighted average exercise price (in dollars per share) \| $ / shares	$ 13.79	$ 13.79
Options outstanding, weighted average remaining contractual term		4 years 9 months 25 days
Options exercisable, weighted average remaining contractual term		4 years 2 months 15 days
Options outstanding, aggregate intrinsic value \| $	$ 0	$ 0
Options exercisable, aggregate intrinsic value \| $	$ 0	$ 0

Stock-based Compensation (Restricted Stock Units) (Details) - Restricted Stock Units (RSUs) [Member] shares in Thousands	6 Months Ended
	Dec. 31, 2015 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Restricted stock units nonvested, number of shares, beginning balance \| shares	1,431
Restricted stock units granted, number of shares \| shares	1,065
Restricted stock units vested, number of shares \| shares	(133)
Restricted stock units forfeited, number of shares \| shares	(14)
Restricted stock units nonvested, number of shares, ending balance \| shares	2,349
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Restricted stock units nonvested, weighted average grant date fair value, beginning balance (in dollars per share) \| $ / shares	$ 16.00
Restricted stock units granted, weighted average grant date fair value \| $ / shares	13.50
Restricted stock units vested, weighted average grant date fair value \| $ / shares	16.00
Restricted stock units forfeited, weighted average grant date fair value \| $ / shares	16.00
Restricted stock units nonvested, weighted average grant date fair value, ending balance (in dollars per share) \| $ / shares	$ 14.87

Geographic and Segment Information (Details) $ in Millions	3 Months Ended								12 Months Ended
Geographic and Segment Information (Details) $ in Millions	Dec. 31, 2015 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Sep. 30, 2014 USD ($)	Jun. 30, 2014 USD ($)	Mar. 31, 2014 USD ($)	Dec. 31, 2015 USD ($) segment	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Sales	$ 1,360	$ 1,486	$ 1,508	$ 1,363	$ 1,549	$ 1,632	$ 1,682	$ 1,569	$ 5,717	$ 6,432	$ 6,859
Net Property, Plant and Equipment	3,177				3,308				$ 3,177	3,308	2,972
Number of reportable segments \| segment									3
North America [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Sales									$ 2,570	2,759	3,138
Net Property, Plant and Equipment	2,184				2,273				2,184	2,273	2,183
Canada [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Sales									140	147	145
Net Property, Plant and Equipment	13				14				13	14	13
Asia Pacific [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Sales									1,393	1,548	1,519
Net Property, Plant and Equipment	136				140				136	140	138
EMEA [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Sales									977	1,190	1,237
Net Property, Plant and Equipment	308				372				308	372	321
Latin America [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Net Sales									777	935	965
Net Property, Plant and Equipment	$ 549				$ 523				$ 549	$ 523	$ 330

Geographic and Segment Information - (Schedule of Segment Information) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting Information [Line Items]
Net sales	$ 1,360	$ 1,486	$ 1,508	$ 1,363	$ 1,549	$ 1,632	$ 1,682	$ 1,569	$ 5,717	$ 6,432	$ 6,859
Adjusted EBITDA									573	876	984
Depreciation and amortization									267	257	261
Equity in earnings of affiliates									22	20	22
Net assets	130				3,673				130	3,673	3,217
Investments in affiliates	136				124				136	124	123
Purchases of plant, property and equipment									519	604	438
Operating Segments [Member] \| Titanium Technologies [Member]
Segment Reporting Information [Line Items]
Net sales									2,392	2,937	3,019
Adjusted EBITDA									326	723	726
Depreciation and amortization									125	125	117
Equity in earnings of affiliates									0	0	0
Net assets	1,659				1,748				1,659	1,748	1,390
Investments in affiliates	0				0				0	0	0
Purchases of plant, property and equipment									255	365	290
Operating Segments [Member] \| Fluoroproducts [Member]
Segment Reporting Information [Line Items]
Net sales									2,230	2,327	2,379
Adjusted EBITDA									300	282	395
Depreciation and amortization									88	83	90
Equity in earnings of affiliates									21	20	22
Net assets	1,567				1,480				1,567	1,480	1,387
Investments in affiliates	127				124				127	124	123
Purchases of plant, property and equipment									142	133	96
Operating Segments [Member] \| Chemical Solutions [Member]
Segment Reporting Information [Line Items]
Net sales									1,095	1,168	1,461
Adjusted EBITDA									29	17	101
Depreciation and amortization									52	48	53
Equity in earnings of affiliates									0	0	0
Net assets	839				782				839	782	734
Investments in affiliates	0				0				0	0	0
Purchases of plant, property and equipment									117	106	52
Corporate and Other [Member]
Segment Reporting Information [Line Items]
Net sales									0	0	0
Adjusted EBITDA									(82)	(146)	(238)
Depreciation and amortization									2	1	1
Equity in earnings of affiliates									1	0	0
Net assets	(3,935)				(337)				(3,935)	(337)	(294)
Investments in affiliates	$ 9				$ 0				9	0	0
Purchases of plant, property and equipment									$ 5	$ 0	$ 0

Geographic and Segment Information - (Reconciliation to Consolidated Income Statements) (Details) - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Segment Reporting [Abstract]
Total Adjusted EBITDA									$ 573	$ 876	$ 984
Interest									(132)	0	0
Depreciation and amortization									(267)	(257)	(261)
Non-operating pension and other postretirement employee benefit costs									3	(22)	(114)
Exchange gains (losses)									19	(66)	(31)
Asset impairments									(73)	0	0
Restructuring charges									(285)	(21)	(2)
Transaction, legal and other charges									(17)	0	0
(Loss) gain on sale of assets and businesses									(9)	40	0
(Loss) income before income taxes	$ (121)	$ (107)	$ (18)	$ 58	$ 120	$ 143	$ 155	$ 132	(188)	550	576
(Benefit from) provision for income taxes									(98)	149	152
Net (loss) income	$ (86)	$ (29)	$ (18)	$ 43	$ 79	$ 108	$ 116	$ 98	$ (90)	$ 401	$ 424

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Millions

12 Months Ended

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

AOCI Attributable to Parent, Net of Tax [Roll Forward]

$ 3,669

^[1]

$ 0

Currency Translation Adjustment [Member]

126

3,669

AOCI Attributable to Parent, Net of Tax [Roll Forward]

(304)

Derivative Instruments [Member]

(285)

AOCI Attributable to Parent, Net of Tax [Roll Forward]

Employee Benefits [Member]

AOCI Attributable to Parent, Net of Tax [Roll Forward]

(311)

Accumulated Other Comprehensive Income (Loss) [Member]

(259)

AOCI Attributable to Parent, Net of Tax [Roll Forward]

(311)

(244)

Quarterly Financial Information Disclosure [Abstract]

$ (536)

$ 19

[1]	These other comprehensive income (loss) components are included in the computation of net periodic benefit costs. Refer to Note 21 for further information.

Quarterly Financial Data (Unaudited) (Details) - USD ($)
$ / shares in Units, $ in Millions

3 Months Ended

12 Months Ended

Jul. 01, 2015

Dec. 31, 2015

Sep. 30, 2015

Jun. 30, 2015

Mar. 31, 2015

Dec. 31, 2014

Sep. 30, 2014

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Net Sales

$ 1,360

$ 1,486

$ 1,508

$ 1,363

$ 1,549

$ 1,632

$ 1,682

$ 1,569

$ 5,717

$ 6,432

$ 6,859

Cost of goods sold

1,147

1,222

1,282

1,111

1,248

1,273

1,311

1,240

4,762

5,072

5,395

Income (loss) before income taxes

(121)

(107)

(18)

120

143

155

132

(188)

550

576

Net income (loss)

(86)

(29)

(18)

108

116

(90)

401

424

Net income (loss) attributable to Chemours

$ (86)

$ (29)

$ (18)

$ 43

$ 79

$ 107

$ 116

$ 98

$ (90)

$ 400

$ 423

Basic earnings (loss) per share (in dollars per share)

$ (0.48)

$ (0.16)

$ (0.10)

$ 0.24

$ 0.44

$ 0.59

$ 0.64

$ 0.54

$ (0.50)

$ 2.21

^[1]

$ 2.34

^[1]

Diluted earnings (loss) per share (in dollars per share)

$ (0.48)

$ (0.16)

$ (0.10)

$ 0.24

$ 0.44

$ 0.59

$ 0.64

$ 0.54

$ (0.50)

$ 2.21

^[1]

$ 2.34

^[1]

Number of basic common shares

180,966,833

[1]

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.